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Abstract 
Proteins are composed of the 20 naturally occurring amino acids and are further 
modified by a variety of post-translational modifications (PTMS). Naturally occurring 
amino acids are diverse in structure and function. Catalytic amino acids, or nucleophilic 
amino acids, are of particular interest because of their contribution to chemical 
transformations in the cell.  
Synthetic covalent modification is a means to further functionalize or diversify 
proteins. These modifications, or enhancements, allow for improved understanding of 
protein structure, function and activity. For instance, isotope labeling of amino acid side 
chains in NMR studies enable investigators to study protein dynamics upon substrate or 
ligand binding. Fluorescence labeling is particularly useful to investigate protein cellular 
localization. Covalent modification is a useful tool to investigate the relative level of 
activity for protein known to be regulated by PTMs. An important feature of covalent 
modification reactions is site specificity, as this dictates the location, number of 
modifications, and protein targets. 
Tyrosine is of particular interest because it is both nucleophilic and aromatic. These 
characteristics contribute to the existence of tyrosine residues in both the protein surface 
and hydrophobic cores. Tyrosine is incorporated into proteins at a relatively low frequency. 
Unlike lysine, which is ubiquitous on protein surfaces, the low number of potential sites 
for general tyrosine modifications makes it an attractive site for surface bioconjugation 
 iv 
modifications. A low number of surface modifications is less likely to perturb native 
protein function. Bioconjugation reactions give access to functionalizing the surface of 
proteins with moieties such as fluorophores, PEG, peptides, or drugs. Tyrosine is an 
attractive target for modifications because it is found in the active sites of a variety of 
enzymes such as sialidases, glutathione-S transferases, corticosteroid 11-beta-
dehydrogensase, DNA topoisomerase, and ferredoxin-NADP+ reductase. Provided here is 
a survey of the known non-selective and selective synthetic chemical modification 
reactions for tyrosine. 
To investigate nucleophilic amino acids, Activity Based Protein Profiling (ABPP) 
may be implemented to investigate the role of these residues. ABPP utilizes small molecule 
covalent probes as a tool to selectively target enzymes in their active state. To investigate 
a protein of interest (POI) (or class of proteins) by ABPP, it is necessary to use a small 
molecule covalent probe that selectively reacts with the POI over other proteins within the 
proteome. Due to this requirement, it is necessary to expand the current ABPP probe 
toolbox to increase the coverage of what proteins in the proteome may be studied. Inspired 
by findings in the literature, our lab sought to explore the utility of various aryl halides for 
implementation in ABPP probes to overcome this limitation. 
This study revealed dichlorotriazine as a biologically relevant and reactive 
electrophile. A focus was placed on a dichlorotriazine containing probe library (LAS1-
LAS20). LAS17 was discovered to be a potent and selective inhibitor of human glutathione 
S-transferase pi (GSTP1). Further studies revealed GSTP1 as a novel therapeutic target for 
the treatment of triple negative breast cancer. Other studies revealed several members of 
the dichlorotriazine library were found to covalently modify purified recombinant human 
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aldolase A (ALDOA) in the presence of a complex cellular background. Additionally, 
LAS9 was identified as an inhibitor of ALDOA retro aldol condensation activity in vitro. 
Lastly, the final chapter highlights two collaborations in which tandem mass 
spectrometry experiments aid in the characterization of experimental data. In the first 
collaboration, a quantitative cysteine reactivity profiling method was used to characterize 
the selectivity of a cysteine reactive covalent NRF2-inducing small molecule, MIND4-17. 
In the second collaboration, analysis of tryptic mass spectrometry data enabled high 
resolution characterization of peptide sequencing for superfolder green fluorescent protein 
(sfGFP) expressed from observed internal nonsense suppression. Identification of the 
misincorporated amino acid facilitated the elucidation of the cross-talk mechanism. 
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Chapter 1 
The Discovery of a Tyrosine-Reactive Irreversible Inhibitor of GSTP1 and Investigating 
the Role of GSTP1 in Triple-Negative Breast Cancer 
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The majority of the work investigating the role of GSTP1 in triple-negative breast cancer 
was performed by members of the Namura lab. Our contribution to the work focused on 
triple-negative breast cancer was the synthesis of LAS17.  
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Introduction to Tyrosine 
Tyrosine residues are responsible for an array of biological activities and functions. 
Tyrosine is the 5th least abundant amino acid in proteins, behind methionine, histidine, 
cysteine, and tryptophan. Tyrosine incorporation constitutes less than 3% of total amino 
acids incorporated into proteins in S. aureus, E. coli, and mammalian cells. 1 Despite the 
low levels of incorporation, tyrosine is not an essential amino acid. In animals, para-
Tyrosine is formed enzymatically from the hydroxylation of phenylalanine catalyzed by 
the liver enzyme, phenylalanine hydroxylase, with the cofactor tetrahydrobiopterin and 
non-heme iron. 2,3 Other organisms, such as plants, fungi, bacteria, and algae, synthesize 
tyrosine from shikimate acid via the shikimate pathway. 4 Like phenylalanine, tyrosine is 
one of only 3 aromatic amino acids. The hydrophobic nature of the phenyl ring favors the 
environment buried in the protein structure, away from solvent exposed surfaces. The 
aromatic nature of the side chain favors interaction with non-protein ligands and enhances 
binding through p-stacking and cation-p interactions. 5 The hydroxyl group allows the side 
chain to exist in two states, protonated and deprotonated. The pKa of the phenolic hydroxyl 
of the side chain is about 10.0, however this value can vary significantly depending on the 
microenvironment of the protein. One study has shown that surface exposed, hydrophobic, 
and hydrogen bonded tyrosines have pKa values of 10, 12, and above 13 respectively.  6 
Despite occurring less frequently, these characteristics favor tyrosine residue placement on 
protein surfaces. The unique distribution of tyrosine residues leads to an assortment of 
functionalities it can participate in, such as catalysis7, acid base chemistry8,9 and function 
as a redox active center 4–7. Tyrosine is an interesting target for selective site modification 
reactions because of the unique biological characteristics and chemistries it confers.  
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Chemical modifications expand upon or employ new functional capabilities in 
proteins through a stable covalent bond. Chemical modification of tyrosines can be both 
naturally occurring, by way of post translational modifications10, or through synthetic 
modifications. Whether displayed on a protein surface or buried in an active site, the 
nucleophilic hydroxyl moiety of the tyrosine side chains makes it an ideal candidate for 
chemical modification. Additionally, the para-substitution of the hydroxyl on the phenyl 
ring of tyrosine is advantageous because modifications at this position do not lead to regio-
isomers. Tyrosine is known to have many different post-translational modifications: 
phosphorylation, sulfation, nitration, oxidation, halogenation, glycosylation, AMPylation, 
cross-linking, and electron-conduit/metal binding. 10 These post translational modifications 
have the ability to alter the function and activity of proteins with high specificity and site 
selectivity. Alternatively, proteins can be covalently modified through synthetic means. To 
be able to study protein function through covalent modification the reaction conditions 
must be agreeable in aqueous solvent and have well-defined reactivity. Subsequent 
functional studies can increase our knowledge of the biological role of tyrosine and its 
reactivity.  
The relatively low abundance of tyrosine residues makes it an ideal target for 
nonselective and selective tyrosine modifications. When applying a general nonselective 
modification strategy all surface exposed tyrosine residues will be modified through a 
bioconjugation reaction. The low abundance of tyrosine residues means the relatively low 
number of points of modification sites which is less likely to perturb protein function, than 
for example lysine. Additionally, tyrosine is a good target for selective covalent 
modifications because it is found in enzyme active sites. This means tyrosine is amenable 
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to functional studies that use covalent probes or inhibitors to interrogate the role of a 
specific protein or protein class. Tyrosine is located in active sites or is a site of regulation 
in several interesting classes of enzymes such as DNA topoisomerases11, tyrosine kinases12, 
sialidases13, nucleotide binders, nucleic acid binders. Discovery of more bioorthogonal, 
tyrosine reactive probes and electrophiles can open up the possibility of targeting 
previously untargeted protein classes for therapeutics and enhance the current use of 
bioconjugates. 
A bioconjugation reaction is the formation of a covalent bond linking a protein or 
other biomolecule with another molecule for added functionality. Typically, in protein 
bioconjugation, reactions modify lysine, cysteine, tyrosine, or tryptophan side chains, 
protein N-termini, or protein C-termini. However, bioconjugation reactions can also occur 
between an unnatural amino acid and its complementary bioorthogonal partner. 14 It is 
possible to achieve multiple degrees of bioconjugation on one substrate by employing 
several different orthogonal and site selective modification strategies. These reactions can 
be used to impart unique functionalities that facilitate our investigation and understanding 
of biological processes. Some of the functionalities made accessible through 
bioconjugation include fluorescence, PEGylation, antibody-drug conjugates, biotinylation, 
isotopic labeling, and halogenation. Addition of a fluorescent functionality can facilitate 
imaging studies that help elucidate cellular localization and distribution and protein 
dynamics through FRET.15 Protein PEGylation has been found to increase protein stability. 
This is useful in the case of increasing protein half-life and solubility when circulating in 
vivo. Antibody-drug conjugates allow drugs to be delivered selectively to targeted cells. 
Conjugating a drug to an antibody results in more beneficial pharmacokinetics, lower IC50 
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values, increased stability, and high cell target specificity than the drug alone. 16 
Development and optimization of nonselective tyrosine modifications has expanded our 
knowledge of biology and has improved our therapeutic capacity. Regardless of the 
advances achieved by bioconjugation, there is a need for selective covalent modification 
strategies with protein or protein class specificity. 
Covalent small molecule probes can target functionally active nucleophilic residues 
in enzymes. By targeting these sites, we can use the probe as a handle to understand the 
activity or functional state of the protein in biological processes. This is the motivation 
behind the field of Activity Based Protein Profiling (ABPP). ABPP uses small molecule 
ABPP probes to target functionally relevant nucleophilic sites over less reactive, more 
structurally important sites. We offer a unique perspective to this area given our interests 
lie in the pursuit of expanding the current chemical ABPP toolkit. 17,18 We achieve this by 
investigating electrophiles previously unexplored in the context of small molecule probe 
design. Tyrosine has been relatively unexplored in the fields of medicine (such as tyrosine 
reactive covalent drugs) and chemical biology through the use of small molecule probes. 
19,20 The work in our lab and by others suggests targeting tyrosine residues, the 
“tyrosinome,” as a means to expand current therapeutic strategies to protein targets and 
diseases previously unexplored. Our lab has developed two different selective small 
molecule tyrosine inhibitors for glutathione S transferase (GST) enzymes, which utilize 
two very different electrophiles: sulfonyl fluoride and dichlorotriazine. 21,22 In this account 
we explore these electrophiles in addition to the current landscape of known selective and 
non-selective chemical tyrosine modifications. 
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Non-selective Tyrosine Modifications 
Derivatization of biomolecules such as proteins through bioconjugation provides a 
means to expound on our knowledge of the chemistry of biological systems. These 
transformations allow researchers to investigate biological interactions, perform imaging 
studies, and develop of diagnostic applications. Bioconjugation reactions must be both 
residue or site-selective and must be biocompatible. These criteria are necessary for 
successful functional studies and utility of the synthetically incorporated functionality. 
Tyrosine residues are ideal candidates for bioconjugation reactions and ligations because 
of the nucleophilicity of the hydroxyl on the phenyl moiety, the low abundance of natural 
incorporation into proteins, the presence of tyrosine on both the surface of proteins and in 
protein active sites, and the facile introduction of tyrosine residues through mutagenesis. 
While the utility and need for synthetic tyrosine modifications have been established, there 
are currently only a few available strategies that have been identified. Here we discuss the 
development of tyrosine selective bioconjugation reactions as they evolved throughout 
time. 
The earliest example of tyrosine selective modifications was in the form of a diazonium-
coupling reaction which yields an ortho-substituted tyrosine (Figure 1-1A). Evidence 
shows histidine residues react with diazonium salts, however due to the pKa (~10) of the 
hydroxyphenyl ring of tyrosine reactivity with tyrosine is preferential at pH 4-9. 23 There 
are numerous examples of the application and utility of diazonium-coupling. 24,25 In a recent 
example, diazonium reagents were also used to install an alkyne onto M13 bacteriophage 
coat protein P8 Tyr residues 21 and 24. These allowed subsequent functionalized with a 
fluorophore through Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) for imaging 
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studies. 26 Diazonium reagents were used to install PEGylation modifications on Tyr 139 
of Tobacco Mosaic Virus (TMV) coat protein to prepare organic-soluble TMV rods for 
application to nanoscale particle studies. This work highlighted the importance of using 
reactive diazonium salts, in which reactivity is enhanced by appropriately placed electron-
withdrawing groups. 27 Diazonium hexafluorophosphate reagents were used to conjugate 
aplaviroc, small-molecule inhibitor of virus entry into host cells, to broadly neutralizing 
antibodies PG9 and PG16 for a new strategy for HIV therapy. It was found that PG9-
aplaviroc conjugates have lower IC50 values than the unmodified PG9 antibody. 28 More 
recently, this method has been used to interrogate the “interactome” of host-pathogen 
interactions. 29 A photocaged diazonium species on the surface of a virus can be activated 
upon irradiation of 350 nm light. The free diazonium group is free to react with tyrosine 
residues on proteins proximal to the virus.  Some drawbacks of using the diazonium 
reagents in solution are the balance of maintaining high diazonium reactivity in aqueous 
buffer while sustaining reagent stability and the ability to introduce biorthogonal 
functionalities. Additionally, NO2-substituted benzene reagents are potentially 
immunogenic. It would be advantageous to develop a method that would allow very 
selective modification of tyrosine, eliminating any reactivity with histidine. Additionally, 
it would be beneficial to minimize the hazards of reagents used and develop a method that 
could modify the oxygen of the phenol moiety of the tyrosine side chain. 
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Figure 1-1. Synthetic nonselective tyrosine conjugation reactions. (A) Diazonium-
coupling reaction. (B) N-acetylimidizole. (C) Tetranitromethane. (D) p-nitrobenzene 
sulfonyl fluoride. (E) IPy2BF4. (F) Palladium-catalyzed cross-coupling with p-allyl 
H
N
OH
O
O
O
N
N
O
OH
NO2
NO2O2N
NO2
NO2
O
S
O
O
O
R
OH
N
H
N
N
O
O
N
N
N
O
O
O
RO2C
Ph
RO2C Ph
N2
O
R
N
RNA
OO
O
P
O
S
F
O
O
N
N
OH
X
R
N
H
OH
N
H
NH
O
H
HN
H S
O
OH
OH
N N
I
BF4-
I
OH
I
AcO
R
Pd(OAc)2
X
NH2
H R
O
A
B
C
D
E
F
G
H
I
J
K
L
M
O
O
R
N
pppRNA
1) Mushroom Tyrosinase
2)
major product
APEX
(NH4)2Ce(NO3)6
H
H
O
HN
O
R
O
O
R
O
HN
O
H
H
Rh Rh
O O
Me
O O
Me
O O
O O
N
N
R
 9 
complexes. (G) Metal free three component Mannich-type reaction. (H) 
Diazodicarboxamides. (I) Dirhodium metallopeptide catalysts. (J) Cerium (IV) ammonium 
nitrate (CAN) oxidation. (K) APEX. (L) Mushroom tyrosinase oxidation, strain-promoted 
addition. 
 
Other early evidence of non-selective tyrosine modifications was with N-
acetylimidizole (Figure 1-1B). Reactivity of a particular tyrosine towards N-
acetylimidizole is a function of the degree of hydroxyl surface exposure. Proteins and 
peptides treated with N-acetylimidizole result in O-acetylation of the hydroxyl group on 
the phenyl side chain of tyrosine at neutral pH. 30,31 N-acetylimidizole has been used to 
investigate the role of tyrosine in Na+-dependent transport in rabbit intestinal brush-
boarders32. In the absence of Na+, treatment of the transporters with N-acetylimidizole 
completely inhibits glucose transport. In the presence of Na+, treatment of the transporter 
with N-acetylimidizole did not hinder glucose transport. This approach supports previous 
work that suggests tyrosine residues play a key role in Na+ transport of the Na+/glucose 
cotransporter. Furthermore, treatment with fluorescein N-acetylimidizole analogue 
revealed that tyrosine acetylation was Na+ sensitive. While studies have shown the utility 
of this method there are some disadvantages. For instance, N-acetylimidizole has cross 
reactivity with amino groups. The percent of lysine residues acetylated by N-
acetylimidizole appears to be protein sequence dependent. 30 Additionally, acetylation is 
easily reversed. Treatment with stoichiometric amounts of hydroxylamine will readily 
reverse the modification. While N-acetylimidizole improves on the requirement of site-
selectivity, the reversibility of the modification limits the utility of the method. 
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Similarly, reversible nitration can be achieved with tetranitromethane (Figure 1-
1C). Tetranitromethane will nitrate the hydroxyl group of tyrosine residues at pH 8. The 
nitrophenoxide modification can be easily observed at the strong 428 nm emission. 
Nitration of tyrosine residues of the Na+/glucose cotransporter by tetranitromethane 
showed similar results to N-acetylimidizole treatment. Treatment of the transporter by 
tetranitromethane inhibited glucose transport in rabbit intestinal brush-boarders in the 
absence of Na+.32 However, one drawback of this strategy is that it is not exclusively site-
selective for tyrosine. At pH 8 cysteine residues are also modified. The site-selectivity of 
tetranitromethane is specific for cysteine at pH 6. Similar to acetylation, nitration is also 
reversible, but through reduction. Tetranitromethane modification of tyrosine residues is a 
step in the right direction but the drawbacks of partial site-selectivity, labile modification, 
and inability to be further functionalized leaves much to be desired. 
Around the same time as methods using N-acetylimidizole and tetranitromethane 
were being developed, evidence had shown p-nitrobenzene sulfonyl fluoride labels 
tyrosine residues with site specificity (Figure 1-1D). 32,33 Modification of tyrosine residues 
by p-nitrobenzene sulfonyl fluoride results in O-(p-nitrobenzesulfonyl) tyrosine. One early 
example of this is p-nitrobenzene sulfonyl fluoride treatment inactivates Ca2+-DNase 
isolated from bovine pancreas. However, p-nitrobenzene sulfonyl fluoride treatment of 
Ca2+-free DNase yields fewer O-(p-nitrobenzesulfonyl) tyrosine sites. These studies are 
consistent with previous studies that indicate a Ca2+ dependent conformational change 
observed in active state, Ca2+-DNase, when compared to inactive state, Ca2+-free DNase. 34 
Despite the demonstrated utility of sulfonyl fluoride reagents, it is unclear why they were 
relatively untouched for the next 20 years. 35 Later, sulfonyl fluoride electrophiles emerge 
 11 
as privileged warheads in chemical proteomics through ABPP probe and irreversible 
covalent inhibitor development.36 
Focus on tyrosine iodination using IPy2BF4 was a step in the right direction towards 
a uniquely tyrosine selective chemical modification (Figure 1-1E). This is an improvement 
over previously used method that uses sodium iodide. Sodium iodide, in the presence of an 
oxidant, has been used to iodinate tyrosine and histidine side chains. In addition to the 
enhanced site-specificity, IPy2BF4 is compatible with the hydrophilic nature and thermal 
instability of amino acid based substrates, making it applicable for bioconjugation. 
Initially, strategies resulted in undesirable mixtures of mono-, diiodinated, and unreacted 
products. 37 Further optimization showed absence of an acid predictably results in the 
diiodinated product. Notably, even further optimization of reaction conditions revealed 
presence of an acid such as HBF4 or TFA resulted in monoiodinated product. However, 
the addition of an acid makes the reaction conditions less ideal for the application of protein 
modification. IPy2BF4 can be used to 125I-iodinate proteins that can aid in the 
crystallographic studies. Iodination is an attractive strategy because of the high electronic 
density and confers information based on the accessibility and confirmation of the Tyr 
residue. 38 This strategy was an improvement over previous methods, such a Bolton-Hunter 
method, that were not residue specific and introduced additional covalent modifications 
that may affect the biological activity. 39 Tyrosine iodination by IPy2BF4 opened the 
possibilities for installation of allylic functionalities through Suzuki-Miyaura cross-
coupling reactions. 
A continuation of this work shows iodination using IPy2BF4 followed by same-pot 
Suzuki-Miyaura cross-coupling reaction conditions in water yields mono- or di-alkylated 
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modifications to the phenyl ring of tyrosine residues. 40 This method was demonstrated on 
a model peptide, Leu-enkephalin, an endogenous neurotransmitter, with morphine-like 
activity. 41 This application demonstrated how this method can be used to further diversify 
peptide libraries. Studies that investigate the physiological implications of this 
modification have not been explored. Additionally, this method has not been applied to 
whole protein substrates. Furthermore, it would be advantageous to deploy a strategy using 
cross-coupling that resulted in one modification per tyrosine residue.  
Conveniently, palladium-catalyzed cross-coupling of biomolecules with 
electrophilic p-allyl complexes can be used to install allylic functionality on the hydroxyl 
of the tyrosine side chain (Figure 1-1F). 42,43 This method has been applied to 
bioconjugation of a-chymotrypsinogen A from bovine, a model protein common to the 
field of tyrosine bioconjugation reactions. 44 a-chymotrypsinogen A is an ideal model 
protein because of the presence of only four tyrosine residues, only two of which are 
solvent expose. A palladium-catalyzed cross-coupling reaction of a-chymotrypsinogen A 
with taurine carbamate was used to install molecules of hydrophobic C17 chains. 
Installation of this group demonstrated the ability to “switch” the solubility of a protein. 
SDS-PAGE analysis confirmed a-chymotrypsinogen A incorporation into small 
unilamellar vesicles. While this method is useful for installing allylic functionalities on the 
hydroxyl of the side chain of tyrosine it would be favorable to develop an additional method 
that resulted in a carbon-carbon bond formation without the use of a metal catalyst. 
Around the same time Francis also developing a metal free three component 
Mannich-type reaction (Figure 1-1G). This strategy results in a carbon-carbon bond 
formation adjacent to the side chain hydroxyl on tyrosine residues on proteins 
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preferentially over peptides. 45 Previously, formaldehyde was used for carbon-carbon bond 
forming protein crosslinking. This formaldehyde crosslinking suffers from lack of control 
for site selectivity in the presence of high formaldehyde concentrations and heat. 46 To 
circumvent the need for lysine to form imine intermediates, this strategy utilizes in situ 
formation of imines using aldehydes and electron-rich anilines. 47 Formaldehyde was 
identified as the optimal aldehyde reagent. Consistent with previous tyrosine 
bioconjugation development efforts, the three component Mannich-type reaction was also 
applied to model protein, a-chymotrypsinogen A. In this study, a-chymotrypsinogen A 
serine protease activity was easily evaluated by monitoring its proteolytic activity on a 
model peptide. The results showed bioconjugation at Y146 resulted in little to no inhibition 
of protease activity compared to the native, active form of a-chymotrypsinogen A after 
exposure to conjugation conditions with formaldehyde and 4-aminophenethyl alcohol. 47 
Optimization of this method led to the use of 13C labeled formaldehyde which was validated 
as a useful tool for the characterization of bioconjugation reactions by NMR. 48 
Theoretically, this method can be used to study the role of tyrosine residue dynamics in 
catalysis, ligand binding, and protein-protein interactions. Drawbacks of the three-
component Mannich-type approach is slow reaction rate with macromolecules such as 
polymers and requires large excess of coupling reagents.24 
Work in the area of tyrosine bioconjugation performed by Barbas was inspired by 
the metal-free Mannich-type approach first reported by Francis, et al. This strategy 
employs capitalization on the efficient aqueous ene-type reaction through the reactivity of 
diazodicarboxylate-related molecules for tyrosine orthogonal bioconjugation (Figure 1-
1H).  49–52 While substituted phenols readily react with diazodicarboxylates in the presence 
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of an activating protic or Lewis acid additive, this strategy is limited to organic solvents 
due to rapid decomposition of diazodicarboxylate reagents in aqueous conditions. 53 
Conveniently, cyclic diazodicarboxamides are not as sensitive to proton activation 
compared to acyclic diazodicarboxamides and are therefore more applicable to aqueous 
chemistry. A survey of diazodicarboxylate and diazodicarboxamide regents revealed 4-
phenyl-3H-1,2,4-triazole-3,5(4H)-dione (PTAD) as a suitable reagent for peptide labeling. 
When equimolar mixture of N-acyl methyl amides of histidine, tryptophan, serine, 
cysteine, lysine, and tyrosine were treated with PTAD only tyrosine modification was 
observed by 1H NMR albeit conversion was incomplete. Studies with a model acyclic 
peptide reaction with PTAD proceeded rapidly, and the reaction conditions were carried 
through experiments using model proteins: a-chymotrypsinogen A, bovine serum albumin 
(BSA), and myoglobin and a cyclic diazodicarboxamide rhodamine. ESI-MS analysis 
confirmed tyrosine modifications on a-chymotrypsinogen A and BSA but unfavorably low 
levels of tyrosine modification on myoglobin. Additionally, the amount of a-
chymotrypsinogen A and BSA labeled by the reagents, 35-96% yield, left room for 
improvement.  
Dirhodium metallopeptide catalysts have shown promise in the modification of 
tyrosine residues, through an O-H insertion resulting in ester formation (Figure 1-1I). In 
this method selectivity was conferred based on sequence recognition in coiled coil protein-
protein interactions in contrast to residue microenvironment, which previously had been 
the major focus. 54 The appeal of this strategy is to be able to target and modify a single 
tyrosine residue previously unreactive in previously developed tyrosine bioconjugation 
reactions. While this strategy has been optimized and applied to model peptide substrates, 
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it has yet to be applied to a whole protein. The proteins and therefore tyrosine residues for 
which this method can be applied are limited to those that bind coiled coil domains. 
Furthermore, application of this method requires rational design and optimization for each 
target. Also, the dirhodium center, which is the site of catalysis anchored through two 
glutamate residue side chains, is reactive with tryptophan and phenylalanine in addition to 
tyrosine as confirmed by MS/MS. This strategy also requires the use of large equivalents 
of the diazo substrate, 50-70 eq., for complete conversion because of the reactivity of the 
metallocarbenoid intermediate with water. 
In an effort to add to the selection of tyrosine modification reactions, focus was 
directed towards increasing yields and decreasing site cross reactivity. A screening of 
electron-rich and oxidizing compounds revealed Cerium (IV) ammonium nitrate (CAN) as 
an oxidant that facilitates the addition of aniline derivatives to tyrosine and tryptophan 
residues through oxidation (Figure 1-1J). 55 The strategy was applied to tyrosine 
modification of angiotensin in HEPES buffer at a pH of 4.5 for 1 h for addition of both 
phenylene diamine and anisidine, as confirmed by MS/MS analysis. Anilines with electron-
donating substituents were found to react more amenably to reaction conditions over 
anilines with nitro- or halogen- substitutions which were found to have low reactivity. 
Alkylated anisidine shows preference for tyrosine over tryptophan which suggests the 
potential for side-chain reactivity specificity conferred by the aniline substrate, though the 
reaction resulted in a mixture of isomeric products. Despite the desire for reaction 
conditions compatible with biological samples, addition of the CAN reagent affectively 
decreases neutral buffer pH to ~4, at which point proteins begin to denature. It has been 
found that increasing the buffering capacity of the buffer has deleterious effects on the level 
 16 
of reactivity. Consistent with previous tyrosine synthetic modification studies, viral MS2 
capsid and a-chymotrypsinogen A were used as model systems to investigate PEGylation 
and modification with cell-targeting peptides on native and introduced surface tyrosine 
residues. Another drawback of this method is the formation of both a major and minor 
conjugation product. The major product results from bond formation on the oxygen of the 
tyrosine side chain. Minor production formation is the result of a carbon-carbon bond 
formation ortho to the tyrosine hydroxyl. More recently tyrosine modification by way of 
reactivity with enzymatically formed intermediates has gained much attention. 
A unique approach to tyrosine modifications was recently demonstrated in the 
context of an enzymatic reaction catalyzed by ascorbate peroxidase (APEX) (Figure 1-1K). 
56 An engineered mitochondrial targeting APEX, mito-APEX, was expressed in HEK cells 
for the purpose of identifying proteins in close proximity to mito-APEX through 
biotinylation. This is accomplished through the reaction of the short-lived biotin-phenol 
radical, generated by mito-APEX, and the interaction of these radicals with proximal 
proteins. Biotin labeling allowed for streptavidin enrichment and subsequent MS analysis 
showed modification by biotin-phenol was specific to tyrosine residues. While the goal and 
motivation of this work was not to develop a tyrosine specific modification strategy, it 
demonstrates the possibility of performing tyrosine specific modifications in live cells. 
Deoxyribozymes have shown promising potential as catalysts for DNA-catalyzed 
tyrosine or serine selective modifications (Figure 1-1L). 57 This method has been 
demonstrated in both tethered and free peptide substrates, but sights are set on achieving 
DNA-catalyzed side chain modifications in whole proteins. From this work, Tyr1, a 
tyrosine specific deoxyribozyme, forms a tyrosine-RNA linkage via conjugation of 5’-
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triphosphorylated RNA oligonucleotide with a tyrosine side chain. 58 This strategy can 
overcome limitations often encountered with small-molecule approaches such as targeting 
proteins in which the structure is deemed “undruggable” or have challenging or shallow 
binding pockets. 
Another method of conjugation is protein cross-linking. Tyrosine residues in the 
presence of horseradish peroxidase (HRP) and H2O2 can undergo a one-electron oxidation 
that favors dimerization with other tyrosine residues. 59,60 Sequential dimerization reactions 
can lead to extensive cross-linking. In one example a tyrosine containing tag is genetically 
introduced to E. coli alkaline phosphatase (BAP) at the C-terminus. HRP recognition of 
the tyrosine containing protein tags lead to cross-linking in the presence of HRP and H2O2, 
but not for the wild type protein. BAP returned to their native monomeric state and function 
upon cleavage of the cross-linked tags through treatment with a protease. 
Most recently progress has been made in the area of strain-promoted tyrosine 
modification reactions. Accessible tyrosine residues are oxidized by mushroom tyrosinase 
which yields a 1,2-quinone intermediate, which can be further modified by a strained 
quinone-alkyne, bicyclo[6.1.0]nonyne (BCN). 61 It has been demonstrated that this strategy 
can be applied to modification of tyrosine residues on a model protein laminarinase A at a 
solvent exposed tyrosine residue incorporated by site-directed mutagenesis. Additionally, 
the method has been applied to an antibody-drug conjugate (ADC) which involved the 
modification of anti-influenza AT1002 and potent peptide based mitotic inhibitor, 
monomethyl auristatin F (MMAF). 
Another recently developed bioconjugation reaction is O-tyrosine modification by 
tetrafluoro-1,4-benzoquinone. 62 This strategy was uncovered in a study that was 
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investigating the reactivity of carcinogenic metabolites of polyhalogenated aromatic 
compounds, halogenated quinones. So far this strategy has only been applied to tyrosine 
and tyrosine containing peptides. This strategy can potentially be used to study the effects 
of tyrosine PTMs on protein function in the cell. One drawback however is the limited 
functionality imparted by the conjugation. 
 
Selective Tyrosine Modifications 
Ideally, covalent selective modifications target a conserved nucleophilic residue in 
a class of proteins or a single residue on a single protein target. These selective molecules 
are particularly helpful in the fields of chemoproteomics and chemical biology through the 
use of ABPP probes (ABP). 63 These probes can be used to interrogate the relative activity 
level of a particular protein or protein class. Selective covalent modulators can also be used 
in the identification of new therapeutic protein targets or off targets, discovery new 
inhibitors and potential therapeutics, and evaluation of drug-target occupancy. 19 The 
criteria for a ABP is that it must selectively target functional reactive residues above all 
other residues. Sites with heightened activity are typically concealed in enzymatic active 
sites or are points of regulation by PTMs. The chemical scaffold of selective covalent small 
molecules can be mechanism-based inhibitors, electrophilic ligand analogues, or in the 
simplest form merely the electrophilic species. Many selective cysteine and serine specific 
small molecules have been identified. A driving force for expanding the current list of 
known selective tyrosine modulators, is to increase the current understanding of tyrosine 
at the molecular level, as it relates to disease. Here is an account of the progress and 
developments achieved in the area of selective tyrosine synthetic modification reactions. 
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Organophosphorus (OP) reagents are large category of small molecules that are 
traditionally used as insecticides and herbicides, but are known to have an effect of 
neuronal transmission in humans. These agents or their metabolites function as 
acetylcholinesterase inhibitors that function by targeting the active site serine residue 
which results in a pooling of acetylcholine. More recently, further characterization of 
additional OP modified protein targets has revealed tyrosine as the site of modification in 
proteins without serine active site residues. Peptidase enzyme papain, isolated from 
papaya, was found to be modified by organophosphorus agent, diisopropyl 
fluorophosphate (DFP), at tyrosine 123 selectively over the other 17 tyrosine residues 
present in the protein. 64 DFP, among other FP reagents, was inspiration for the 
development of the mechanism-based FP-biotin ABP. FP probe analogues were found to 
only react with active serine hydrolases in contrast to the inactive form. Application of FP-
biotin to whole proteomes has revealed over 100 distinct targets. 63 OP agents have been 
found to modify tyrosine residues on tubulin and albumin. 65,66 While OP based probes such 
as FP-biotin give access to the ability to investigate the role and activity of some tyrosine 
residues, it would be advantageous to have an entirely tyrosine selective strategy. 
Another broadly reactive ABP with reactivity towards tyrosine residues is the 
carbon electrophile based phenylsulfonate ester (SE) probe (Figure 1-2A). 67 SE was found 
to react with aspartate, glutamate, histidine, and tyrosine residues in mouse tissue 
proteome. SE selectively reacts with the active site proton acceptor, tyrosine 183, of mouse 
corticosteroid-11 b-dehydrogenase 1. The reactivity profile of SE towards tyrosine residues 
is a welcome addition to the ABP toolbox. However, the promiscuity of the probe leaves 
room for improvement.  
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Figure 1-2. Protein and residue targets of selective tyrosine chemical modifications. (A) 
SE probe modifies Tyr 183 of mouse corticosteroid-11 b-dehydrogenase 1 (PDB: 1Y5R). 
(B) 5’-FSBA modifies Tyr 190 of bovine liver glutamate dehydrogenase (PDB: 1HWZ). 
(C) DTBSF (NSC 127755) modifies Tyr 31 of chicken liver dihydrofolate reductase (PDB: 
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1DR2). (D) SF-p1-yne and parent compound SF-p1 modify Tyr 143 of mRNA-decapping 
scavenger enzyme (DcpS) (PDB: 4QDV). (E) DAS1 and LAS17 target conserved tyrosine 
residues in the active sites of GSTP1 (PDB:6GSS). (F) Alkyne-hinged 3- fluorosialyl 
fluoride (DFSA) modifies Tyr 334 human cytosolic sialidase Neu2 (PDB: 1SNT). 
 
The sulfonyl fluoride warhead has been shown to be a privileged electrophile in the 
field of ABPP and chemical biology. 36 Work this this area began with the development of 
covalent ATP and NADH analogues to identify the residues situated around the NADH 
binding domains. 5’-p-fluorosulfonylbenzoyladenosine (FSBA) inhibits glutamate 
dehydrogenase similar to the natural allosteric inhibitor, NADH (Figure 1-2B). Sequence 
analysis revealed that FSBA covalently modifies tyrosine 190 and lysine 420 of bovine 
liver glutamate dehydrogenase. 68 More recently global proteomics studies with FSBA have 
been performed, leading to the identification of purine-binders in Jurkat cells. 69 This study 
identified 185 unique FSBA-labeling sites through the technique COmbined FRActional 
DIagonal Chromatography (COFRADIC). Of the 185 unique FSBA-labeling sites, 124 
were identified at tyrosine modifications. One example, tyrosine-protein kinase lck, proto-
oncogene from the Src family, was identified as being modified by FBSA at tyrosine 393, 
a known autocatalytic phosphorylation site. This finding that FBSA showed reactivity 
towards Lck was consistent with previous reports.70 This study demonstrated FSBA has a 
preference for tyrosine modifications over all other nucleophilic residues.  
Another early sulfonyl fluoride, DTBSF (NSC 127755), was identified through a 
screening of potential triazine based dihydrofolate reductase inhibitors.71 DTBSF was 
found to label chicken liver dihydrofolate reductase at tyrosine 31. The structure of DTBSF 
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is similar to the chemotherapeutic methotrexate, a known substrate analogue noncovalent 
inhibitor of dihydrofolate reductase. Inhibition of dihydrofolate reductase inhibits 
tetrahydrofolate synthesis causes downstream DNA and protein synthesis inhibition. 
DTBSF and its analogues can be used to develop more effective chemotherapeutics and 
give insight into potential off targets. However, global proteomics studies using DTBSF 
have not been explored. 
More recently, a high-throughput phenotypic study revealed a sulfonyl fluoride 
inhibitor as an attractive potential therapeutic for spinal muscular atrophy. In this study a 
noncovalent small molecule, D156844, was found to upregulate the expression of SMN 
protein, known to be downregulated in the diseased state. Use of radiolabeled inhibitor 
identified mRNA-decapping scavenger enzyme (DcpS) as the protein target. Rational 
design of covalent DcpS inhibitors sought to specifically target tyrosine residues, proximal 
to the inhibitor binding area. Chemoproteomic strategies with the ABP version of SF-p1, 
SF-p1-yne, facilitated target occupancy studies with the parent compound (Figure 1-2D). 
This work demonstrates the utility of investigating the mechanism of action of covalent 
inhibitors with the help of ABPs. 
Another useful SF containing small molecule is the serine protease inhibitor (2-
aminoethyl)benzenesulfonyl fluoride (AEBSF). Despite the affinity of AEBSF for active 
site serine residues in serine proteases, AEBSF has been found to modify tyrosine 547 of 
porcine serine exopeptidase, dipeptidyl peptidase IV (DPIV). 72 The reactivity of AEBSF 
inspired work in our lab to develop a serine protease ABP. We synthesized DAS1, which 
utilizes the backbone of AEBSF and contains an alkyne handle for incorporation of a 
reporter group, enabling target functionalization and identification (Figure 1-2E). 73 
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Analysis of DAS1 protein targets revealed reactivity towards serine protease in a whole 
proteome. Furthermore, we demonstrated that pretreatment with AEBSF outcompeted 
labeling with DAS1. A surprising result from the proteome reactivity analysis indicated 
DAS1 treatment enriched for 10 different glutathione s transferases (GSTs). 21 GST 
enzymes are most well known for their cellular detoxification activity. 74 GSTs catalyze the 
conjugation of electrophilic species with the sulfur of glutathione. Furthermore, site of 
labeling MS studies revealed DAS1 has reactivity towards a functional conserved tyrosine 
residue in GSTs. However, DAS1 is not the first SF containing small molecule to target 
tyrosine residues in GSTs. 
Alkyne-hinged 3- fluorosialyl fluoride (DFSA), a probe with an electrophile 
specific to the sialic-acid scaffold, modifies a tyrosine within sialidase active sites (Figure 
1-2F). 75 DFSA was show to be a tool for detecting influenza infections, due to the ability 
to react with sialidases that are essential for the pathology of invasion and escape. 76 In this 
study human cytosolic sialidase, Neu2, was found to be modified by DFSA at tyrosine 334. 
Ester-protected DFSA (PDFSA) is an improvement over previous sialidase targeting 
ABPs, quinone methide and photoaffinity probes, by overcoming issues of nonspecific 
labeling and insufficient cell permeability. Unfortunately, the mechanism-based specificity 
of the electrophile to the sialic-acid target-specific scaffold excludes its use from 
application of broad tyrosine profiling experiments. 
GST modification by SF reagents has previously been demonstrated by labeling 
with 4-(fluorosulfonyl)benzoic acid (4-FSB). Colman et al. has used FSB to probe 
glutathione S-transferase (GST) enzymes in rat liver isozyme 1-1 at Tyr 8 and in isozyme 
4-4 at Tyr 115, and Tyr 7 and Tyr 106 of pig lung glutathione S-transferase Pi (GSTP). 77–
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79 These studies have shown that Tyr 8 of rat liver isozyme 1-1 contributes to the catalytic 
activity, but is not essential for enzyme function. This study revealed the presence of a 
reactive tyrosine residue in the active site binding pocket of GST enzymes. 
More recently our lab developed another specific tyrosine reactive probe. LAS17 
is selective for glutathione S transferase pi (GSTP1) over the other GST isoforms (Figure 
1-2E). 22 LAS17 utilized a dichlorotriazine electrophile and features a leucine methyl ester 
directing group. Treatment of human GSTP1 results in loss of catalytic GSTP1 activity. 
Mouse xenograft studies showed treatment with LAS17 decreased tumor growth rate and 
decreased the size of the tumor. 80 Furthermore, LAS17 was used to characterize GSTP1 as 
a driver of triple-negative breast cancer metabolism and pathogenicity. Typically, patients 
diagnosed with triple-negative breast cancer have a poor prognosis. 81 GSTP1 expression 
levels are upregulated in triple-negative breast cancer compared to other forms of breast 
cancer. Triple-negative breast cancer cells treated with LAS17 showed a decrease in cell 
survival, which was consistent with cell survival studies with GSTP1 knockdown cells. 
This demonstrated that chemical treatment with LAS17 has the same effect as genetically 
altering the expression of GSTP1. Inactivation of GSTP1 disrupts GSTP1-induced 
activation of GAPDH, leading to a dysregulated glycolytic metabolism, resulting in lower 
levels of ATP.  
Breast cancer is the second leading cause of cancer related deaths for US women. 
The average risk of a woman in the US to develop breast cancer in her lifetime is 12.3%.82 
There have been strong initiatives to encourage early screening which have resulted in a 
decrease in the mortality rate. The US Preventive Services Task Force (USPSTF) 
recommends mammogram screening ever two years after the age of 50.83 Breast cancer is 
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a broad term that encompasses a variety of disease states that are characterized by their 
unique histology, biology, pathology, and clinical prognosis.84 Typically, aggressive breast 
cancers have a poor prognosis that can be attributed to epithelial–mesenchymal transition 
(EMT) which is commonly seen in cancer metastasis.85 One particular aggressive breast 
cancer with poor survival rates is triple-negative breast cancer (TNBC). 
TNBC is characterized by the absence of three proteins: oestrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). TNBC 
is the most common breast cancer subtype observed in BRCA1 carriers, and occurs most 
frequently in young African-American women.81 Currently, there are very few therapeutic 
options for treatment of TNBC. Due to the absence of HER2, typical chemotherapeutic 
strategies cannot be used to treat TNBC. Alternatively, here we report the identification of 
a member of the cytosolic glutathione S-transferase (GST) superfamily, glutathione S-
transferase Pi 1 (GSTP1), as a metabolic driver of TNBC through an activity based 
chemoproteomics approach. Furthermore, we report an investigation of the effects of 
chemical and genetic inhibition of GSTP1 on TNBC survival in vitro and in vivo. Until this 
point, exclusive GSTP1 inhibition has not been proposed as a strategy for the treatment 
and eradication of TNBC.  
The glutathione S-transferase (GST) Fold, Phase II detoxifying enzymes, consists 
of four distinct superfamilies (cytosolic, Kappa class mitochondrial, MAPEG, and 
fosfomycin resistance) which are differentiated by structure.86 Cytosolic GSTs are the most 
extensively studied GST family, which consist of proteins with variable and overlapping 
functions. The abundance of attention has been given to the 7 distinct classes of cytosolic 
GSTs and is likely due to the fact that they are found in all life forms. Cytosolic GSTs have 
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both a glutathione (GSH) and a hydrophobic binding pocket. GSTs have been particularly 
helpful in the field of protein science. Researchers have taken advantage of the strong 
affinity of the GSH binding domain to aid in protein purification of GST tagged 
recombinant proteins. Incorporation of a GST GSH binding domain facilitates affinity 
purification tag with GSH functionalized beads.76 
Activities of cytosolic GSTs include: GHS conjugation, tyrosine and phenylalanine 
degradation87, isomerase88, prostaglandin synthesis89, protein glutathionylation90, cellular 
signaling regulation91, and regulation of ion channels.92 The most well studied activity of 
cytosolic GSTs is the conjugation of glutathione (GSH) to electrophilic compounds (Figure 
1-3). This class of molecules includes carcinogens, chemotherapeutics, xenobiotics, and 
pesticides or naturally occurring metabolites from oxidative stress such as aldehydes, 
epoxides, hydroperoxides, and quinones.74,93 The role of GSTs in medicine, namely the 
neutralization of drugs and xenobiotics has fueled efforts to broaden our understanding of 
their role in biology.94 
 
 
Figure 1-3. Catalytic cellular detoxification activity of GSTs. 
 
GSTP1 is the most ubiquitous member of the soluble GST protein superfamily and 
is primarily responsible for catalyzing the conjugation of GSH to exogenous and 
endogenous electrophiles as a mechanism of cellular detoxification.95 GSTP1 is believed 
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to exist and function as a homodimer (Figure 1-4). In addition to its catalytic function, 
GSTP1 has also been demonstrated to regulate the Jun N-terminal kinase (JNK)/mitogen-
activated protein kinases (MAPK) signaling pathway through protein–protein interaction 
with JNK.91This protein-protein interaction is disrupted by self-redox regulation of post 
translational modification, S-glutathionylation, of Cys47 and Cys101.90 Tyrosine 
phosphorylation of GSTP1 by the epidermal growth factor receptor (EGFR) kinase 
promotes formation of the GSTP1–JNK complex, which suppresses downstream JNK 
signaling.96 A variety of human cancers, including breast, colon and ovarian cancers, 
express high levels of GSTP1 relative to healthy tissue.97 Furthermore, human tumor cell 
lines that exhibit resistance to chemotherapeutic agents have elevated GSTP1 levels.98 
Resistance is attributed to GSTP1- catalyzed inactivation of chemotherapeutic alkylating 
agents through conjugation of GSH. 
 
Figure 1-4. Surface representation of GSTP1 homodimer. GSH is shown in in the GSH 
binding domain as spheres (PDB: 6GSS). 
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Due to the confirmed roles of GSTP1 in promoting tumorigenesis and drug 
resistance, GSTP1 has emerged as a promising cancer therapeutic target. Many GSH 
analogs, small molecules and natural products have been identified as GSTP1 inhibitors.91 
Reversible GSTP1 inhibitors include 8-methoxypsoralen, piperlongumine, aloe emodin, 
and benstatin A,91,99,100 as well as Telintra (Ezatiostat), which was in clinical trials for the 
treatment of myelodysplastic syndrome.101,102 GSTP1 contains four cysteine residues, two 
of which (Cys47 and Cys101) have been shown to be highly reactive and targeted by 
irreversible GSTP1 inhibitors.103 These cysteine-targeted covalent modifiers of GSTP1 
include quercetin,104 and S-(N-benzylthio-carbamoyl) glutathione (BITC-SG).105 
Quercetin targets Cys47, whereas BITC-SG covalently modifies Cys47 and Cys101 via an 
S-thiocarbamoylation reaction.104,105 
In addition to the two characterized reactive cysteines, GSTP1 has also been shown 
to contain reactive tyrosine residues that are susceptible to modification by sulfonyl-
fluoride electrophiles. These sulfonyl fluorides have been shown to target the equivalent 
of tyrosine 8 and tyrosine 108 in mouse, rat, and pig GSTP1.21,78,79,106 Mutation of the 
equivalent of Y108 to phenylalanine in the Schistosoma japonicum GST resulted in loss of 
GSTP1 activity,21 indicating the functional importance of this tyrosine residue. Previous 
sulfonyl-fluoride probes used for tyrosine labeling are not selective for GSTP1, and 
covalently modify various other proteins within the proteome.21,73 Here, we report the 
development of a selective, irreversible GSTP1 inhibitor, LAS17, which covalently 
modifies the functional tyrosine, Y108, in human GSTP1. LAS17 was discovered through 
screening a library of dichlorotriazine-containing compounds and shown to selectively 
modify GSTP1 within human cancer-cell proteomes.  
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This work was inspired by pervious initiatives focused around investigating the 
proteome reactivity of a library of aryl-halides.107 This effort was motivated by the desire 
to expand the currently available set of activity based protein profiling probes (ABPs). 
ABPs are tools implemented in the field of activity based protein profiling (ABPP). 
Activity based protein profiling utilizes covalent small molecule probes to selectively 
target reactive residues in proteins, which correlates to overall enzymatic activity.63 
Understanding the relative reactivity of a protein can give insight into the functional 
properties of the protein. One limitation of the field of ABPP is that in order for a protein 
to be studied it must be the target of an ABP. With this limitation comes the incentive to 
expand the so-called “chemical probe tool box,” thus expanding the protein targets 
available for exploration.18 
Our efforts to expand the currently available ABPs was inspired by the report of a 
cysteine specific inhibitor of peroxisome proliferator activated receptor-g (PPARg).108 
PPARg plays a role in fat storage and PPARg deficient mice are protected against high-fat 
induced obesity and insulin resistance.109 In this study, GW9662, was found to inhibit the 
activity of PPARg through selective modification of cysteine 285. The covalent adduct was 
achieved through a nucleophilic aromatic substitution (SNAr) reaction between the sulfur 
atom of the cysteine side chain and displacement of a chloride from the p-
chloronitrobenzene electrophile. We hypothesized that other aryl-halide compounds, such 
as dichlorotriazine would undergo the same reaction with nucleophilic amino acid side 
chains (Figure 1-5). This inspired the synthesis of an aryl-halide containing probe 
library.107Evaluation of the aryl-halide probe library for protein reactivity and site of 
modification revealed that dichlorotriazines predominately targeted lysine residues within 
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a proteome, in contrast to p-chloronitrobenzenes that are highly cysteine selective (Figure 
1-6). 
 
 
Figure 1-5. Proposed nucleophilic aromatic substitution reaction mechanism with RB7 
that results in a covalent modification to protein targets. 
 
 
Figure 1-6. Amino acid specific reactivity profile of p-chloronitrobenzene (RB2) and 
dichlorotriazine (RB7) probes. (Figure adapted from Shannon, D.A. et al 2014.) 
 
To further explore the unique reactivity of the dichlorotriazine electrophile and 
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sought to synthesize a library of probes with the following functionalities: (1) a 
dichlorotriazine electrophile for covalent modification of the protein target; (2) a bio-
orthogonal alkyne handle for CuAAC-mediated target identification; and (3) a diversity 
element to direct the probes toward diverse subsets of the proteome (Figure 1-7).  
 
Figure 1-7. Dichlorotriazine library probe design. 
 
Dichlorotriazines have been used by the textile industry as irreversible dyes. The 
covalent modification of the dye to cellulose present in cotton and flax prevents fading due 
to repeated wash cycles and bleaching.110 While dichlorotriazine dyes have positively 
impacted the textile industry, the environmental effects of dichlorotriazine waste has been 
less favorable. Dichlorotriazine dyes have been found to covalently modify enzymes in 
biological samples in inhibit enzyme activities. One example of this is Vilmafix Blue AR 
(VBAR) which covalently modifies lysine 81 and/or lysine 217 of NADH-dependent 
bovine heart mitochondrial L-malate dehydrogenase.111 VBAR inhibits L-malate 
dehydrogenase in a time and concentration manner. Inhibition of L-malate dehydrogenase 
prevents reduction of oxaloacetate and a dysregulation of the citric acid cycle.  
Dichlorotriazine library members contains a terminal alkyne functionality that 
allows for evaluating target occupancy and promiscuity of the individual probes in cellular 
and in vivo systems, using established copper(I)-catalyzed azide–alkyne cycloaddition 
(CuAAC) methods.112,113 CuAAC gives access to further conjugation of protein targets 
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through the addition of a reporter group. Reporter groups allow for visualization or 
enrichment of the protein target. Examples of reporter groups are rhodamine-azide for in-
gel fluorescence imaging and biotin-azide for protein target enrichment on streptavidin 
functionalized beads. 
Dichlorotriazine library members also contain a diversity element. The 
incorporation of a diversity element gives both the protein target and probe addition 
binding contact points. Addition of these points favor more selective molecular 
interactions, which can fine tune the selectivity of the probe for a subset of the proteome. 
The selectivity of a probe library member with a diversity element will therefore be more 
selective for a protein or protein class above a probe containing the electrophile and alkyne 
alone. 
 
Results and Discussion 
 
Dichlorotriazine Library Synthesis and Evaluation 
The dichlorotriazine probe library was synthesized via a 3-step divergent synthesis 
(Scheme 1-1). First, 4-pent-yn-ol (1) was tosylated with tosylchloride to generate a 
common intermediate (2). Then, the common intermediate (2) was then diversified through 
an SN2 reaction with primary amine of 20 commercially available directing groups (3). 
Lastly, the resulting secondary amines were coupled to cyanuric chloride through an SNAr 
reaction to afford the final library members (LAS1-LAS20) (Figure 1-8). 
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Scheme 1-1. Synthesis of dichlorotriazine library. 
 
Figure 1-8. Dichlorotriazine probe design and library members, LAS1-LAS20. 
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 LAS1-LAS20 were evaluated for covalent protein labeling in soluble HeLa cell 
lysates. Lysates were treated with 1 µM of each compound for 1 hour. Next, samples were 
subjected to CuAAC conditions with rhodamine-azide. Following the addition of 
rhodamine-azide, samples were resolved on SDS-PAGE and imaged for in-gel 
fluorescence visualization (Figure 1-9). These in-gel fluorescence screening studies 
demonstrated that several library members intensely labeled a low molecular weight 
protein band (~25 kD) (Figure 1-10). Of the 20 compounds, LAS17 (Figure 1-11A) 
containing the L-leucine methyl-ester directing group, was chosen for subsequent study 
due to the high intensity of labeling for the ~25 kD protein and minimal labeling of other 
proteins within the cell lysates Furthermore, treatment of live HeLa cells with 1 µM of 
LAS17 demonstrated the cellular permeability, potency, and selectivity of this compound 
for covalent modification of the ~25 kD within a cellular context (Figure 1-11B). The 
potency and selectivity observed in the live cell treatment was consistent with the reactivity 
profile observed in LAS17 treatment of lysates (Figure 1-12). 
 
 
 
 
Figure 1-9. Probe library reactivity evaluation workflow in HeLa cell lysates. 
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Figure 1-10. Evaluation of dichlorotriazine probe library (LAS1-LAS20) reactivity in 
soluble HeLa cell lysates (2.0 mg/mL). 
 
 
 
Figure 1-11. Live cell labeling. (A) Structure of LAS17. (B) LAS17 reactivity evaluation 
workflow in live HeLa cell labeling experiment.  
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Figure 1-12. Evaluation of LAS17 reactivity in live HeLa cell treatment. 
 
Identification of GSTP1 as the Target of LAS17 
 To identify the ~25 kD protein, HeLa cell lysates treated with either DMSO or 1 
µM of LAS17 were subjected to CuAAC with biotin-azide (Figure 1-13). Biotinylated 
proteins were enriched on streptavidin-agarose beads. Unreacted proteins were removed 
by washing. Bead-bound proteins were subjected to on-bead trypsin digestions, and tryptic 
digests were subjected to LC/LC-MS/MS analysis. Spectral counts for proteins identified 
in three DMSO-treated samples were compared to LAS17-treated samples to identify 
proteins specifically labeled by LAS17 (Table 1-1, Table 1A-1). These data identified 
GSTP1 as the ~25 kD protein target of LAS17. 
 
Figure 1-13. Sample preparation and mass spectrometry analysis workflow for protein 
target identification of LAS17. 
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Protein Mol Weight (Da) DMSO LAS17 
GSTP1 Glutathione S-Transferase 23342 0 24 
HSP90AB1 Heat Shock Protein HSP 90-beta 83264 4 24 
TKT Transketolase 67878 3 23 
TUBA4A Tubulin alpha-4A chain 49924 4 22 
PKM Pyruvate kinase isozymes M1/M2 57937 6 22 
EEF1A1 Elongation factor 1-alpha 1 50141 5 20 
FLNA Filamin-A 280737 6 20 
TUBB Tubulin beta chain 49671 6 19 
PGK1 Phosphoglycerate kinase 1 44615 1 14 
HSP90AA1 Heat sock protein HSP 90-alpha 84660 0 12 
 
Table 1-1. The top 10 proteins with the greatest difference in average spectral counts 
among three trial for DMSO and LAS17 treated samples. 
 
Confirmation of GSTP1 as the Target of LAS17 
 To confirm the LC/LC-MS/MS findings, human GSTP1 with an N-term 
hexahistidine affinity tag was recombinantly expressed in E. coli and purified to 
homogeneity from the soluble fraction. The purified protein was treated with 1 µM of 
LAS17 and analyzed for in-gel fluorescence (Figure 1-14A). Significant protein labeling 
of purified GSTP1 was observed, confirming that LAS17 covalently modifies GSTP1 
(Figure 1-14B). 
 
Figure 1-14. Evaluating LAS17 reactivity towards purified recombinant GSTP1. (A) 
Workflow to evaluate LAS17 reactivity towards purified, recombinant GSTP1. (B) 
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Recombinant, purified GSTP1 was treated with LAS17 and subjected to CuAAC, SDS-
PAGE and in-gel fluorescence and Coomassie Blue staining.  
 
LAS17 Treatment Inhibits GSTP1 Activity 
 To determine if LAS17 inhibits GSTP1 activity, an in vitro activity assay was 
performed that spectroscopically monitored the conjugation of GSH to 1-bromo-2,4-
dinitrobenzene (BDNB). LAS17 inhibited in vitro GSTP1 activity after a 1 hr 
preincubation with LAS17 in a concentration dependent manner (Figure 1-15A). Given the 
covalent mode of action for LAS17, time-dependent inhibition of GSTP1 was monitored, 
affording a second-order rate constant of inactivation (kinact/KI) of 31,200 M-1s-1 (Figure 1-
15B-C). To determine if the presence of other proteins affects the inhibitory activity of 
LAS17, inhibition studies were performed within the context of a complex background of 
HeLa cell lysates. The results demonstrate that the presence of other cellular proteins does 
not affect the inhibitory function of LAS17. 
 
 
Figure 1-15. (A) in vitro GSTP1 activity in the presence of increasing concentrations of 
LAS17. (B-C) in vitro concentration and time-dependent inhibition of GSTP1 by LAS17. 
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Characterization of LAS17 Mechanism of Inhibition of GSTP1 
 The visualization of protein labeling after denaturing SDS-PAGE, and the time-
dependent inhibition observed for LAS17, confirmed that this compound functions by 
covalently modifying GSTP1. However, given the high reactivity observed for the 
dichlorotriazine electrophile in previous proteome reactivity screening, we sought to 
determine in LAS17 was covalently modifying a single amino acid or multiple sites within 
GSTP1. To determine the stoichiometry of modification, intact-protein mass spectrometry 
of purified GSTP1 was performed in the presence of 3 equivalents of LAS17 (Figure 1-
16A). The de-convoluted mass of the DMSO GSTP1 samples was determined to be 25779 
Da (Figure 1-16B), whereas the mass of the LAS17 treated GSTP1 sample was determined 
to be 26102 Da (Figure 1-16C). The mass difference between the DMSO treated sample 
and the LAS17 treated sample is +322 Da. This mass spectrometry analysis indicates a 
single modified species corresponding to modification of GSPT1 with LAS17 at a single 
site, thus a stoichiometry of 1:1 (LAS17:GSTP1 monomer).  
 
Figure 1-16. Intact-protein mass spectrometry of DMSO or LAS17 treated purified 
GSTP1. (A) Intact-protein mass spectrometry workflow. De-convoluted spectra of (B) 
DMSO and (C) LAS17 treated GSTP1. 
LC-MSDMSO or LAS17
A
B C25779 26102
 40 
 
To identify the site of GSTP1 labeling by LAS17, purified wild-type (WT) GSTP1 
was incubated with LAS17 or DMSO and subjected to denaturation, reduction, cysteine 
alkylation, and trypsin digestion (Figure 1-17). The resulting tryptic-peptide mixtures were 
analyzed by LC-MS/MS. The generated fragmentation spectra were searched for a 
differential modification mass of +322.12 on all potentially nucleophilic amino acids. 
There analyses identified Y108 as the site of modification by LAS17 on GSTP1 (Figure 1-
18). To confirm Y108 as the site of modification, a Y108F mutant was generated. The 
Y108F mutant was expressed and purified in tandem with WT GSTP1. Both the WT and 
Y108F-mutant GSTP1 were treated with LAS17 and analyzed by in-gel fluorescence. The 
results show that replacing the nucleophilic tyrosine residue with a phenylalanine 
eliminated the ability of LAS17 to covalently modify GSTP1, thereby confirming that 
modification was selectively occurring that this residue (Figure 1-19A). Y108 is located in 
the GSH binding site, and is conserved among the pi, mu, and theta GST classes in humans 
(Figure 1-19B). 
 
Figure 1-17. Workflow to determine the site of labeling of LAS17 on purified WT GSTP1. 
 
DMSO or LAS17 Trypsin Digest LC/LC-MS/MS
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Figure 1-18. Fragmentation (MS/MS) spectra of the YVSLIY*NYEAGKDDYVK peptide 
of GSTP1 confirming that the LAS17 modification (+322.12 Da) is present on Y108, which 
is indicated with *.  
 
 
Figure 1-19. (A) In-gel fluorescence analysis of purified Y108F mutant compared to WT 
GSTP1, confirms Y108 as the site of labeling (B) Proximity of Y108 to the GSH binding 
site of GSTP1 (PDB: 6GSS). 
Since the dichlorotriazine electrophile was previously shown to covalently modify 
lysine residues in proteomes, we sought to confirm LAS17 was not modifying a lysine 
residue on GSTP1. This was achieved by generating lysine to alanine mutants at each of 
the 12 lysine residues on GSTP1. Mutation of these lysine residues did not result in a 
decrease in LAS17 labeling compared to the WT control, further confirming that covalent 
modification was occurring at Y108 (Figure 1-20A). Additionally, a C47S mutant was 
A
WT Y108F
Fluorescence:
Coomassie Blue:
B
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generated, which did not show loss of fluorescence compared to the WT control (Figure 1-
20B). 
 
 
Figure 1-20. LAS17 labeling screening of (A) lysine and (B) cysteine mutants. 
 
Lastly, activity assays with the Y108F mutant showed that LAS17 had negligible 
effect on the activity of the mutant protein in comparison to WT GSTP1 (Figure 1-21). 
These assay data thereby confirm that the inhibitor activity of LAS17 is solely due to the 
covalent modification of Y108. Residue This tyrosine residue has been found to be within 
hydrogen bond distance of the sulfur of GSH. This tyrosine residue favors formation and 
participates in stabilization of the thiolate.114 
 
Figure 1-21. The Y108F mutant is resistant to LAS17-mediated inhibition compared to 
the wild-type GSTP1. 
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The work in the sections was performed by Louie, S.M., et al. Our contribution to 
the project was the synthesis of LAS17. 
To identify TNBC specific metabolic drivers, an activity based chemoproteomic 
strategy was used to screen a panel of non-TNBC and TNBC cell lines. A lysine-reactive 
dichlorotriazine probe, RB7, and cysteine-reactive iodoacetamide alkyne were used to 
identify proteins with reactive functional residues. Lysine and cysteine residues were 
chosen in this study because they are nucleophilic amino acids that have been shown to 
contribute to enzymatic activity and function.18,107Probe protein targets from each of the 
cell lines were identified by mass spectrometry analysis of enriched tryptic digests. A 
filtering cut off criteria of a >5-fold increase in spectral counts following data analysis 
revealed unique metabolic enzymes are upregulated in TNBC cells compared to non-
TNBC cells (Figure 1-22A). GSTP1 was found to be the most upregulated protein target 
across TNBC cell lines compared to non-TNBC cell lines (Figure 1-22B). Additionally, 
GSTP1 was found to have higher expression levels in precancerous cells line, MCF10A, 
and TNBC cells compared to non-TNBC cells by Western blotting (Figure 1-22C). This 
finding suggests that GSTP1 is a TNBC specific therapeutic target. 
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Figure 1-22. (A) Chemoproteomic profiling of a panel non-TNBC and TNBC cell lines 
with RB7. (B) GSTP1 reactivity in TNBC cells from each individual cell line and combined 
average spectral counts from non-TNBC and TNBC. (C) GSTP1 expression was measured 
across cell lines by Western blot. GSTP1 expression was normalized to actin loading 
control. 
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To confirm GSTP1 as a true therapeutic target for the treatment of TNBC, two 
GSTP1 knockdown 231MFP TNBC cell lines (shGSTP1-1 and shGSTP1-2) were 
generated. GSTP1 mRNA levels were assessed by qPCR and GSTP1 expression levels 
were assessed by Western blot (Figure 1-23A). These results show significant decreases in 
mRNA and protein levels, confirming successful GSTP1 knockdown. These knockdown 
cell lines showed impaired survival in serum-free media, but did not show decreased levels 
of cell proliferation compared to controls (Figure 1-23B). Furthermore, xenograft mouse 
studies, injected with shControl 231MFP and shGSTP1-1 231MFP knockdowns, showed 
decreased tumor growth rate for the shGSTP1-1 mouse compared to the shControl in 
immune-deficient mice (n=8) (Figure 1-23C). These results show that genetic inactivation 
of GSTP1 in TNBC results in decreased pathogenicity.  
 
Figure 1-23. Effect of genetic inactivation of GSTP1 in vitro and in vivo. (A) Two 
independent shGSTP1 231MFP knockdown cell lines confirmed by qPCR and Western 
blotting. (B) GSTP1 231 MFP knockdown proliferation and survival studies. Assays were 
assessed by Hoechst stain. (C) Xenograft mouse models show impaired 231MFP tumor 
growth in shGSTP1-1 mice compared to shControl mice. 
 
The results from the genetic studies motivated efforts to investigate if the same 
decrease in pathogenicity can be achieved by chemical inhibition of GSTP1. Thus, LAS17 
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was chosen to investigate the pharmacological potential of chemical inactivation of GSTP1 
in TNBC. In vitro treatment of purified GSTP1 with LAS17 showed to have a 50% 
inhibitory concentration (IC50) of 0.5 µM (Figure 1-24A). Consistent the results seen in 
shGSTP1, a survival assay shows significant decrease in cell survival in the LAS17 treated 
sample compared to the control (Figure 1-24B). Lastly, similar to the shGSTP1 xenograft 
studies, once daily treatment of immune-deficient mice with daily LAS17 (20 mg/kg) 
treatment starting at 2 or 16 days post subcutaneous injection with 231MFP cells shows 
decreased tumor growth rate in addition to decreased tumor size compared to the control 
(Figure 1-24C). Mice treated with LAS17 did not experience significant decreases in total 
body weight. LAS17 treatment of additional TNBC cell lines, HCC38, HCC70, and 
HCC1143 also resulted in significant decreases in cell survival (Figure 1-24). 
 
Figure 1-24. Effect of chemical inactivation of GSTP1 by LAS17 in vitro and in vivo. (A) 
LAS17 has an IC50 of 0.5 µM for the inhibition of GSTP1. (B) LAS17 treatment results in 
decreased cell survival. (C) Xenograft mouse models show impaired tumor growth in daily 
LAS17 treated mice 2 and 16 days post subcutaneous injection of 231MFP cells compared 
to vehicle treated mice. 
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Figure 1-25. Survival assay of LAS17 treated TNBC cell lines. 
 
Focus was then directed on elucidating the mechanism by which GSTP1 influences 
the pathogenicity of TNBC. GSTP1 is known to participate in protein-protein interactions 
as a modulator of signaling pathways. GSTP1 is known to interact with a member of the 
family of MAPK proteins, JNK. Additionally, GSTP1 has the ability to influence cellular 
levels of GSH, thus modulating the ratio of reduced and oxidized glutathione 
(GSH/GSSG), which is a hallmark of oxidative stress conditions. However, data suggests 
that neither of these are the mechanisms by which GSTP1 contributed to the pathogenicity 
of TNBC (data not shown).  
These findings were further confirmed through metabolic profiling mapping 
experiments that revealed an alternative mechanism. Single-reaction monitoring (SRM)-
based liquid chromatography-tandem MS (LC-MS/MS) method was used to monitor and 
quantify levels of ~200 metabolites spanning glycolytic, tricarboxylic acid (TCA) cycle, 
amino acid, nucleotide, and lipid metabolism. Additionally, an untargeted LC-MS method 
(m/z range set to 100-1,200) was used to identify metabolites that were altered upon GSTP1 
inactivation. Through these methods the following metabolites were found to be lowered 
in the two shGSTP1 231MFP cell lines and with LAS17 treatment: lactic acid, ATP, 
nucleotides, diacylated phospholipids, and alkylacyl ether lipids. Conversely, the following 
metabolites were found to be increased in the two GSTP1 inactivation conditions: acyl 
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carnitines (ACs), ceramides, and lysophospholipids (Figure 1-26). Metabolite level 
differences in the two GSTP1 activation conditions were attributed to alterations that can 
be attributed to chronic GSTP1 inactivation (knockdown) versus acute GSTP1 inactivation 
(LAS17 treatment). 
 
Figure 1-26. (A) Identification of metabolites that were significantly (p < 0.05) changed 
in the same direction in both shGSTP1-1 and shGSTP1-2 cells compared to shControl cells. 
(B) Identification of metabolites that were significantly (p<0.05) changed in levels in 
LAS17-treated (10 µM, 20 h) 231MFP cells compared to DMSO-vehicle-treated controls. 
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(C) Common metabolites that were significantly (p<0.05) changed between LAS17 
treatment and shGSTP1 cells. Mapping of common observed metabolic changes to 
metabolic pathway maps suggested GSTP1 plays a role in the dysregulation of glycolysis, 
lipid metabolism, energetics, and oncogenic signaling pathways. To confirm these findings 
a number of the metabolite fluctuations were investigated independently.  
 
Investigating the Influence of GSTP1 Activity in Glycolytic Metabolism 
 The observed decrease of lactic acid, in the metabolomics study resulting from 
GSTP1 inactivation, suggests a reduced glycolytic metabolism compared to controls. To 
confirm GSTP1 as a regulator of lactic acid levels, lactic acid secretion of 231MFP cells 
was monitored over time. The results show a significant decrease in the levels of lactic acid 
secreted by the GSTP1 inactivated, shGSTP1 and LAS17 treated, 231MFP cells compared 
to the controls, shControl and DMSO vehicle treated (Figure 1-27A). In an effort to identify 
the glycolytic enzymes influenced by GSTP1 activity, a stably overexpressing FLAG-
tagged GSTP1 231MFP cell line was generated. FLAG pulldown on lysates from the 
FLAG-tagged-GSTP1 cell line enriched for seven proteins compared to the mock control 
(Figure 1-27B). Glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
was significantly enriched in the GSTP-FLAG expressing FLAG pulldown compared to 
the mock. However, endogenous GAPDH was not able to be detected using this method. 
Exogenous GADPH pulldown was observed upon the addition of pure and active GAPDH 
enzyme GSTP-FLAG expressing cell lysates. To investigate the effect of the protein-
protein interaction between GSTP1 and GAPDH on GAPDH activity, GAPDH activity 
was monitored in vitro. GAPDH activity is greatly increased in the presence of GSTP1. 
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However, this enhancement is partially suppressed by LAS17 pre-treatment of GSTP1 
(Figure 1-27C). Control experiments confirm the reduction in GAPDH activity is not a 
result of direct LAS17 inhibition of GAPDH (data not shown). 
 
Figure 1-27. (A) Decreased levels of lactic acid secretion in media as determined by lactic 
assay kit. (B) Proteins enriched in FLAG pulldown proteomics experiment. (C) GSTP1 
enhances the activity of GAPDH. LAS17 pretreated GSTP1 enhances GAPDH activity to 
a lesser degree. 
 
GSTP1 Inhibition Impairs Oncogenic Signaling Pathways 
 Indication of reduced levels of ATP and increased levels of ACs (C18:0 AC) in the 
metabolomic profiling studies suggests enhanced phosphorylation and activity of AMP 
kinase (AMPK) and downstream phosphorylation and inhibition of A (CoA) carboxylase 
(ACC). Inhibition of mammalian target of rapamycin (mTOR) linked to the activation of 
AMPK has previously been demonstrated as a strategy to impair cancer 
pathogenicity.115To investigate the effect of GSTP1 inhibition on activation of AMPK and 
inactivation ACC, GSTP1 inhibited cells and controls were evaluated for AMPK and ACC 
phosphorylation in conjunction with AMPK and ACC expression levels by Western 
blotting (Figure 1-28A-B). These results further suggest that observed reduced levels of 
GSTP1 anti-FLAG pulldown
A B C
0.000
0.005
0.010
0.015
0.020
0.025
ac
tiv
ity
GAPDH activity
GAPDH
GSTP1
LAS17
+ + +
- + +
- - +
*
*
#
GSTP1 activates
GAPDH activity
 51 
ATP and increase levels of ACs can be correlated to activation of AMPK and thus 
impairment of oncogenic signaling. Furthermore, mTOR inactivation is further confirmed 
by the reduce levels of phosphorylated S6, a downstream target of mTOR, in GSTP1 
inactivated cells compared to the controls (Figure 1-28C). Additionally, survival of 
231MFP cells treated with mTOR inhibitor, Torin 1, showed a decrease in survival 
compared to the control (Figure 1-28D). Furthermore, co-treatment of LAS17 and Torin 1 
did not show an additive effect on cell survival. This suggests LAS17 inhibits an essential 
target upstream of mTOR.  
 
Figure 1-28. Effect of GSTP1 inhibition on oncogenic signaling pathways. (A) Genetic 
inhibition of GSPT1 results in increased amounts of p-AMPK and p-ACC compared to 
control cells. (B) Chemical inhibition of GSTP1 by LAS17 results in increased amounts of 
p-AMPK and p-ACC compaired to control cells. (D) mTOR inhibitor, Torin 1, and LAS17 
do not have a synergistic effect on inhibiting cell survival. 
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Conclusions 
 In summary, we report the discovery and characterization of LAS17, a potent and 
selective tyrosine-directed irreversible inhibitor for GSTP1. Given the well-characterized 
role of GSTP1 in cancer pathogenesis and chemotherapeutic resistance, LAS17 provides a 
unique mode of irreversible GSPT1 inhibition, targeting a functional tyrosine residue 
(Y108), in contrast to previously reported cysteine-targeted compounds. Despite the high 
reactivity of the dichlorotriazine electrophile of LAS17, high selectivity is observed for 
GSTP1 within a complex proteome. The structural basis for this selectivity is currently 
unknown. Lastly, the presence of the terminal alkyne functionality for CuAAC provides 
the ability to determine target engagement and off-targets in cell-based and in vivo systems 
using CuAAC-mediated conjugation of reporter tags for visualization and enrichment of 
LAS17-bound proteins. LAS17 is a valuable addition to the currently available collection 
of reversible and irreversible GSTP1 inhibitors. LAS17 can be utilized as an activity-based 
probe (ABP) to interrogate GSTP1 activity in cancer, and as a pharmacological modulator 
of GSTP1 to further interrogate the therapeutic potential of this enzyme. 
 GSTP1 was revealed to be a unique, upregulated metabolic driver of TNBC in a 
global lysine reactivity profiling experiment. Genetic inactivation studies (knockdown) of 
GSTP1 in 231MFP, a TNBC cell line, revealed impaired glycolytic metabolism. This data 
was complemented by studies utilizing chemical inactivation of GSTP1 in 231MFP, made 
accessible, in part, by the use of the potent and selective GSTP1 inhibitor, LAS17. 
Metabolomics mapping experiments indicate reduced levels of macromolecular building 
blocks and ATP in the GSTP1 inactivated samples compared to controls, suggesting a role 
in the regulation of glycolysis and signaling. However, we recognize there may be other, 
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additional mechanism involved that are consistent with the metabolomic changes observed 
that remain unexplored in this study.  
FLAG-GSTP1 pulldown proteomics experiments revealed glycolytic enzyme 
GAPDH as a protein-protein binding partner with GSTP1. In a study of GAPDH activity, 
we observed a dramatic increase in GAPDH activity in the presence of GSTP1. When 
GSTP1 is pretreated with LAS17, GAPDH activity is enhanced to a lesser degree. While 
we recognize the activation of GAPDH is only modestly reduced by LAS17 treatment, it 
is possible that in the context of a cell there are additional underlying mechanisms that are 
involved in GSTP1 correlated activation of GAPDH. GAPDH catalyzes the 
interconversion of glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate through the 
addition or removal of an inorganic phosphate group with one equivalent of NADH or 
NAD+ in the reverse. GAPDH activity was shown to be insensitive to LAS17 treatment. 
Future interests lie in understanding and characterizing the mechanism by which GSTP1 
interact is with GAPDH on the molecular level. 
Additionally, we show inactivation of GSTP1 results in impaired oncogenic 
signaling as suggested by the metabolomic studies. GSTP1 inactivation leads to the 
increase of active p-AMPK which results in impaired breast cancer pathogenicity. 
Furthermore, we show GSTP1 inactivation leads to the increase of inactive p-ACC, 
consistent with the observed decrease in AC levels. 
These data together suggest GSTP1 as a novel target, uniquely to TNBC over other 
forms of breast cancer. Our studies of GSTP1 inhibition, namely GSPT1 inactivation by 
LAS17, suggest GSTP1 inhibitors can be used as a stand-alone treatment for TNBC. These 
findings can be attributed to the power and usefulness of activity-based chemoproteomic 
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studies in conjunction with metabolomic studies to uncover underlying pathways and 
drivers in TNBC. 
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Experimental Procedures 
 
General 
All reagents were purchased from Sigma Aldrich unless otherwise noted. All 
compounds were characterized by 1H and 13C NMR on either a Varian (Palo Alto, CA) 500 
MHz or 600 MHz spectrometer. Chemical shifts (δ) are reported in parts per million (ppm) 
with chemical shifts referenced to internal standards: CDCl3 (7.26 ppm for 1H, 77.8 ppm 
for 13C). Coupling constants (J) are reported in Hertz (Hz) and multiplicities are 
abbreviated as singlet (s), broad singlet (bs), doublet (d), triplet (t), pentet (p), multiplet 
(m), doublet of doublets (dd), and doublet of triplets (dt). High resolution mass spectra 
(HRMS) were obtained at the Mass Spectrometry Facility at Boston College (Chestnut 
Hill, MA). Analytical thin layer chromatography (TLC) was performed on Sorbent 
Technologies Silica G TLC Plates w/UV354 (0.25 mm). All compounds were visualized 
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on TLC by UV and/or KMnO4 staining. Column chromatography was carried out using 
forced flow of indicated solvent on Sorbent Technology Standard Grade Silica Gel, 40-63 
µm particle size, 60 Å pore size (Sorbent Technologies). PBS buffer, DMEM/High glucose 
media, and penicillin streptomycin (Pen/Strep) were purchased from Thermo Scientific 
(Waltham, MA). Primers were ordered from Eurofins MWG Operon (Hunstville, AL), and 
sequencing was performed by Genewiz (Cambridge, MA). 
 
Synthesis of 1-methyl-4-(pent-4-yn-1-ylsulfonyl)benzene (2) 
To an oven dried flask equipped with a stir bar, 4-pentyn-1-ol (11.8 mmol, 1.0 eq.), 
triethylamine (TEA) (23 mmol, 1.95 eq.), and dichloromethane (DCM) (33 mL) was added 
under N2. The resulting solution was cooled to 0 ° C using an ice bath. Next, the 4-
toluenesulfonyl chloride (12.5 mmol, 1.06 eq.) was added in one portion. The reaction 
vessel was purged with N2 and allowed to slowly warm to 22 ° C. The reaction was 
quenched after 12 hrs with water (20 mL) and extracted with DCM (3 X 20 mL). The 
combined organic layers were dried over sodium sulfate (Na2SO4) and then concentrated 
in vacuo. The crude oil was purified by silica column chromatography (9:1, Hexanes 
(Hex):Ethylacetate (EtOAc)). The product was isolated as a clear oil (83 %). 1H NMR (500 
MHz, CDCl3) δ 7.80 (d, J = 8.3 Hz, 2H), 7.35 (dd, J = 8.7, 0.7 Hz, 2H), 4.15 (t, J = 6.1 Hz, 
2H), 2.45 (d, J = 0.7 Hz, 3H), 2.26 (td, J = 6.9, 2.7 Hz, 2H), 1.88 (t, J = 2.6 Hz, 1H), 1.88-
1.83 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 144.9, 133.1, 130.0, 128.1, 82.24, 77.16, 
69.56, 68.85, 27.87, 21.78, 14.84. HRMS m/z calculated for C12H14O2S [M+H]+: 239.0664. 
Found: 239.0739.  
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Synthesis of methyl pent-4-yn-1-yl-L-leucinate (3) 
To an oven dried flask equipped with a stir bar and reflux condenser, methyl L-
leucinate hydrochloride (0.95 mmol 1.0 eq.), sodium iodide (0.47 mmol, 0.5 eq.), and 
potassium carbonate (2.37 mmol, 2.5 eq.) in acetonitrile (ACN) (1.6 mL) was added under 
N2. The resulting mixture was allowed to heat to 90 °C and stirred for 1 hr before the drop-
wise addition of tosylated alcohol (1) (1.04 mmol, 1.1 eq.). The reaction was allowed to 
mix for 12 hrs before being cooled and diluted with DCM. The suspension was filtered to 
remove solid precipitate. The remaining supernatant was concentrated in vacuo. The crude 
oil was purified by silica column chromatography (9:1–1:1 Hex:EtOAc) after dry loading. 
The product was isolated as a clear oil (36% yield). 1H NMR (500 MHz, CDCl3) δ 3.72 (d, 
J = 1.4, 3H), 3.33 – 3.24 (m, 1H), 2.77 – 2.65 (m, 1H), 2.53 (dt, J = 12.71, 7.10, 1H), 2.26 
(td, J = 7.5, 7.1, 2.4, 2H), 1.93 (dt, J = 4.2, 1.8, 1H), 1.79 – 1.61 (m, 3H), 1.46 (tt, J = 7.4, 
1.7, 2H), 0.91 (ddd, J = 11.9, 6.6, 1.3 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 176.7, 84.20, 
77.16, 68.57, 60.10, 51.72, 46.98, 42.97, 29.06, 25.07, 22.84, 22.46, 16.30. 
 
Synthesis of methyl N-(4,6-dichloro-1,3,5-triazin-2-yl)-N-(pent-4-yn-1-yl)-L-leucinate 
(LAS17) (4) 
To an oven dried flask equipped with a stir bar was added, cyanuric chloride (0.211 
mmol, 1 eq.) and tetrahydrofuran (THF) (6 mL), under N2. Diisopropylethylamine (DIEA) 
(0.222 mmol, 1.05 eq.) and (2) (0.211 mmol, 1 eq.) were dissolved in THF (8 mL) and the 
resulting solution was added drop-wise to the cyanuric chloride solution. The reaction 
vessel was purged with N2. The resulting mixture was allowed to cool to 0 °C in an ice 
bath. The reaction was allowed to warm to 22 °C over 12 hrs while stirring. The crude 
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product was purified by silica column chromatography (1:1 DCM:Hex–DCM). The 
product was isolated as a yellow-white solid (52% yield). 1H NMR (600 MHz, CDCl3) δ 
5.16 (dd, J = 10.0, 4.8, 1H), 3.79 (ddd, J = 14.1, 10.5, 5.2, 1H), 3.73 (s, 3H), 3.41 (ddd, J 
= 14.1, 10.5, 5.4, 1H), 2.32 (dtd, J = 16.4, 6.7, 2.7, 1H), 2.25 (dddd, J = 17.0, 7.7, 6.2, 2.7, 
1H), 2.01 (t, J = 2.7, 1H), 2.00 – 1.90 (m, 2H), 1.88 – 1.74 (m, 2H). 13C NMR (151 MHz, 
CDCl3) δ 171.4, 170.7, 170.1, 165.8, 83.28, 69.74, 58.55, 52.96, 46.45, 38.28, 30.07, 26.51, 
25.21, 23.42, 22.09, 16.50. HRMS m/z calculated for C15H20Cl2N4O2 [M+H]+: 359.0963. 
Found 359.1047. 
 
LAS1-LAS16, LAS18-LAS20 were synthesized following a similar general protocol as 
detailed here for LAS17. 
 
Evaluating Protein Labeling in HeLa Cell Lysates 
HeLa cells were grown in complete DMEM media with FBS, penicillin, and 
streptomycin on 20 cm cell culture plates. Cells were harvested and sonicated to lyse to 
form whole cell lysates. These lysates were separated by centrifugation at 45,000 rpm for 
45 min at 4 °C to yield soluble and membrane proteins. The supernatant was collected and 
the pellet was discarded. Protein concentrations for soluble lysates were determined using 
a standard Bradford Assay (Bio-Rad DC Protein Assay). HeLa soluble protein lysates (50 
µL, 2 mg/mL) were pretreated with probe (1 µM, 50X stock in DMSO) at RT for 1 hr. 
Samples then underwent click chemistry with TAMRA-azide (Lumiprobe, 25 µM, 50X 
stock in DMSO), TCEP (1 mM, 50X fresh stock in water), TBTA ligand (100 µM, 17X 
stock in DMSO:t-butanol = 1:4), and copper(II) sulfate (1 mM, 50X stock in water) 
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followed by incubation at RT for 1 hr. SDS-PAGE loading buffer 2X (reducing, 50 µL) 
was added to the samples and 25 µL of this solution was separated by SDS-PAGE at 100 
volts for 130 minutes on a 10% polyacrylamide gel. Gels were visualized on a Hitachi 
FMBIO II multiview flatbed laser-induced fluorescent scanner. After analysis, gels 
underwent a typical procedure for Coomassie staining and destaining. Stained gels were 
visualized on a Stratagene Eagle Eye apparatus by COHU High performance CCD camera. 
 
Protein Target Identification by LC/LC-MS/MS 
HeLa soluble protein lysates in DPBS (pH 7.4) (500 µL, 2 mg/mL) were aliquoted 
and LAS17 (1 µM) or DMSO was added to the appropriate samples. Two aliquots were 
made for each inhibitor concentration or DMSO equaling 2 tubes for one final sample. All 
samples were then treated with biotin-azide (100 µM, 50X stock in DMSO), TCEP (1 mM, 
50X fresh stock in water), TBTA ligand (100 µM, 17X stock in DMSO:t-butanol = 1:4), 
and copper(II) sulfate (1 mM, 50X stock in water) followed by incubation at 22 °C for 1 
hr. Samples were combined pairwise and centrifuged (6500 g, 4 min, 4 °C) to pellet the 
precipitated proteins. The pellets were resuspended in cold methanol by sonication and the 
two samples were combined. Centrifugation was followed by a second cold methanol 
wash, after which the pellet was solubilized in DPBS containing 1.2% SDS via sonication 
and heating (90 °C, 5 min).  
The SDS-solubilized proteome samples were diluted by 5 mL of DPBS for a final 
SDS concentration of 0.2%. The solution was incubated with 100 µL of streptavidin-
agarose beads (Thermo Scientific, washed 3X with DPBS to remove storage buffer) 
overnight at 4 °C. Samples were rotated at 22 °C for 2 hr before being washed by 5 mL 0.2 
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% SDS/DPBS, 3 X 5 mL DPBS, and 3 X 5 mL water. The beads were pelleted by 
centrifugation (1400 X g, 3 min) between washes. 
The washed beads were suspended in 500 uL of 6 M urea/DPBS and 10 mM DTT 
(from 20X stock in water) and placed in a 65 °C heat block for 15 min. Iodoacetamide (20 
mM from 50X stock in water) was then added and the samples were allowed to react at 37 
°C for 30 min while shaking. Following reduction and alkylation, the beads were pelleted 
by centrifugation and resuspended in 200 µL of 2 M urea/DPBS, 1 mM CaCl2 (100X stock 
in water), and sequencing-grade trypsin (2 µg). The digestion was allowed to proceed 
overnight at 37 °C while shaking. The beads were pelleted by centrifugation and washed 
with 2 X 50 µL water. The washes were combined with the supernatant from the trypsin 
digestion step. Formic acid (15 µL) was added to the samples, which were stored at -20 °C 
until mass spectrometry analysis. 
LC/LC-MS/MS analysis was performed on an LTQ-Orbitrap Discovery mass 
spectrometer (ThermoFisher) coupled to an Agilent 1200 series HPLC. Peptide digests 
were pressure loaded onto a 250 µm fused silica desalting column packed with 4 cm of 
Aqua C18 reverse phase resin (Phenomenex). The peptides were eluted onto a biphasic 
column (100 µm fused silica with a 5 µ, tip, packed with 10 cm C18 and 4 cm Partisphere 
strong cation exchange resin (SCX, Whatman) using a gradient 5-100% Buffer B in Buffer 
A (Buffer A: 95% water, 5% acetonitrile, 0.1% formic acid; Buffer B: 20% water, 80% 
acetonitrile, 0.1% formic acid). The peptides were then eluted from the SCX onto the C18 
resin and into the mass spectrometer using 4 salt steps previously described.2 The flow rate 
through the column was set to ~0.25 µL/min and the spray voltage was set to 2.75 kV. One 
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full MS scan (FTMS) (400-1800 MW) was followed by 8 data dependent scans (ITMS) of 
the nth most intense ions. 
The tandem MS data were searched using the SEQUEST algorithm using a 
concatenated target/decoy variant of the human UniProt database. A static modification of 
+57.02146 on cysteine was specified to account for alkylation by iodoacetamide. 
SEQUEST output files were filtered using DTASelect. 
 
Overexpression and Purification of GSTP1 
The cDNA for WT-GSTP1 was subcloned into a pET-47b N-term His Tag 
expression vector using a forward primer (5’-CCAGGATCCGCCGCCCTACA-3’) 
containing a BamH1 restriction site and a reverse primer (5’-
AGCCTCGAGTCACTGTTTCCCG) containing a Xho1 restriction site. All constructs 
were verified by sequencing (Genewiz, Cambridge, MA). Constructs were transformed 
into BL21 competent E. coli (New England Biolabs). From an overnight LB culture with 
antibiotics at 37 °C, 5 mL were added to 500 mL LB (pH 7.0) with antibiotics and were 
grown to OD600 of 0.8. Protein expression was induced with IPTG (400 µM, 250X stock 
in water) for 5 hrs at 37 °C. Soluble cell lysates in DPBS (pH 7.4) were purified using Ni-
NTA chromatography with imidazole concentrations of 25 mM and 500 mM in DPBS (pH 
7.4) for the wash and elution steps, respectively. Purification fractions were analyzed for 
purity using SDS-PAGE. Imidazole was removed from pure protein fractions using NAP-
5 desalting columns that had been buffer exchanged with DPBS. 
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LAS17 Labeling of Purified GSTP1  
Purified GSTP1 (50 µL, 0.2 mg/mL) was pretreated with LAS17 (50 nM, 50X stock 
in DMSO) at 22 °C for 1 hr. Samples then underwent click chemistry with TAMRA-azide 
(Lumiprobe, 25 µM, 50X stock in DMSO), TCEP (1 mM, 50X fresh stock in water), TBTA 
ligand (100 µM, 17X stock in DMSO:t-butanol = 1:4), and copper(II) sulfate (1 mM, 50X 
stock in water) followed by incubation at 22 °C for 1 hr. SDS-PAGE loading buffer 2X 
(reducing, 50 µL) was added to the samples and 25 µL of this solution was separated by 
SDS-PAGE at 100 volts for 145 minutes on a 12% polyacrylamide gel. Gels were 
visualized on a Bio-Rad ChemiDoc MP Imaging System using the rhodamine setting. After 
analysis, gels underwent a typical procedure for Coomassie staining and destaining. 
Stained gels were visualized on a Bio-Rad ChemiDoc MP Imaging System. 
 
Intact-protein MS Analysis 
Purified GSTP1 (50 µL, 0.2 mg/mL) was pretreated with DMSO or probe (30 µM, 
50X stock in DMSO) at 22 °C for 1 hr. Samples were centrifuged at 13,000 rpm for 5 min 
at RT to remove any insoluble particles. Samples were diluted by half in water and analyzed 
by LC/MS. 10 µL samples were injected onto a Aeris WIDEPORE 3.6u XB-C18 using an 
Agilent 1260 Infinity and were analyzed by an Agilent 6230 TOF Mass Spectrometer. Peak 
masses were extracted using Agilent MassHunter Qualitative Analysis B.06.00 software. 
Deconvolution software MagTran was used to determine the mass of the protein from the 
peak lists generated by mMass software. 
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Evaluating the Site of Modification 
100 µg of GSTP1 in DPBS was treated with DMSO or LAS17 (10 µM, 50X stock 
in DMSO) for 1 hr at 22 °C. Protein was precipitated by addition of 100% trichloroacetic 
acid in PBS and incubated at -80 °C overnight. Thawed samples were centrifuged at 15K 
for 10 min at 22 °C and the supernatant was discarded. The remaining protein pellet was 
washed with 500 µL of cold acetone, vortexed to resuspend the pellet and centrifuged at 
15K for 10 min at 22 °C. The supernatant was again discarded and the pellet was allowed 
to air dry until trace amounts of acetone were gone. The pellet was resuspended in 30 µL 
of 8M urea in PBS, then 70 µL 100 mM ammonium bicarbonate in PBS and 1.5 µL of 1 M 
DTT in PBS were added. Samples were incubated at 65 °C for 15 minutes. Samples were 
alkylated for 30 minutes at room temperature with the addition of 2.5 µL of 500 mM 
iodoacetamide in PBS. Sample volume was increase to 224 µL by addition of 120 µL PBS, 
then 2 µg of sequencing-grade trypsin (Promega) and 2.5 µL of 100 mM CaCl2 was added. 
Samples were agitated over night at 37 °C. Then trypsin was quenched with 10 µL of 
formic acid (~5% of final volume) and were centrifuged at 15K for 20 minutes at room 
temperature to pellet undigested protein. Supernatant was transferred to a new tube and 
stored at -20 °C. Samples were analyzed by LC-MS/MS using a LTQ Orbitrap XL mass 
spectrometer (ThermoFisher) coupled to an EASY-nLC 1000 nanoLC (ThermoFisher). 10 
µL of peptide digests were loaded onto 100 µm fused silica column with a 5 µm tip packed 
with 10 cm of Aqua C18 reverse phase resin (Phenomenex) using the EASY-nLC 1000 
autosampler. The digests were eluted using a gradient 0-100% Buffer B in Buffer A (Buffer 
A: 95% water, 5% acetonitrile, 0.1% formic acid; Buffer B; 20% water, 80% acetonitrile, 
0.1% formic acid). The flow rate through the column was set to 400 nL/min and the spray 
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voltage was set to 3.5 kV. One full MS scan (FTMS) (400-1800 MW) was followed by 7 
data dependent scans (ITMS) of the nth most intense ion with dynamic exclusion. The 
tandem MS data were searched using the SEQUEST algorithm using a concatenated 
target/decoy variant of the human IPI databases. A static modification of +57.02146 on 
cysteine was specified to account for iodoacetamide alkylation and differential 
modification of +322.12 (LAS17) were specified on tyrosine to account for probe 
modification. Modification searches on cysteine and lysine confirmed cysteine and lysine 
residues were not modified by LAS17. SEQUEST output files were filtered using 
DTASelect 2.0. 
 
Verification of the Site of Labeling  
Purified GSTP1 tyrosine mutants (50 µL, 0.2 mg/mL) or lysine mutants (50 µL, 0.5 
mg/mL) were pretreated with LAS17 (50 µM, 50X stock in DMSO) at 22 °C for 1 hr. 
Samples then underwent click chemistry with TAMRA-azide (Lumiprobe, 25 µM, 50X 
stock in DMSO), TCEP (1 mM, 50X fresh stock in water), TBTA ligand (100 µM, 17X 
stock in DMSO:t-butanol = 1:4), and copper(II) sulfate (1 mM, 50X stock in water) 
followed by incubation at RT for 1 hr. SDS-PAGE loading buffer 2X (reducing, 50 µL) 
was added to the samples and 25 µL of this solution was separated by SDS-PAGE at 100 
volts for 145 minutes on a 12% polyacrylamide gel. Gels were visualized on a Bio-Rad 
ChemiDoc MP Imaging System using the rhodamine setting. After analysis, gels 
underwent a typical procedure for Coomassie staining and destaining. Stained gels were 
visualized on a Bio-Rad ChemiDoc MP Imaging System. 
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GSTP1 Mutants 
To verify the site of modification identified by mass spectrometry, tyrosine 108 was 
mutated to phenylalanine using an adopted QuikChange lightening MSDS protocol. 
(primer:  5’-
CCCTCATCTTCACCAACTATGAGGCGGGCAAGGATGACTATGTGAAGGCACT
GCC -3’).  
To confirm LAS17 was not modifying any of the lysine residues on GSTP1 we 
used the QuikChange Kit (Agilent Technologies, Santa Clara, California) to mutate each 
of the lysine residues to alanine. 
Primers: 
K30A Forward: 
5’-GAGCTGGGCGGAGGAGGTGGTGACCGTGGAGACGTGGC-3’ 
K30A Reverse: 
5’-CCTCCTCCGCCCAGCTCTGGCCCTGATCTGCCAGCAG-3’ 
K45A Forward: 
5’-CTCACTCGCAGCCTCCTGCCTATACGGGCAGCTCCCC-3’ 
K45A Reverse: 
5’-GAGGCTGCGAGTGAGCCCTCCTGCCACGTCTCCACG-3’ 
K55A Forward: 
5’-GCTCCCCGCGTTCCAGGACGGAGACCTCACCCTG-3’ 
K55A Reverse: 
5’-CCTGGAACGCGGGGAGCTGCCCGTATAGGCAGGAGG-3’ 
K82A Forward: 
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5’-CTATGGGGCGGACCAGCAGGAGGCAGCCCTGGTG-3’ 
K82A Reverse: 
5’-GGCCGCACCCTTGGGCTCTATGGGGCGGACCAG-3’ 
K103A Forward: 
5’-GGCGTGGAGGACCTCCGCTGCGCATACGTCTCCC-3’ 
K103A Reverse: 
5’-GCCCGCCTCATAGTTGGTGTAGATGAGGGAGCGTATGCGCAGCG-3’ 
K116A Forward: 
5’-GAGGCGGGCGCGCGGATGACTATGTGAAGGCACTGCCCGG-3’ 
K116A Reverse: 
5’-
GTCATCCGCGCCCGCCTCATAGTTGGTGTAGATGAGGGAGACGTATTTGCAG
CGG-3’ 
K121A Forward: 
5’-GACTATGTGGAGGCACTGCCCGGGCAACTGAAGCC-3’ 
K121A Reverse: 
5’-
CAGTGCCTCCACATAGTCATCCTTGCCCGCCTCATAGTTGGTGTAGATGAGGG
-3’ 
K128A Forward: 
5’-GCCCGGGCAACTGGCGCCTTTTGAGACCCTGC-3’ 
K128A Reverse: 
5’-GCAGGGTCTCAAAAGGCGCCAGTTGCCCGGGC-3’ 
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K141A Forward: 
5’-CCAGGGAGGCGCGACCTTCATTGTGGGAGACCAGATCTCCTTCG-3’ 
K141A Reverse: 
5’-GAAGGTCGCGCCTCCCTGGTTCTGGGACAGCAGGG-3’ 
K189A Forward: 
5’-CGGCCCGCGCTCAAGGCCTTCCTGGCCTCCC-3’ 
K189A Reverse: 
5’-CCTTGAGCGCGGGCCGGGCGCTGAGGCG-3’ 
K191A Forward: 
5’-CCAAGCTCAAGGCCTTCCTGGCCTCCCCTGAGTACG-3’ 
K191A Reverse: 
5’-GAAGGCCGCGAGCTTGGGCCGGGCACTGAGG-3’ 
K209A Forward: 
5’-CCTCCCCATCAATGGCAACGGGGCACAGTGACTCGAGGC-3’ 
K209A Reverse: 
5’-CGAGTCACTGTGCCCCGTTGCCATTGATGGGGAGGTTCACGTACTC-
3’ 
 
GSTP1 Activity Assay 
Purified recombinant GSTP1 was diluted to 0.02 mg/mL in Assay Buffer (100 mM 
NaH2PO4, pH 7.0). Samples were then incubated with LAS17 or DMSO for varying time 
points. A prepared stock of 250 mM L-Glutathione, reduced (GSH) substrate in water was 
diluted to 4 mM in Assay Buffer. Equal volumes of treated GSTP1 (25 µL) and GSH (25 
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µL, 4mM) were combined to afford final GSTP1 concentrations of 0.01 mg/mL and GSH 
concentrations of 2 mM . A substrate stock solution of 75 mM 1-bromo-2,4-dinitrobenzene 
(BDNB) in ethanol was diluted to 2 mM in Assay buffer. 50 µL of GSTP1/GSH mixture 
was aliquoted into wells of a 96 well plate (Costar, Catalog # 3595). The reaction (Scheme 
1-2) was started by adding 50 µL of the 2 mM BDNB in Assay Buffer to each well. 
Reaction was monitored by kinetic mode for 5 minutes at an absorbance of 340 nm.  
 
Scheme 1-2. Activity assay monitors the GSTP1 catalyzed conjugation of GSH to BDNB. 
 
The following experimental procedures are from Louie, S.M., Grossman, E.A., Crawford, 
L.A., Ding, L., Camarda, R., Huffman, T.R., Miyamoto, D.K., Goga, A., Weerapana, E. 
and Nomura, D.K. 2016. GSTP1 Is a Driver of Triple-Negative Breast Cancer Cell 
Metabolism and Pathogenicity. Cell Chemical Biology. 23, 5, 567–578. 
 
Cell Culture 
The 231MFP cells were obtained from Prof. Benjamin Cravatt and were generated 
from explanted tumor xenografts of MDA-MB-231 cells. MCF7, MCF10A, T47D, ZR751, 
MDA-MB-361, HCC1143, HCC38, HCC70, MDA-MB-468, and HEK293T cells were 
obtained from the American Type Culture Collection. HEK293T cells were cultured in 
DMEM containing 10% (v/v) fetal bovine serum (FBS) and maintained at 37 C with 5% 
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CO2. 231MFP, MDA-MB-361, and MDA-MB 468 cells were cultured in L15 medium 
containing 10% FBS and maintained at 37 C with 0% CO2. MCF10A cells were cultured 
in DMEM/ F12K medium containing 5% horse serum, 20 ng/mL epidermal growth factor, 
100 ng/mL cholera toxin, 10 ng/mL insulin, and 500 ng/mL hydrocortisone, and 
maintained at 37 C with 5% CO2. MCF7, T47D, ZR751, HCC1143, HCC38, and HCC70 
cells were cultured in RPMI medium containing 10% FBS and maintained at 37 C with 5% 
CO2. 
 
Lysine Reactivity Profiling 
Cells were washed with PBS and harvested by scraping. 1 mg of protein was 
incubated with 10 µM dichlorotriazine-alkyne, RB7, for 30 min at room temperature. 
Following incubation, biotin-azide, TCEP, TBTA ligand, and Cu(II)SO4 were added and 
incubated for an additional hour at room temperature. Following incubation, the mixture 
was subject to centrifugation at 6500 X g for 4 minutes. The supernatant was removed and 
500 µL of ice cold methanol was added to each tube. Solubilized protein was centrifuged 
at 6500 X g for 4 minutes at 4 °C and supernatant was removed. Pellet was washed again 
with 500 µL of ice cold methanol and subject to centrifugation once more. The supernatant 
was removed and 1 mL of 1.2% SDS/PBS (w/v) was added until pellet was resolubilized. 
Mixture was heated at 90 °C for 5 minutes, then centrifuged for 5 minutes at 6500 X g. The 
1 mL sample was then added to 5 mL of PBS. Avidin-agarose beads (Thermo Scientific) 
were washed with PBS and 170 µL of the bead slurry was added to each sample that was 
subsequently rotated overnight at 4 °C. Samples were then warmed on a rotator at room 
temperature the following day and subject to centrifugation at 1400 X g for 3 minutes. The 
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supernatant was removed and the beads were washed with 5 mL of 0.2% SDS/PBS (w/v), 
then subject to centrifugation at 1400 X g for 3 minutes. Beads were then transferred to 
Micro Bio-Spin columns (BioRad) and washed three times with PBS, followed by three 
times with water. The washed beads were then transferred to 500 µL of 6 M urea. 25 µL of 
195 mM DTT was added to each sample, which was then incubated at 65 °C for 20 minutes. 
Tubes were cooled to room temperature before adding 25 µL of 400mM iodoacetamide 
solution, then incubated at 37 °C for 30 minutes. The reaction was diluted by adding 950 
µL of PBS, then centrifuged at 1400 X g for 2 minutes, after which the supernatant was 
removed. 200 µL of 2 M urea and 0.5 µg/µL of Sequencing Grade Trypsin (Promega) were 
added and samples were incubated overnight at 37°C. Beads were centrifuged at 1400 x g 
for 3 minutes. Supernatant was added into a Micro Bio-Spin column to elute tryptic 
peptides while filtering out beads. Samples were acidified and stored at -80 °C until they 
were ready for proteomic analysis. Tryptic digests were analyzed using a Thermo LTQ-
XL and quantified by spectral counting. 
 
Evaluation of GSTP1 Expression in Pre-cancerous, Non-TNBC, and TNBC Cells 
qPCR was performed using the manufacturer’s protocol for Fisher Maxima SYBR 
Green with 10 mM primer concentrations or for Bio-Rad SsoAdvanced Universal Probes 
Supermix. Primer sequences for Fisher Maxima SYBR Green were derived from Primer 
Bank. Primer sequences for Bio-Rad SsoAdvanced Universal Probes Supermix were 
designed with Primer 3 Plus. 
 
 
 70 
General Western Blotting Protocol 
E-cadherin antibody was obtained from BD Biosciences. Vimentin antibody was 
obtained from Sigma. Antibodies to cyclophilin, GSTP1, b-actin, phospho-AMPK a 
(Thr172), AMPK a, phospho-ACC (Ser79), ACC, phospho-S6, total S6, phospho-JNK 
(Thr183/Tyr185), JNK, and GAPDH were obtained from Cell Signaling Technology. 
FLAG antibody was obtained from Cayman Chemicals. 
Cells were lysed in lysis buffer (CST) containing both protease and phosphatase 
inhibitors. Proteins were resolved by electrophoresis on 4%–15% Tris-glycine precast 
Mini-PROTEAN TGX gel (Bio-Rad) and transferred to nitrocellulose membranes using 
the iBlot system (Invitrogen). Blots were blocked with 5% nonfat milk in Tris-buffered 
saline containing Tween 20 (TBST) solution for 1 hr at room temperature, washed in 
TBST, and probed with primary antibody diluted in recommended diluent per 
manufacturer over- night at 4 °C. Following washes with TBST, the blots were incubated 
in the dark with an IR-linked secondary antibody at room temperature for 1 hr. Blots were 
visualized using an Odyssey Li-Cor scanner after additional washes. 
 
Constructing GSTP1 Knockdown Cell Lines 
We used two independent short-hairpin oligonucleotides to knock down the 
expression of GSTP1 and one short-hairpin oligonucleotide to knock down the expression 
of CDH1 using previously described methods.116For generation of stable shRNA lines, 
lentiviral plasmids in the pLKO.1 backbone containing shRNA (Sigma) against human 
GSTP1 were transfected into HEK293T cells using Fugene (Roche). Lentivirus was 
collected from filtered cultured medium and used to infect the target cancer cell line with 
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Polybrene. Target cells were selected over 3 days with 1 mg/mL puromycin. The short-
hairpin sequences used for generation of the GSTP1 knockdown lines were: 
shGSTP1-1, 
CCGGCGCTGACTACAACCTGCTGGACTCGAGTCCAGCAGGTTGTAGTCAGCG
TTTTTG;  
shGSTP1-2, 
CCGGCCTCACCCTGTACCAGTCCAACTCGAGTTGGACTGGTACAGGGTGAGG
TTTTTG. 
The short-hairpin sequence used for generation of the CDH1 knockdown line was 
CCGGAGAAGGGTCTGTTCACGTATTCTCGAGAATACGTGAACAGA 
CCCTTCTTTTTTG. 
The control shRNA was targeted against GFP with the target sequence 
GCAAGCTGACCCTGAAGTTCAT. Knockdown was confirmed by qPCR or western 
blotting. 
 
Cellular Phenotype Assays 
Cell proliferation, serum-free cell survival, and migration assays were performed 
in a manner similar to previously described assays.116,117Migration assays were performed 
using Transwell chambers (Corning) with 8µm pore-sized membranes coated with 
collagen. 50,000 cells were seeded into the top chamber and allowed to migrate for 24 
hours. Chambers were fixed with Diff-Quik (Dade Behring) solutions. 
Cell survival and proliferation assays were performed using the WST-1 reagent 
(Roche) for the MCF7 cell line. Cells were seeded in a 96-well plate with a volume of 200 
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µL serum-free media for survival and serum-containing media for proliferation (20,000 
cells for survival and 10,000 cells for proliferation). WST-1 reagent was added to each well 
and incubated at 37 °C for 30 minutes before measuring absorbance. Cell survival measures 
cell death under serum-free and non-proliferative conditions, whereas cell proliferation 
assays are performed in the presence of serum and measures proliferation of cells. 
Cell survival and proliferation assays for the 231MFP cells were performed using 
Hoechst 33342 dye (Invitrogen) according to manufacturer’s protocol. Briefly, cells were 
seeded into 96-well plates (40,000 for survival and 20,000 for proliferation) in a volume 
of 200 µL and allowed to adhere overnight. Medium was removed from each well and 100 
µL of staining solution containing 10% formalin and Hoechst 33342 dye was added to each 
well and incubated for 15 minutes in the dark at room temperature. After incubation, 
staining solution was removed and wells were washed twice with PBS before imaging. 
Cell survival assays were also performed using Hoechst 33342 dye for the HCC38, 
HCC70, and HCC1143 cell lines with the exception of HCC38 shGSTP1 cells that were 
performed using the WST-1 reagent. Cell survival assays using Hoechst 33342 were 
performed as described above. Cell survival assay for HCC38 shGSTP1 cells was 
performed with WST-1 reagent as described above. 
 
Tumor Xenograft Studies 
Human tumor xenografts were established by transplanting cancer cells ectopically 
into the flank of C.B17 severe combined immunodeficiency (SCID) mice (Taconic Farms) 
as previously described. 118 In brief, cells were washed twice with PBS, trypsinized, and 
harvested in serum-containing medium. Harvested cells were washed twice with serum-
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free medium and resuspended at a concentration of 2.0 X 104 cells/mL, and 100 mL was 
injected. Tumors were measured every 2 days with calipers. Animal experiments were 
conducted in accordance with the guidelines of the Institutional Animal Care and Use 
Committees of the University of California, Berkeley. 
 
GSTP1 Activity Assay 
The IC50 of LAS17 was determined using a GSTP1 activity assay. 1-Chloro-2,4-
dinitrobenzene (CDNB) was incubated with 200 mM reduced glutathione and 1 mg of 
active GSTP1 protein with 100, 10, 1, 0.1, 0.01, 0.001, and 0 mM LAS17. GSTP1 catalyzes 
the conjugation of glutathione to CDNB, generating the reaction product glutathione-DNB 
conjugate, which absorbs at 340 nm. The rate of increase in the absorption of the product 
is proportional to GSTP1 activity and was used to measure GSTP1 activity. 
 
Metabolomic Profiling of Cancer Cells 
Metabolomic analyses were conducted using previously described 
methods.116,117,119–121Briefly, 2 million cells were plated overnight, serum starved for 2 
hours prior to harvesting, after which cells were washed twice with PBS, harvested by 
scraping, and flash frozen. 
For nonpolar metabolomic analyses, flash frozen cell pellets were extracted in 4 
mL of 2:1:1 chloroform/methanol/PBS with internal standards dodecylglycerol (10 
nmoles) and pentadecanoic acid (10 nmoles). Organic and aqueous layers were separated 
by centrifugation, and organic layer was extracted. Aqueous layer was acidified with 0.1% 
formic acid followed by re-extraction with 2 mL chloroform. The second organic layer was 
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combined with the first extract and dried under nitrogen, after which lipids were 
resuspended in chloroform (120 µL). A 10 µL aliquot was then analyzed by both single-
reaction monitoring (SRM)-based LC-MS/MS or untargeted LC-MS. 
For polar metabolomic analyses, frozen cell pellets were extracted in 180 µL of 
40:40:20 acetonitrile/methanol/water with internal standard d3 N15- serine (1 nmole). 
Following vortexing and bath sonication, the polar metabolite fraction (supernatant) was 
isolated by centrifugation. A 20 µL aliquot was then analyzed by both single-reaction 
monitoring (SRM)-based LC-MS/MS or untargeted LC-MS. 
For the SRM transitions where we monitor the transition of parent masses to the 
loss of the headgroup (e.g. loss of phosphocholine from phosphatidylcholine), we have 
ascertained the acyl chain specificities from previously described procedures.121For 
phospholipids such as PCs and PEs, we ascertained fatty acid acyl chain composition from 
phospholipids using a mobile phase containing both ammonium hydroxide and formic acid 
and monitored the fatty acid fragmentations from [M-H+HCO2H] m/z at 40 V collision 
energy in negative ionization mode. For other phospholipids such as PAs and PIs, we 
monitored the fatty acid fragmentations from [M-H] m/z at 40 V collision energy in 
negative ionization mode in mobile phase containing just ammonium hydroxide. For the 
lipids that we have measured in this study, the designated acyl chains represent the primary 
fatty acids that were on the lipid backbone. However, this method is less sensitive than 
monitoring the loss of headgroup from the phospholipid, and thus we used SRM transitions 
for many phospholipids where we monitored for loss of headgroups (e.g. PCs, PEs, PSs, 
PAs, PIs). 
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Relative levels of metabolites were quantified by integrating the area under the 
curve for each metabolite, normalizing to internal standard values, and then normalizing to 
the average values of the control groups. 
 
Lactic Acid Secretion 
Lactic acid secretion from L-15 medium was measured by collecting medium and 
performing a colorimetric lactic acid assay using a kit purchased from Abcam in 
accordance with the manufacturer’s protocol. 
 
Constructing FLAG-Tagged GSTP1 Cells 
GSTP1 cDNA (Dharmacon) was subcloned into the pENTR4-FLAG vector 
(Addgene). This entry vector was recombined via an attL-attR (LR) reaction into a pLenti 
CMV puro DEST vector (Addgene). For generation of the FLAG- tagged GSTP1 line, the 
lentiviral plasmid containing FLAG-GSTP1 was transfected into HEK293T cells using 
Fugene (Roche). Lentivirus was collected from filtered cultured medium and used to infect 
the target cancer cell line with Polybrene. Target cells were selected over 3 days with 1 
mg/mL puromycin. 
 
Anti-FLAG Pulldown Studies 
Pulldown studies were performed used Anti-FLAG M2 magnetic beads (Sigma) 
according to the manufacturer’s protocol. FLAG-tagged GSTP1-overexpressing and GFP-
overexpressing control cells were lysed in lysis buffer (CST), and 500 mg of lysate was 
incubated with 32 mL of anti-FLAG magnetic beads for 2 hr at 4 °C. Beads were collected 
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and washed three times with Tris-buffered saline before elution with 4% SDS (w/v) in 120 
mM Tris-HCl. Samples were heated to 95 °C for 3 min. Eluent was subsequently prepared 
for proteomic profiling with a shotgun proteomic analysis protocol as described below. 
 
Shotgun Proteomic Profiling of Anti-FLAG Pulldown 
Pulldown products were precipitated in 20% trichloroacetic acid at 80 C overnight 
and centrifuged at 10,000 X g at 4 °C for 10 min to pellet protein. Pelleted proteins were 
washed three times with 8 M urea in PBS. After solubilization, 30 ml of 0.2% 
ProteaseMAX Surfactant (Promega) was added and the resulting mixture was vortexed 
followed by the addition of 40 mL of 100 mM ammonium bicarbonate and 10 mM tris(2-
carboxyethyl)phosphine (TCEP). After 30 min, 12.5 mM iodoacetamide was added and 
allowed to react for 30 min in the dark before adding 120 mL of PBS and 1.2 mL of 1% 
ProteaseMAX Surfactant. The protein solution was vortexed, and 0.5 mg/mL sequencing-
grade trypsin (Promega) was added and allowed to react overnight at 37 °C. The peptide 
solution was then centrifuged at 10,000 X g before the supernatant was subsequently 
analyzed by LC-MS/MS. 
 
GAPDH Activity Assay 
GAPDH activity was measured using a colorimetric kit purchased from BioVision 
and performed according to the manufacturer’s protocol. Active human GSTP1 and active 
human GAPDH full-length proteins were purchased from Abcam. Proteins were co-
incubated at 37 °C for 1 hr before GAPDH activity was measured using the kit. 
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Chapter 2 
The Discovery of a Lysine-Reactive Covalent Probe for ALDOA 
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Introduction 
Lysine is an essential amino acid, and it is one of most ubiquitously incorporated 
amino acids observed in proteins. On average, the pKa of the amino side chain of a surface 
exposed lysine is ~10.4. This means at neutral pH (7.4) the vast majority of these lysine 
residues are in the protonated state, functioning to enhance protein structure and stability. 
1 The other basic amino acid residues are arginine and histidine. Protonated lysine residues 
can also participate catalytically as proton donors in acid base chemistry. Lysine residues 
buried in a protein have been found to have a perturbed pKa as much as ~5 units due to 
influences by the residue’s microenvironment or ligand binding. 2–4 These deprotonated 
lysine residues are able to function as nucleophiles in chemical reactions. 
In acid-base chemistry, lysine side chain amino groups typically act as a general 
base. One common example of this role is found in catalytic dyads and triads. Classically, 
serine proteases have been thought to contain a catalytic triad. Conversely, there is a 
proposed group of serine proteases that do not contain the essential histidine residue, rather 
function with a catalytic dyad, Ser/Lys. 5In the catalytic dyad, the lysine residue functions 
as a general base to stabilize the oxygen anion, enhancing the nucleophilicity of the serine 
side chain. One proposed example of the serine proteases containing a catalytic dyad is E. 
coli LexA repressor. 6Mutagenesis studies of LexA repressor have shown that lysine 156 
and serine 119 are essential for activity (Figure 2-1A). A catalytic Ser/Lys dyad has been 
proposed for the b-lactamase TEM1, which hydrolyzes b-lactam rings. However, 
conflicting NMR titration experiments results in controversial roles for lysine 73 (Figure 
2-1B). 
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Figure 2-1. (A) LexA repressor catalytic dyad residues (PDB:1jhf). (B) TEM1 b-lactamase 
proposed catalytic residues (PDB: 1btl). 
 
 Protein kinases have a conserved lysine residue in their catalytic domain of 
subdomain II. This residue has been found to be essential for transfer for the phosphate 
group from ATP to an amino acid side chain. 
In animals and plants class I fructose-bisphosphate aldolase (also referred to as FBP 
aldolase, FBA, aldolase, or ALDO) is one of 10 enzymes in glycolysis which is responsible 
for the conversion of glucose into pyruvate as well as the generation of ATP. Class II 
aldolase, found in fungi, bacteria, and yeast, is a metalloenzyme that uses cobalt(II) for 
direct binding to the substrate. 7 Like other lyase enzymes, in this reaction aldolase 
catalyzes a breakdown of its substrate, which in this case is D-fructose 1,6-bisphosphate. 
More specifically, aldolase catalyzes the reverse aldol condensation of D-fructose 1,6-
bisphosphate (F1,6BP) to dihydroxyacetone phosphate (DHAP) + D-glyceraldehyde 3-
phosphate (GADP) through a Schiff base mechanism (Scheme 2-1). Aldolase is a 
homotetramer and is expressed as 3 variants in vertebrates. 8,9Aldolase A (ALDOA or 
GSD12) is expressed in muscle, aldolase B (ALDOB) is expressed in the liver, and aldolase 
C (ALDOC) is expressed in the brain (Figure 2-1). BLAST 10analysis of the variants shows 
A B
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the greatest similarity between ALDOA and ALDOAC with 82% homology. The sequence 
homology between ALDOA/ALDOB and ALDOB/ALDOC is 70% for both. 
 
Scheme 2-1. ALDO catalyzes the interconversion of D-fructose 1,6-bisphosphate 
(F1,6BP) and D-glyceraldehyde 3-phosphate (GADP) + dihydroxyacetone phosphate 
(DHAP). 
 
Figure 2-1. Overlay of ALDOA (Orange, PDB: 1ALD), ALDOB (Red, PDB: 1XDM), and 
ALDOC (Tan, PDB: 1XFB) crystal structures. 
 
 Aldolase enzymes have been found to participate in protein-protein interactions, 
suggesting they have both structural and catalytic related activities. A search for 
interactions of ALDOA in the BioGRID general repository for interactions indicates 126 
unique physical interactions, of which 106 were identified in high throughput and 20 were 
identified through low throughput experiments. 11One example of ALDOA protein-protein 
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interactions is that ALDOA is known to bind actin in the cytoskeleton, however the exact 
relevance and function of this interaction is unknown. 12,13The interaction of ALDOA with 
actin is found to be reversed in cells with the addition of 2-deoxyglucose, a known substrate 
inhibitor of glycolysis. 14,15Aldolase was also found to bind a C-terminal peptide, residues 
408-451, of a-tubulin with known structural similarity to full length a-tubulin. This 
interaction was found to inhibit aldolase activity. 16 
There are multiple diseases associated with decreased aldolase activity and 
stability. Deficiency in ALDOA have been associated with Glycogen Storage Disease Type 
12 (GSD12) disease. This metabolic disorder is characterized by mutations in ALDOA 
gene that results in decreased thermal stability 17,18, reduced catalytic ALDOA activity 19, 
or reduced substrate affinity 19,20. Patients with the disease typically have hemolytic anemia 
and may have intellectual disabilities, short stature, muscle weakness and fatigue and other 
abnormal phenotypes as a result of ALDOA deficiency. 21,22 
Additionally, ALDOA activity has been linked to cancer cell metabolism. It has 
been established that cancer cells experience increased aerobic glycolysis, resulting in the 
production of large amount of ATP that fuel the progression and spread of cancer cells. 
23High levels of ATP turn off or inhibit AMPK activity, which is linked to decreased cancer 
survival and pathogenicity, serving as a regulatory mechanism. Since glycolysis is essential 
to cancer cell survival, glycolytic enzymes have been proposed as therapeutic targets for 
the treatment of the disease. Inhibition of ALDOA has been shown to break the forward 
reactions of glycolysis and shows promise in inhibiting tumor growth in vivo. 24 
Homozygous or heterozygous mutations or deletions in ALDOB that result in 
decreased ALDOB activity cause Hereditary Fructose Intolerance (HFI). Mutations or 
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deletions can result in decreased enzymatic catalytic activity 25–27, improper folding 28, and 
thermal instability 25. Typically, fructose intolerance appears when fructose is added to an 
infant’s diet. 29Patients with HFI suffer from hypoglycemia and severe abdominal 
symptoms, and with continued exposure hepatic and renal injury. Severity of the disease 
symptoms are directly correlated to patient diet. 30The disease is managed by avoiding 
foods that contain fructose. 
While there are 3 variants of ALDO, the genes for which are all found on different 
chromosomes, ALDOA has received the most attention in the literature, likely due to the 
fact that rabbit muscle aldolase is easily isolated. 31,32All three human aldolases have a 
conserved active site lysine residue (Figure 2-2). The active site, K229 makes a covalent 
Schiff-base intermediate through attack of the carbonyl carbon and subsequent loss of 
water. 33Also, each of the aldolases have a conserved active site proton acceptor, E187, that 
stabilizes the Schiff base intermediate. K229 and E187 are believed to function in a 
catalytic dyad. 34The exact mechanism for aldolase is not fully understood. For example, 
the amino acid responsible for the ring opening of D-fructose 1,6-bisphosphate is unknown, 
but is proposed to be initiated by K177 or K229. 35,36There are many proposed key amino 
acids that have been identified through mutagenesis and crystallography studies.  
 
Figure 2-2. Active site residues K229 and E187 of ALDOA (PDB: 1ALD). 
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The active site lysine, K229, of ALDOA is an interesting target for ABP given the 
many functional roles of ALDOA. Lysine residues play a variety of roles that can be both 
functional, such as active sites, or structural, participating protein-protein interactions. 
These activities contribute to the demand for lysine, an essential amino acid, to be obtained 
from the diet. The pKa of the amino group of the lysine side chain is 10.4 in water, however 
the pKa of a lysine side chain in a protein can be depressed as far as 5.3, likely due to 
influence from the surrounding protein microenvironment. 2Lysine residues can function 
as a nucleophile but also participate in acid/base chemistry. Protein kinases have a 
conserved lysine residue in the ATP-binding pocket. 37,38Lysine residues, positively 
charged at physiological pH, are often located on the surface of proteins, enhancing that 
stability of the protein. 1Human serum albumin uses its many surface lysine residues to 
bind endogenous and exogenous molecules for transport through the blood system (Figure 
2-3). 39Lysine residues are also commonly involved in post translational modifications such 
as acetylation, methylation, ubiquitination, and phosphorylation which function as a 
mechanism of cellular signaling or as a means to alter the function and activity of the 
protein. 40 
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Figure 2-3. Human serum albumin. (A) Lysine residues shown in green. (B) Cation-pi 
interaction of K199 and ring of Warfin. (PDB: 2BXD) 
 
One way to study reactive lysine residues is through the use of ABPs. While the 
biological role of lysine is vast, the number of lysine reactive electrophiles employed in 
ABPP is limited. One challenging aspect of targeting lysine residues is the additional 
presence of primary amines, protein N-terminal amines. Nonspecifically, primary amines 
in proteins can be modified by reductive alkylation with aldehydes, succinimidyl esters, 
sulfonyl chlorides, isocyanates, and thioisocyanates. 41,42Directed lysine modification has 
been demonstrated with ATP and ADP analogues broadly at the conserve lysine in protein 
kinase active sites. 43 Most recently, efforts have been directed towards modification of 
functional, but not necessarily catalytic lysine residues. One study uses a pentynoic acid 
sulfotetrafluorophenyl ester to investigate ligandable lysine residues in a proteome. 44The 
disparity between the number of nucleophilic and functional lysine residues and the 
number of selective lysine modifications motivates our interest to close the gap. Selective 
lysine ABPs will give access to studies that will increase our knowledge of the biological 
role of lysine in the proteome. More specifically, identification of an ABP and/or inhibitor 
of ALDOA will give access to understanding the underlying biological consequences of 
ALDOA inhibition in GSD12 disease and cancer and may give insight into new therapeutic 
strategies for the treatment of the diseases. 
Currently, there are known inhibitors of ALDOA (Figure 2-4). 1,2-
cyclohexanedione (CHD) is known to inhibit ALDOA activity through the modification of 
arginine residue, R55. 45CHD has been shown to modify lysine and arginine residues on 
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other proteins, thus CHD is not ideal for selective ALDOA inhibition studies. 
46,47Phosphoric acid mono-(2,3-dioxo-butyl) ester is a substrate inhibitor that was designed 
to modify the active site lysine of ALDOA. However, Phosphoric acid mono-(2,3-dioxo-
butyl) ester modifies an arginine residue in aldolase A from rabbit muscle. 48A Chemical 
library screen revealed compound TDZD-8 which modifies C239 which is located distal 
to the active site. 24TDZD-8 was used to show impaired glycolysis in MDA-MB-231 breast 
cancer cells. This list is just sampling of the known ALDOA inhibitors. 
 
 
 
 
Figure 2-4. Sampling of known ALDOA inhibitors. 
 
As mentioned in Chapter 1, our efforts to expand the current chemical tool box of 
ABPs started with inspiration from literature referencing a cysteine reactive arylhalide 
containing inhibitor of PPAR-g. 49Our investigation of the proteome reactivity of a 
dichlorotriazine electrophile revealed preferential reactivity towards lysine residues. 50Here 
we report the discovery of a dichlorotriazine containing, lysine selective small molecule 
inhibitor of ALDOA. 
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Results and Discussion 
 
Dichlorotriazine Library Synthesis and Evaluation 
See Chapter 1, Results and Discussion section on page 32. 
 
Evaluation of the dichlorotriazine library in HeLa cell soluble lysates and 
subsequent MS analysis revealed LAS17 as a selective ABP for the protein GSTP1. 
However, we desired to further characterize the protein targets of some of the additional 
dichlorotriazine library members. 
 
Identification of ALDOA as a target of LAS1, LAS6, and LAS12 
Given the desire to discover and characterize a lysine reactive ABP motivated by 
the identification of the dichlorotriazine electrophile (Chapter 1), we chose identify the 
protein targets of select dichlorotriazine containing probe library members. LAS1, LAS6, 
and LAS12 showed both individual differences and similarities in their reactivities toward 
the proteome in the in-gel fluorescence imaging studies (Figure 1-10).  
To identify the protein targets of LAS1, LAS6, and LAS12, HeLa cell lysates were 
treated with the individual probe library members (1 µM) or DMSO and were subjected to 
CuAAC with biotin-azide as previously described in Chapter 1 (Figure 1-13). To identify 
common targets of LAS1, LAS6, and LAS12, the tryptic data was filtered to include 
proteins for which there were at least three spectral counts for the probe treated samples 
and zero spectral counts in the DMSO treated sample (Table 2-1, Table 2A-1). Since 
ALDOA has an active site lysine, it is an ideal candidate to demonstrate the utility of a 
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lysine reactive ABP. For this reason, we sought to investigate the potential of a 
dichlorotriazine probe as an inhibitor of ALDOA. Instead of choosing one member of the 
dichlorotriazine library for further studies, we moved forward with a panel of probe library 
members in an effort to identify the most selective probe members in addition to the best 
inhibitor. 
 
Protein MW(Da) DMSO LAS1 LAS6* LAS12* 
HSP90AB1 Heat shock protein HSP 90-b 83264 0 26 28 21 
HSPD1 60 kDa heat shock protein, mito 61055 0 11 22 29 
HSP90AA1 Heat shock protein HSP 90-a 84660 0 20 20 18 
GSTP1 Glutathione S-transferase P 23342 0 4 24 28 
ACLY ATP-citrate synthase 120839 0 11 15 21 
PGK1 Phosphoglycerate kinase 1 44615 0 21 12 8 
EEF2 Elongation factor 2 95338 0 6 8 25 
PGAM1 Phosphoglycerate mutase 1 28804 0 9 9 14 
ALDOA Fructose-bisphosphate aldolase A 39420 0 13 5 7 
GANAB Neutral alpha-glucosidase AB 106874 0 7 7 8 
 
Table 2-1. The top 10 commonly identified proteins among LAS1, LAS6, and LAS12 
treated samples represented by number of observed spectral counts for each protein (* 
n=2). 
 
Confirmation of ALDOA as a Target of Dichlorotriazine Probes 
 To confirm the LC/LC-MS/MS findings, human ALDOA with a C-term 
hexahistidine affinity tag was recombinantly expressed in E. coli and purified to 
homogeneity. The purified protein (0.2 mg/mL) was treated with 250 nM of individual 
probe library members, conjugated with fluorophore through CuAAC, and analyzed for in-
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gel fluorescence (Figure 2-5). The results from the library screen showed that the 
fluorescence signal from LAS12, LAS15, LAS16, and LAS19 were the most intense.  
 
Figure 2-5. Labeling of purified ALDOA with dichlorotriazine library members. (A) 
Representative image of purified ALDOA (0.2 mg/mL) treated with respective probe 
library members (250 nM) analyzed by in-gel fluorescence. (B) Fluorescence intensities of 
n=3 ALDOA labeling studies. Relative fluorescence intensities were normalized to protein 
abundance (Commassie Blue) which were then normalized to LAS15, represented on each 
gel.  
 
Next, we sought to evaluate the specificity of these four probes in a complex 
background to simulate a context more similar to that of a cell. LAS12, LAS15, LAS16, 
and LAS19 were evaluated for ALDOA labeling in the context of MCF7 lysates (Figure 
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2-6). LAS 15, LAS16, and LAS19 showed labeling of exogenous ALDOA. Next, we chose 
to investigate the potential of the dichlorotriazine probes to selectively label endogenously 
expressed ALDOA, to better investigate the reactivity and selectivity in a more native 
setting. To investigate the labeling potential of LAS 15, LAS16, and LAS19 to label 
overexpressed ALDOA, ALDOA-Myc was over expressed in HEK293T cells. HEK239T 
overexpressing ALDOA-Myc soluble cell lysates were treated with LAS 15, LAS16, and 
LAS19. However, we did not see a difference in labeling intensity around the anticipated 
molecular weight of ALDOA (Figure 2-7). 
 
 
 
Figure 2-6. Labeling of purified ALDOA in MCF7 background lysates with 
dichlorotriazine library members. (A) Representative image of purified ALDOA (0.2 
mg/mL) with MCF7 background (1.0 mg/mL) treated with respective probe library 
members (250 nm) analyzed by in-gel fluorescence. (B) Fluorescence intensities of n=3 
ALDOA labeling studies. Fluorescence intensity was normalized to LAS12. 
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Figure 2-7. Labeling studies of overexpressed ALDOA-Myc in HEK293T lysates with 
LAS15, LAS16, and LAS19 (250 nM) compared to mock lysates (2.0 mg/mL). 
 
LAS9 Treatment Inhibits ALDOA Activity 
 To determine if any of the dichlorotriazine probes inhibit ALDOA activity, an in 
vitro assay was performed. In this assay the activity of ALDOA was monitored through a 
coupled assay. ALDOA converts F1,6BP to DHAP and GADP. Triosephosphate isomerase 
(TPI) catalyzes the interconversion of DHAP to GADP. GADP is then irreversibly 
converted to 1,3BPG by glyceraldehyde phosphate dehydrogenase (GAPDH) and one 
equivalent of NADH. ALDOA activity can be indirectly determined by spectroscopically 
monitoring the disappearance of NADH at 340 nm (Figure 2-8). LAS9 showed the greatest 
ability to inhibit ALDOA activity in vitro. A concentration screen of indicates LAS9 has 
an IC50 of 8.14 µM for the inhibition of ALDOA (Figure 2-9). 
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Figure 2-8. Evaluation of in vitro ALDOA activity in the presence of various 
dichlorotriazine probe library members at 1 µM, 10 µM, and 50 µM. LAS19 treatment at 
50 µM showed complete inhibition of ALDOA activity. 
 
Figure 2-9. LAS9 has an IC50 of 8.14 µM for the inhibition of ALDOA. 
 
Characterization of Dichlorotriazine Probe Site of Modification of ALDOA 
 The visualization of protein fluorescence labeling after denaturing SDS-PAGE 
confirmed that the dichlorotriazine probes modify ALDOA covalently. We sought to 
determine the site of labeling of select library members on ALDOA. This was 
accomplished using purified ALDOA as previously described in Chapter 1 (Figure 1-18). 
LAS9 was chosen for site of labeling evaluation due to the observed strong inhibitory effect 
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of ALDOA activity and apparent in vitro labeling. LAS16 was chosen because of the high 
fluorescence signal intensity observed in the gel based assays of purified ALDOA and 
ALDOA in the presence of MCF7 background lysates. However, LAS16 treatment of 
ALDOA was shown to possess negligible inhibitory capabilities. LAS8 serves as a control 
as it was shown to label ALDOA only moderately in vitro and also does not appear to 
inhibit ALDOA activity in vitro. Tryptic peptides were searched for differential masses on 
lysine, cysteine, and tyrosine residues (Table 2-2). 
 
Probe Peptide Spectral Counts Residue 
LAS8  
(K, +234.9777) 
(C, +177.0458) 
R.IVAPGK*GILAADESTGSIAK.R 5 K27 
K.VDK*GVVPLAGTNGETTTQGLDGLSER.C 2 K110 
A.SIC*QQNGIVPIVEPEILPDGDHDLKR.C 1 C177 
LAS9  
(K, +237.9777) 
H.RIVAPGK*GILAADESTGSIAK.R 1 K27 
R.IVAPGK*GILAADESTGSIAK.R 2 K27 
K.ENLK*AAQEEYVK.R 1 K321 
LAS16 
(K, +352.0939) 
K.K*ELSDIAHR.I 1 K13 
R.IVAPGK*GILAADESTGSIAK.R 3 K27 
K.GILAADESTGSIAK*R.L 1 K41 
K.GGVVGIK*VDK.G 1 K107 
K.VDK*GVVPLAGTNGETTTQGLDGLSER.C 1 K110 
K.DGADFAK*WR.C 1 K146 
K.AAQEEYVK*R.A 1 K229 
 
Table 2-2. Tryptic peptides identified to have a differential modification corresponding to 
a modification on lysine. 
 
 Site of labeling mass spectrometry studies revealed unique modification sites for 
each of the probes evaluated. LAS8 modifies K27, K110, and C177. K27 is located at the 
base of the active site beta-sheet barrel in a flexible loop that could potentially participate 
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in acid-base chemistry of ALDOA catalysis. K110 is located on a flexible loop at the 
opening of the active site binding pocket. K110 has been found to be modified as acetylated 
lysine. The effects of this modification on ALDOA activity are unclear. 51C177 is located 
on the surface of ALDOA, and is distal to the active site binding pocket opening. LAS9 
modifies K27, and K321. K321 has also been found to be acetylated. Mutagenesis studies 
of K to Q simulates acetylation in K321Q, resulting in a significant increase in activity for 
K321Q over WT ALDOA. LAS16 modifies the most resides out of all the probes analyzed 
for site of modification, K13, K27, K41, K107, K110, K146, and K229. However, LAS16 
is the only probe library member shown to modify the active site lysine, K229 (Figure 2-
10). K13 is located on an alpha-helix near the N-term region. K41 is located at the base of 
the active site binding pocket on an alpha-helix. Data suggests K41 interacts with the 
negatively charged 6-phosphate on the F1,6BP substrates. 33K107 is located on a beta-sheet 
at the opening of the active site binding pocket. The presence of positively charges lysine 
residues (K107 and K110) at the opening of the active site may function to attract 
negatively charges molecules into the active site binding pocket of ALDOA. K146 is 
located on one of the eight beta-sheets that make up the active site binding domain, and it 
located very close to active site residue, K229. Data suggests K146 interacts with the 
negatively charges 1-phosphate of F1,6BP. 33Conflicting reports suggest K107 is involved 
in phosphate binding and K149 plays an essential role in carbon-carbon bond 
breaking/formation, cleavage and condensation of the C3-C4 bond of F1,6BP. 52K229 is 
the active site nucleophile of ALDOA and is located on a beta-sheet in the active site 
binding pocket proximal to E187, the catalytic acidic residue.  
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Figure 2-10. Fragmentation (MS/MS) spectra of the AAQEEYVK peptide of ALDOA 
confirming that the LAS16 modification (+352.0939 Da) is present on K229, which is 
indicated with *. 
 
 This data together suggests LAS8, LAS9, and LAS16 have different modes of 
action on ALDOA. First, LAS9 was the only probe library member to exhibit significant 
inhibition of ALDOA activity. LAS9 was the only probe evaluated that modifies K321, 
which is known to be a site of regulatory acetylation. The unique selectivity for K321 may 
explain the apparent inhibitory effect of LAS9. On the other hand, LAS16 was among the 
probe library members to label ALDOA with the highest intensity, as determined by in-gel 
fluorescence (Figure 2-5). Site of labeling studies of LAS16 treated ALDOA indicate the 
highest number of unique side chains modifications, compared to LAS8 and LAS9. This 
suggests the promiscuity of LAS16 labeling of ALDOA contributes to the intense 
fluorescence signal. 
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It is important to note the number of spectral counts from this data set are of low 
confidence. Additional optimization of the protocol and additional technical replicates will 
improve the significance of the findings mentioned above. 
 
Future Work 
 While the work in this chapter leads to the discovery of a covalent irreversible 
inhibitor of ALDOA, there is opportunity to expand on the findings with future 
experiments. One such study is the confirm site of labeling studies through mutagenesis. 
Fluorescence-based gel experiments of ALDOA mutants corresponding to the identified 
sites of labeling for the probe library members will confirm the mass spectrometry based 
findings. Furthermore, activity assays with the mutants will give insight into the role of the 
residue in the catalytic mechanism. 
Since the activity assay performed is an indirect assessment of ALDOA activity, 
this is a potential area for improvement. A more direct, and therefore ideal way to assess 
ALDOA activity would be to monitor the conversion of F1,3BP to DHAP and GADP. This 
can be accomplished using mass spectrometry with the use of an internal standard to 
quantify amounts of F1,3BP and chemically sequester the products of ALDOA through a 
non-reversible reaction to disfavor ALDOA reverse activity based on Le Chatelier’s 
principle. 
 To fully understand the potential utility of the dichlorotriazine library it would be 
beneficial to understand the in situ reactivity and selectivity of the probe members. So far, 
the dichlorotriazine library has been screened in HeLa cell lysates. It would be beneficial 
to investigate the reactivity of the library in additional cell types. We anticipate the proteins 
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targeted by the library member to vary among cell type given the inherent variability in 
protein expression, activity, and functional state. Additionally, we can investigate 
additional protein targets of the dichlorotriazine probe library that utilized active site lysine 
residues.  
 
Conclusions 
 In summary, we report the discover and characterization of LAS9, a lysine and 
cysteine reactive irreversible inhibitor of human ALDOA. Additionally, we report the 
discovery and characterization of LAS16, a lysine selective, yet not site selective, probe 
for human ALDOA, that modifies the active site lysine, K229.  
The site of labeling data in conjunction with the inhibition studies suggests K321 
plays a role in the mechanism or activity of ALDOA. Since K321 is located distal to the 
active site it is possible that K321 modification by LAS9 results in allosteric inhibition of 
ALDOA. 
 Additional significance of K321 modification is linked to the known regulatory 
mechanism of acetylation. Histone deacetylases (HDACs) and histone acetyl transferases 
(HATs) are known to regulate protein acetylation. NAD-dependent HDAC, Sirtuin 2 
(SIRT2) was found to regulate acetylation of ALDOA. 51SIRT2 knockdown cell lines show 
hyperacylation of K321 and K110 of ALDOA. Mutagenesis studies show a correlation 
between ALDOA acylation and activity. The observed site selectivity of LAS9 suggest it 
can potentially be used to probe the state of K321 modification in acetylation studies. 
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Experimental Procedures 
 
General 
All reagents were purchased from Sigma Aldrich unless otherwise noted. All 
compounds were characterized by 1H and 13C NMR on either a Varian (Palo Alto, CA) 500 
MHz or 600 MHz spectrometer. Chemical shifts (δ) are reported in parts per million (ppm) 
with chemical shifts referenced to internal standards: CDCl3 (7.26 ppm for 1H, 77.8 ppm 
for 13C). Coupling constants (J) are reported in Hertz (Hz) and multiplicities are 
abbreviated as singlet (s), broad singlet (bs), doublet (d), triplet (t), pentet (p), multiplet 
(m), doublet of doublets (dd), and doublet of triplets (dt). High resolution mass spectra 
(HRMS) were obtained at the Mass Spectrometry Facility at Boston College (Chestnut 
Hill, MA). Analytical thin layer chromatography (TLC) was performed on Sorbent 
Technologies Silica G TLC Plates w/UV354 (0.25 mm). All compounds were visualized 
on TLC by UV and/or KMnO4 staining. Column chromatography was carried out using 
forced flow of indicated solvent on Sorbent Technology Standard Grade Silica Gel, 40-63 
µm particle size, 60 Å pore size (Sorbent Technologies). PBS buffer, DMEM/High glucose 
media, and penicillin streptomycin (Pen/Strep) were purchased from Thermo Scientific 
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(Waltham, MA). Primers were ordered from Eurofins MWG Operon (Hunstville, AL), and 
sequencing was performed by Genewiz (Cambridge, MA). 
 
Protein Target Identification by LC/LC-MS/MS 
HeLa soluble protein lysates in DPBS (pH 7.4) (500 µL, 2 mg/mL) were aliquoted 
and LAS1, LAS6, LAS12 (1 µM) or DMSO was added to the appropriate samples. Two 
aliquots were made for each inhibitor concentration or DMSO equaling 2 tubes for one 
final sample. All samples were then treated with biotin-azide (100 µM, 50X stock in 
DMSO), TCEP (1 mM, 50X fresh stock in water), TBTA ligand (100 µM, 17X stock in 
DMSO:t-butanol = 1:4), and copper(II) sulfate (1 mM, 50X stock in water) followed by 
incubation at 22 °C for 1 hr. Samples were combined pairwise and centrifuged (6500 g, 4 
min, 4 °C) to pellet the precipitated proteins. The pellets were resuspended in cold 
methanol by sonication and the two samples were combined. Centrifugation was followed 
by a second cold methanol wash, after which the pellet was solubilized in DPBS containing 
1.2% SDS via sonication and heating (90 °C, 5 min).  
The SDS-solubilized proteome samples were diluted by 5 mL of DPBS for a final 
SDS concentration of 0.2%. The solution was incubated with 100 µL of streptavidin-
agarose beads (Thermo Scientific, washed 3X with DPBS to remove storage buffer) 
overnight at 4 °C. Samples were rotated at 22 °C for 2 hr before being washed by 5 mL 0.2 
% SDS/DPBS, 3 X 5 mL DPBS, and 3 X 5 mL water. The beads were pelleted by 
centrifugation (1400 X g, 3 min) between washes. 
The washed beads were suspended in 500 uL of 6 M urea/DPBS and 10 mM DTT 
(from 20X stock in water) and placed in a 65 °C heat block for 15 min. Iodoacetamide (20 
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mM from 50X stock in water) was then added and the samples were allowed to react at 37 
°C for 30 min while shaking. Following reduction and alkylation, the beads were pelleted 
by centrifugation and resuspended in 200 µL of 2 M urea/DPBS, 1 mM CaCl2 (100X stock 
in water), and sequencing-grade trypsin (2 µg). The digestion was allowed to proceed 
overnight at 37 °C while shaking. The beads were pelleted by centrifugation and washed 
with 2 X 50 µL water. The washes were combined with the supernatant from the trypsin 
digestion step. Formic acid (15 µL) was added to the samples, which were stored at -20 °C 
until mass spectrometry analysis. 
LC/LC-MS/MS analysis was performed on an LTQ-Orbitrap Discovery mass 
spectrometer (ThermoFisher) coupled to an Agilent 1200 series HPLC. Peptide digests 
were pressure loaded onto a 250 µm fused silica desalting column packed with 4 cm of 
Aqua C18 reverse phase resin (Phenomenex). The peptides were eluted onto a biphasic 
column (100 µm fused silica with a 5 µm, tip, packed with 10 cm C18 and 4 cm Partisphere 
strong cation exchange resin (SCX, Whatman) using a gradient 5-100% Buffer B in Buffer 
A (Buffer A: 95% water, 5% acetonitrile, 0.1% formic acid; Buffer B: 20% water, 80% 
acetonitrile, 0.1% formic acid). The peptides were then eluted from the SCX onto the C18 
resin and into the mass spectrometer using 4 salt steps previously described. The flow rate 
through the column was set to ~0.25 µL/min and the spray voltage was set to 2.75 kV. One 
full MS scan (FTMS) (400-1800 MW) was followed by 8 data dependent scans (ITMS) of 
the nth most intense ions. 
The tandem MS data were searched using the SEQUEST algorithm using a 
concatenated target/decoy variant of the human UniProt database. A static modification of 
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+57.02146 on cysteine was specified to account for alkylation by iodoacetamide. 
SEQUEST output files were filtered using DTASelect. 
 
Overexpression and Purification of ALDOA from E. Coli 
The cDNA for WT-ALDOA was subcloned into a pET-23a C-term His Tag 
expression vector. All constructs were verified by sequencing (Genewiz, Cambridge, MA). 
Constructs were transformed into BL21 competent E. coli (New England Biolabs). From 
an overnight LB culture with antibiotics at 37 °C, 5 mL were added to 500 mL LB (pH 7.0) 
with antibiotics and were grown to OD600 of 0.8. Protein expression was induced with 
IPTG (100 µM, 250X stock in water) for 5 hrs at 37 °C. Soluble cell lysates in DPBS (pH 
7.4) were purified using Ni-NTA chromatography with imidazole concentrations of 25 mM 
and 500 mM in DPBS (pH 7.4) for the wash and elution steps, respectively. Purification 
fractions were analyzed for purity using SDS-PAGE (Figure 2-11). Imidazole was removed 
from pure protein fractions using NAP-5 desalting columns that had been buffer exchanged 
with DPBS. 
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Figure 2-11. Fractions from ALDOA purification were analyzed for purity by SDS-PAGE. 
 
Dichlorotriazine Library Labeling of Purified ALDOA  
Purified ALDOA (50 µL, 0.2 mg/mL) was pretreated with probes (250 nM, 50X 
stock in DMSO) at 22 °C for 1 hr. Samples then underwent click chemistry with TAMRA-
azide (Lumiprobe, 25 µM, 50X stock in DMSO), TCEP (1 mM, 50X fresh stock in water), 
TBTA ligand (100 µM, 17X stock in DMSO:t-butanol = 1:4), and copper(II) sulfate (1 
mM, 50X stock in water) followed by incubation at 22 °C for 1 hr. SDS-PAGE loading 
buffer 2X (reducing, 50 µL) was added to the samples and 25 µL of this solution was 
separated by SDS-PAGE at 100 volts for 145 minutes on a 10% polyacrylamide gel. Gels 
were visualized on a Bio-Rad ChemiDoc MP Imaging System using the rhodamine setting. 
After analysis, gels underwent a typical procedure for Coomassie staining and destaining. 
Stained gels were visualized on a Bio-Rad ChemiDoc MP Imaging System. 
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Dichlorotriazine Library Labeling of Recombinant ALDOA in MCF7 Background 
Samples of purified ALDOA (50 µL, 0.2 mg/mL) in the presence of MCF7 
background lysates (1.0 mg/mL) were pretreated with probes (250 nM, 50X stock in 
DMSO) at 22 °C for 1 hr. Samples then underwent click chemistry with TAMRA-azide 
(Lumiprobe, 25 µM, 50X stock in DMSO), TCEP (1 mM, 50X fresh stock in water), TBTA 
ligand (100 µM, 17X stock in DMSO:t-butanol = 1:4), and copper(II) sulfate (1 mM, 50X 
stock in water) followed by incubation at 22 °C for 1 hr. SDS-PAGE loading buffer 2X 
(reducing, 50 µL) was added to the samples and 25 µL of this solution was separated by 
SDS-PAGE at 100 volts for 145 minutes on a 10% polyacrylamide gel. Gels were 
visualized on a Bio-Rad ChemiDoc MP Imaging System using the rhodamine setting. After 
analysis, gels underwent a typical procedure for Coomassie staining and destaining. 
Stained gels were visualized on a Bio-Rad ChemiDoc MP Imaging System. 
 
Dichlorotriazine Library Labeling of ALDOA-Myc in HEK293T 
Mock and ALDOA-Myc overexpressing soluable cell lysates (50 µL, 2.0 mg/mL) 
were pretreated with probes (250 nM, 50X stock in DMSO) at 22 °C for 1 hr. Samples then 
underwent click chemistry with TAMRA-azide (Lumiprobe, 25 µM, 50X stock in DMSO), 
TCEP (1 mM, 50X fresh stock in water), TBTA ligand (100 µM, 17X stock in DMSO:t-
butanol = 1:4), and copper(II) sulfate (1 mM, 50X stock in water) followed by incubation 
at 22 °C for 1 hr. SDS-PAGE loading buffer 2X (reducing, 50 µL) was added to the samples 
and 25 µL of this solution was separated by SDS-PAGE at 100 volts for 145 minutes on a 
10% polyacrylamide gel. Proteins were transferred to nitrocellulose membranes at 75 V 
for 2 hrs in Tris-buffered saline (TBS) buffer. Blots were blocked with 5% nonfat milk in 
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Tris-buffered saline containing Tween 20 (TBST) solution for 2 hrs at room temperature 
with aggitation, washed in TBST, and probed with primary anti-Myc antibody (Cell 
Signaling) diluted in TBST over- night at 4 °C. Following washes with TBST, the blots 
were incubated in the with an HRP-linked secondary antibody (Cell Signaling) at room 
temperature for 2 hrs. Blots were visualized on a Bio-Rad ChemiDoc MP Imaging System 
using the rhodamine setting to evaluate probe modification and chemiluminescence to 
detect ALDOA-Myc expression levels. 
 
Evaluating the Site of Modification 
100 µg of ALDOA in DPBS was treated with DMSO, LAS8, LAS9, or LAS16 (1 
µM, 50X stock in DMSO) for 1 hr at 22 °C. Protein was precipitated by addition of 100% 
trichloroacetic acid in PBS and incubated at -80 °C overnight. Thawed samples were 
centrifuged at 15K for 10 min at 22 °C and the supernatant was discarded. The remaining 
protein pellet was washed with 500 µL of cold acetone, vortexed to resuspend the pellet 
and centrifuged at 15K for 10 min at 22 °C. The supernatant was again discarded and the 
pellet was allowed to air dry until trace amounts of acetone were gone. The pellet was 
resuspended in 30 µL of 8M urea in PBS, then 70 µL 100 mM ammonium bicarbonate in 
PBS and 1.5 µL of 1 M DTT in PBS were added. Samples were incubated at 65 °C for 15 
minutes. Samples were alkylated for 30 minutes at room temperature with the addition of 
2.5 µL of 500 mM iodoacetamide in PBS. Sample volume was increase to 224 µL by 
addition of 120 µL PBS, then 2 µg of sequencing-grade trypsin (Promega) and 2.5 µL of 
100 mM CaCl2 was added. Samples were agitated over night at 37 °C. Then trypsin was 
quenched with 10 µL of formic acid (~5% of final volume) and were centrifuged at 15K 
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for 20 minutes at room temperature to pellet undigested protein. Supernatant was 
transferred to a new tube and stored at -20 °C. Samples were analyzed by LC-MS/MS using 
a LTQ Orbitrap XL mass spectrometer (ThermoFisher) coupled to an EASY-nLC 1000 
nanoLC (ThermoFisher). 10 µL of peptide digests were loaded onto 100 µm fused silica 
column with a 5 µm tip packed with 10 cm of Aqua C18 reverse phase resin (Phenomenex) 
using the EASY-nLC 1000 autosampler. The digests were eluted using a gradient 0-100% 
Buffer B in Buffer A (Buffer A: 95% water, 5% acetonitrile, 0.1% formic acid; Buffer B; 
20% water, 80% acetonitrile, 0.1% formic acid). The flow rate through the column was set 
to 400 nL/min and the spray voltage was set to 3.5 kV. One full MS scan (FTMS) (400-
1800 MW) was followed by 7 data dependent scans (ITMS) of the nth most intense ion 
with dynamic exclusion. The tandem MS data were searched using the SEQUEST 
algorithm using a concatenated target/decoy variant of the human IPI databases. A static 
modification of +57.02146 on cysteine was specified to account for iodoacetamide 
alkylation and differential modifications were specified on lysine to account for probe 
modification. Modification searches on cysteine and tyrosine were performed. SEQUEST 
output files were filtered using DTASelect 2.0. 
 
ALDOA Activity Assay 
Adapted from Bergmeyer, H.U. (1974) Methods of Enzymatic Analysis, Second Edition, 
Volume I, 430 
 Purified recombinant ALDOA was diluted in PBS. ALDOA samples were then 
incubated with probes at various concentrations or DMSO for 1 hr. For a final 100 µL 
reaction mix, F1,6BP (0.19 µM, 30X stock), Tris HCl Buffer pH 7.4 (90 mM, 100 mM 
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stock,), NADH (0.13 mM, 30X stock), TPI (1 unit), and GAPDH (5 units), were mixed 
together and allowed to pre-incubate for 10 min. The reaction was initiated with the 
addition of ALDOA (0.16 µM, 4X stock). Reaction was monitored by kinetic mode every 
30 seconds for 5 minutes at an absorbance of 340 nm. 
 
Scheme 2-2. Coupled activity assay monitors the GAPDH catalyzed consumption of 
NADH as a result of the production of GADP by ALDOA and TPI. 
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Chapter 3 
Mass Spectrometry Strategies to Address Experimental Challenges 
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Introduction 
 In Analytical Chemistry, mass spectrometry is used to determine the mass to charge 
ratio (m/z) of an ion for a chemical compound. The m/z can be used to infer the mass of 
the parent compound, and thus the chemical composition and identity. While the field of 
mass spectrometry only started in the late 19th century, the popularity and utility of the 
technology has made significant advances during that time. 1 Most notably, half of the 2002 
Nobel Prize in Chemistry was awarded to two individuals, John B. Fenn 2 and Kiochi 
Tanaka 3, for their individual contributions to the mass spectrometry field which have 
facilitated advances in the developing field of Chemical Biology. 
 In the most basic form, mass spectrometers are comprised of three different 
components: ion source, mass analyzer, and detector. During sample analysis, the ion 
source converts the analyte into charged ions. Ions are then attracted into the mass 
spectrometer with an applied electrical current. Some common ionization sources are 
electrospray ionization (ESI), chemical ionization, and matrix-assisted laser desorption 
ionization (MALDI). Next, the mass analyzer selects and sorts the ions based on their m/z. 
Some common mass analyzers are time-of-flight (TOF), quadrupoles, and ion traps such 
as: quadrupole ion trap and orbitrap. 4 Lastly, the detector senses a change in current and 
interprets the signal from the ions. Detectors are usually an electron multiplier (EM) or in 
the case of ion traps, metal plates in the mass analyzer itself can be used to detect changes 
in voltage.  
 The development of tandem mass spectrometry increased the utility and scope of 
the experiments available to be applied to complex samples and molecules, particularly 
those of biological origin. Further expansion of utility came when chromatography, such 
 131 
as gas chromatography (GC) or liquid chromatography (LC), was coupled to the ion source, 
providing a dimension of analytical separation to the analysis of complex samples. In LC 
tandem mass spectrometry (LC-MS/MS) complex samples are first separated by LC and 
are then typically ionized by either ESI or low flowrate nanoESI. 5 Once the ions enter the 
mass spectrometer the m/z is determined for the ions eluting at that particular time, known 
as the precursor or parent ions, which is defined as MS1. After determination of the MS1, 
select ions from the MS1 are targeted for fragmentation. Fragmentation can occur by 
different methods both chemically and physically, however a popular fragmentation 
technique is low-energy collision-induced dissociation, which favors cleavage of the amide 
bond of the peptide backbone and generates b and y ions. 6 The spectra of the m/z of the b 
and y ions generated by fragmentation of a singular ion from the MS1 is called an MS2. 
Ions targeted for fragmentation can be predetermined or determined experimentally by 
indicating the number of ions from MS1 desired to be targeted for generation of a 
fragmentation spectra (MS2). 
The power of this technology is rooted in the ability to determine the amino acid 
sequence of the peptide precursor ion. For example, consider the peptide N-ACDEF-C, 
which has a mass of 583.1948. Then consider the peptide N-DEFAC-C, which also has a 
mass of 583.1948. While the mass of these two peptides is the same, this data does not 
confer information about the sequence of the peptide. In data analysis, the absence of amino 
acid sequence information makes correlating the protein of origin in a complex proteome 
impossible. However, alignment of the unique sequence dependent characteristics of the 
fragmentation spectra of the b and y ions of both the experimentally determined MS2 and 
a theoretical MS2 make data analysis feasible (Table 3-1). 
 132 
m/z of B+ B ion # ACDEF Y ion # m/z of Y+ 
72.04444 1 A CDEF 4 513.16502 
175.05362 2 AC DEF 3 410.15584 
290.08056 3 ACD EF 2 295.12889 
419.12316 4 ACDE F 1 166.0863 
      
      
      
m/z of B+ B ion # DEFAC Y ion # m/z of Y+ 
116.03426 1 D EFAC 4 469.17519 
245.07686 2 DE FAC 3 340.1326 
392.14527 3 DEF AC 2 193.06419 
463.18238 4 DEFA C 1 122.02707 
 
Table 3-1. Calculated m/z values for b and y ions of theoretical peptides with identical 
precursor masses. 
  
Here we report the use of mass tandem spectrometry based experimental strategies 
to solve experimental challenges in two collaborations. Implementation of tandem mass 
spectrometry in these studies gave access to critical data which enabled experimental 
validation and optimization.  
The first collaboration involves the use a proteome wide profiling of quantitative 
cysteine reactivity to investigate the promiscuity of the cysteine reactive small molecule, 
MIND4-17, which was found to react with a cysteine on the protein Kelch-like ECH-
associated protein 1 (KEAP1). Here, tandem mass spectrometry was used to determine the 
additional protein targets of MIND4-17 as an assessment of the promiscuity of the cysteine 
reactive small molecule. The proteome scale analysis supports the proposed mechanism of 
action of MIND4-17. 
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The second collaboration involves the determination of undesired natural amino 
acid incorporation into sfGFP, due to mischarged orthogonal tRNA, at an engineered 
internal nonsense codon. Here, tandem mass spectrometry enabled identification of key 
players involved in the observed cross-talk. Identification of the natural amino acid 
incorporated at the nonsense position enabled experimental optimization to overcome and 
eliminate cross-talk. This optimization enhanced the utility and validated the novel strategy 
for unnatural amino acid incorporation in bacterial and eukaryotic cells. 
KEAP1 tightly regulates nuclear factor-erythroid 2 p45-related factor 2 (NRF2) 
protein levels, thus NRF2 signaling ability. In the cytoplasm KEAP1 acts as a regulator by 
serving as an adaptor protein between NRF2 and CUL3-based E3 ubiquitin ligase. 7–9 In 
the absence of stress, KEAP1 efficiently promotes the polyubiquitination of NRF2, leading 
to its degradation by the ubiquitin–proteasome degradation system (UPS). 
Polyubiquitination is mediated by the association of the KEAP1 Kelch domain with the 
amino-terminal Neh2 domain of NRF2 (Figure 3-1). 10–13 However, in the presence of 
stress, NRF2 degradation is impaired by a conformational change in the 
KEAP1/NRF2/CUL3 complex that occurs when oxidants or electrophilic chemicals 
modify the sensory cysteines of KEAP1. 14–17 Human KEAP1 has 27 cysteine residues, and 
the pattern of cysteine residues modified by a particular electrophilic molecule is called the 
cysteine code. 18 It is unclear which or if all 27 cysteines are sensory cysteine residues.  
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Figure 3-1. Kelch domain of KEAP1 (aas 325-609) shown in gray with the Neh2 domain 
of NRF2 (shown as sticks) (PBD: 3ZGC). Currently, there is no crystal structure of full 
length KEAP1. 
 
Since modification of KEAP1 results in the impaired degradation of NRF2, during 
times of stress NRF2 begins to accumulate and eventually translocates to the nucleus. Once 
in the nucleus, NRF2 binds to antioxidant response elements (AREs) which activate 
transcription responses as a result to the stress sensed by KEAP1. 15 Phase II enzymes are 
transcribed as a result of NRF2 signaling, among many additional downstream proteins. 
Phase II enzymes, such as glutathione S-transferases (GSTs), NAD(P)H:quinone 
oxidoreductase 1 (NQO1), heme oxygenase (decycling) 1 (HO-1), and catalytic (GCLC) 
and regulator (GCLM) subunits of glutamate-cysteine ligase, are cellular protector proteins 
against carcinogens and oxidants through oxidation, reduction, hydrolysis, or conjugation 
reactions. 19,20 More recently, NRF2 is also linked to the mechanism of anti-inflammatory 
effects. 
The pathogenicity of Huntington’s disease (HD), an inherited autosomal-dominant 
and highly penetrant neurodegenerative disorder, commonly manifests itself in oxidative 
stress and neuroinflammation mechanisms. HD patients experience physical and 
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psychological changes including disordered movements and cognitive decline. 21 HD 
results from aggregate of the large protein (350 kDa) huntingtin (HTT) found highly 
expressed in the brain. Aggregate formation is linked to the expansion (n>37) of a 
polymorphic trinucleotide repeat sequence (CAG)n within the gene encoding HTT, and is 
not observed with wild type HTT. 22 Observed neuroinflammation in HD patients may be 
a result of not fully engaged or inhibited NRF2 signaling since all ARE gene products are 
not responsively upregulated in HD patient brain tissue. 23 Further evidence from HD 
mouse model suggests that protective NRF2 signaling is not fully activated and/or muted. 
Studies have found pharmacological stimulation of NRF2s in HD mouse model is 
efficacious and associated with increased expression of antioxidant proteins and reduction 
of ROS levels in brain. 24,25 Recent work of our collaborator identified a unique structural 
scaffold of triazole-containing small molecules that potently induces expression of 
canonical ARE genes (NQO1, GCLM, GCLC, HMOX1/HO-1) in primary mouse cells and 
causes a pronounced reduction of ROS. 26  
The work presented here is a continuation of the previous publication. Here, we 
elucidated the molecular mechanism by which the most potent lead compound, MIND4-
17, developed from this scaffold induces NRF2 activation, and used this highly selective 
probe to examine specific activation responses and potential benefits of NRF2 signaling in 
mouse and human HD models. More specifically, my contribution to the work was to 
evaluate the selectivity of MIND4-17 towards KEAP1 through a global proteomic 
screening using a broadly reactive cysteine ABP, iodoacetamide alkyne. 
The second collaboration highlighted in this chapter is focused on the field of 
unnatural amino acid incorporation. This technique allows researchers to investigate or 
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modify the structure and function of proteins with control over the specific site and number 
of modifications. This is an improvement over the use of bioconjugation reactions to 
incorporate new functional groups into proteins, since traditional bioconjugation methods 
are limited in the sites available for modification as well as the yield and stoichiometry of 
modifications per protein, which is dictated by protein sequence. Synthetic incorporation 
of unnatural amino acids in peptides through solid phase peptide synthesis (SPPS) is the 
limited to the size of the peptide that can be synthesized (<50 aa) through this method and 
the ability to ensure proper protein folding. 27 However, the use of semisynthetic methods, 
allow access to the synthesis of much larger macromolecules. The portion of the protein 
containing the unnatural amino acid is synthesized using SPPS, and the rest of the protein 
is synthesized recombinantly. Some of the semisynthetic strategies fall under the category 
of native chemical ligation: native chemical ligation with homocysteine, Staudinger 
ligation, intein-mediated method, and through a Click reaction. 28 The drawback of the 
semisynthetic method is that the protein is not synthesized in a native cell environment, 
hindering the ability to study the protein in a relevant context. To overcome this drawback, 
focus has been directed towards translational incorporation of unnatural amino acids. This 
method results in the synthesis of the modified protein in the context of a cell, where it is 
more feasible and relevant to perform studies that probe the function and activity of the 
protein. Enabling a cell to incorporate an unnatural amino acid, thus expanding the genetic 
code, has been accomplished through various strategies which include stop codon 
suppressor tRNAs, orthogonal aminoacyl-tRNA synthetases, codon expansion and non-
natural base pairs. 28 
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In the case of orthogonal aminoacyl-tRNA synthetases, an engineered aminoacyl-
tRNA synthetase-tRNA pair is used to deliver an unnatural amino acid to a desired 
engineered position, such as a nonsense codon. It is essential for the aminoacyl-tRNA 
synthetase-tRNA pair to be orthogonal to the host’s translational machinery. To ensure 
orthogonality, typically aminoacyl-tRNA synthetase-tRNA pairs are chosen from 
organisms of a different domain of life, thus contains evolutionarily divergent components. 
29 Typically, genetic code expansion of bacterial relies on aminoacyl-tRNA synthetase-
tRNA pairs derived from eukaryotes and archaea. Alternatively, genetic code expansion of 
eukaryotes relies on aminoacyl-tRNA synthetase-tRNA pairs derived from bacteria, since 
archaeal derived aminoacyl-tRNA synthetase-tRNA pairs are typically cross-reactive in 
eukaryotes. The use of two distinct sets of aminoacyl-tRNA synthetase-tRNA pairs for 
genetic code expansion in eukaryotes and bacterial leads to a significant technical 
disadvantage; the two individual systems must be separately genetically encoded and 
optimized using the in vivo selection systems developed using E. coli and S. cerevisiae as 
hosts. The platform for E. coli selection is more facile and more successful for genetically 
encoding new unnatural amino acids than the S. cerevisiae platform. The potential for using 
one system for both bacterial and eukaryote expression has been demonstrated with the use 
of archaea-derived pyrrolysyl-tRNA synthetase-tRNAPyl, which contains naturally 
occurring TAG codon pair. The scope of unnatural amino acids that can be incorporated 
by this pair is limited by the preference for unnatural amino acids with structural similarity 
to lysine. The focus of this study was to investigate the potential of a novel strategy that 
would overcome the limitations of the need to use two separate selection systems for one 
unnatural amino acid for incorporation into proteins in bacterial and eukaryotic cells. The 
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strategy requires an endogenous bacterial aminoacyl-tRNA synthetase-tRNA pair to be 
replaced by an aminoacyl-tRNA synthetase-tRNA pair from a eukaryote. This substitution 
allows the liberated endogenous bacterial aminoacyl-tRNA synthetase-tRNA pair to be 
available for unnatural amino acid incorporation. Additionally, this strategy allows the use 
of the preferred, more facile bacterial selection for directed evolution of the liberated 
endogenous bacterial aminoacyl-tRNA synthetase-tRNA pair. 
 
Results and Discussion 
 
The following results and discussion pertain to the KEAP1/NRF2 project. 
 
Triazole-Containing Inducers Enhance NOQ1 Activity 
To elucidate the mechanism of NRF2 activation, comparison of the potencies of 
lead compound from previous study, MIND4, new candidate MIND4-17 (Figure 3-2A), 
and a series of structural triazole-containing analogs were assayed in a quantitative NQO1 
inducer bioassay in murine Hepa1c1c7 cells (Figure 3-2B). 30 The NQO1 bioassay is a 
coupled assay that indirectly measures the activity of NQO1 by monitoring the spontaneous 
electron transfer and colorimetric change of yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (oxidized) to purple formazan (MTT) (reduced) as a result 
of the electron transfer from NADPH, generated by GAPDH, by NQO1 to menadione 
which converts to menadiol. The concentration that doubles the specific activity (CD value) 
for NQO1 was used as a measure of inducer potency and compound ranking. Within this 
lead series, MIND4-17 was confirmed to be the inducer of highest potency (CD = 0.15 
 139 
µM), comparable to the naturally occurring inducer sulforaphane (SFP) (CD = 0.18 µM) 
and significantly more potent than the clinically approved NRF2 activator dimethyl 
fumarate (DMF) (CD = 9 µM). This data indicates an increase of NQO1 activity as a result 
of NRF2 activation. 
 
Figure 3-2. (A) Structures of triazole-containing compounds parent MIND4 and lead-
inducer MIND4-17 (B) Concentration-dependent activity test (n=8) of MIND4-17, 
structural analogs MIND4-17-15, MIND4, MIND4B, and already known, control NRF2 
inducers SFP and DMF in quantitative NQO1 inducer bioassay. 
 
NRF2 Inducer Treatment Enhances NRF2 Induction Products 
Since NQO1 transcription is a product of NRF2 activation, focus was directed to 
investigate whether the observed increase in NQO1 activity was correlated to increased 
levels of NQO1 and GCLM, another product of NRF2 activated transcription. Western 
blotting of NQO1 and GCLM proteins after treatment for 24 hrs with MIND4-17 and DMF 
in mutant HD rat embryonic striatal cells ST14A shows an increase in protein expression, 
indicating the compounds induce NRF2 activation (Figure 3-3A). The observed increase 
in products of NRF2 activated transcription in the HD mouse model further suggests the 
NRF2 system is not functioning at a suboptimal capacity. To further investigate the 
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mechanism of apparent NRF2 activation, we screened the effects of MIND4-17 and other 
MIND4 analogs on induction of NQO1 expression NRF2-null mouse embryonic 
fibroblasts (MEF) cells and which did not result in an increase of NQO1. These data 
together support the hypothesis that observed NOQ1 induction by the compounds and 
increased activity are NRF2 dependent (Figure 3-3B). 
 
Figure 3-3. (A) Evaluation of NRF2-responsive NQO1 and GCLM protein levels in 
MIND4-17 and DMF-treated mutant HD ST14A cells. (B) Evaluation of NRF2-responsive 
protein levels indicates no observed induction of NQO1 in NRF2-KO MEFs treated with 
MIND4-17 and its analogs compared to control. 
 
NRF2 is Stabilized as a Result of Treatment with NRF2 Inducing Compounds 
Since stabilization of NRF2 is an essential step in the activation of the pathway and 
a marker of redirection from UPS, the stabilization of NRF2 in cells treated with MIND4-
17 and its structural analogs preceded the induction of NQO1 was accessed. A 5 hr 
exposure to SFP, MIND4-17, and lower potency inducers MIND4 and MIND4B resulted 
in accumulation of detectable levels of NRF2 protein (Figure 3-4A). To determine the 
response time of NRF2 activation by the compounds, cells treated with MIND4-17 at 
different time points were analyzed for NRF2 protein levels. Nuclear accumulation of 
NRF2 was observed as early as 30 min after cell exposure to MIND4-17 (0.5 µM) and 
remained elevated for at least 5 hr (Figure 3-4B). 
A BHD MUTANT NRF2 KO MEF WT
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Figure 3-4. (A) NRF2 accumulation is concentration dependent. MIND4-17 showed the 
most NRF2 accumulation. (B) NRF2 in cytoplasmic and nuclear fractions from WT MEFs 
treated with 0.5 µM MIND4- 17 show time-dependent accumulation.  
 
MIND4-17 Promiscuity Assessed by Quantitative Cysteine Reactivity Profiling 
Next, focus was directed towards further conformation that the induction of 
antioxidant response elements are specifically due to NRF2 activation as a result of the 
singular cysteine modification of KEAP1 and not an unidentified off target. To determine 
whether MIND4-17 promiscuously alkylated other reactive cysteines within the proteome, 
a quantitative cysteine reactivity profiling strategy was used to globally identify cysteine 
residues that demonstrate significant loss of reactivity after preincubation with compound, 
MIND4-17 (Figure 3-5). 31 Following MIND4-17 (10 µM) treatment HeLa cell soluble 
lysate (2.0 mg/mL) samples were treated with a promiscuous cysteine reactive 
iodoacetamide-alkyne (IA) probe (100 µM). Excess IA probe was removed by methanol 
washes and IA probe reacted proteins were coupled to biotinylated isotopic cleavable 
linkers through CuAAC (Figure 3-6). Proteins modified by IA probe were enriched on 
streptavidin beads overnight and unreacted proteins were removed by wash steps. Bead 
bound proteins were subjected to on bead trypsin digestion overnight. In solution tryptic 
peptide digests were removed and set aside, leaving peptides containing the cysteine 
residue modified by IA probe remaining bound to the beads. To elute the peptides of 
A B
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interest beads were treated three times with sodium dithionite solution that cleaves the 
diazo linkage of the cleavable linker, and the resulting washes were combined with final 
water wash steps to yield the final sample. 32 
 
 
Figure 3-5. Quantitative MS workflow. Light samples were pretreated with MIND4-17 
(10 µM) and heavy samples were pretreated with DMSO. Both light and heavy samples 
were then treated with IA probe (100 µM). Figure adapted from Qian Y, et al. 2013. 
 
 
Figure 3-6. Structure of isotopically labeled Azo-L and Azo-H tags. Incorporation of the 
heavy valine residue provides a mass difference of 6 Da between Azo-L and Azo-H. Figure 
adapted from Qian Y, et al. 2013. 
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Of the >300 reactive cysteine-containing peptides identified in our quantitative MS 
studies, only four residues showed a greater than twofold change in cysteine reactivity upon 
treatment with MIND4-17 (Figure 3-7, Table 3-2, Table 3A-1). The small subset of 
sensitive cysteine residues identified in the global quantitative analysis experiment 
suggests MIND4-17 has a high level of selective reactivity towards KEAP1. Within the 
subset of cysteines with no change in reactivity were hyper-reactive cysteine residues such 
as the active-site nucleophile of GAPDH, attesting to the low reactivity of the MIND4-17 
across even highly reactive cysteines within the proteome.  
 
 
 
Figure 3-7. Plot of cysteine reactivity ratios identified in cysteine proteome profiling after 
MIND4-17 pretreatment. The four proteins with ratios above 2 (indicated in red) are 
Cytosolic phospholipase A2 (PLA2G4A), DNA-dependent protein kinase catalytic subunit 
(PRKDC), Proteasome subunit beta type-5 (PSMB5), and 40S ribosomal protein S5 
(RPS5). Highly reactive GAPDH active site cysteine (indicated in yellow) has a ratio of 
0.86. 
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IPI Protein Symbol Peptide Ratio 
P47712 Cytosolic phospholipase A2 PLA2G4A CSVSLSNVEAR 3.37 
P78527 DNA-dependent protein kinase catalytic subunit PRKDC INQVFHGSCITEGNELTK 2.4 
P28074 Proteasome subunit beta type-5 PSMB5 VIEINPYLLGTMAGGAADCSFWER 2.29 
P46782 40S ribosomal protein S5 RPS5 AQCPIVER 2.09 
 
Table 3-2. Peptides with ratios greater than 2.0 which indicate sensitivity to MIND4-17 
treatment. 
 
 We note that we did not detect any cysteine containing peptides from KEAP1. 
Tryptic KEAP1 peptide containing C319 has been previously detected using this method 
(IA probe, 100 µM) in MDA-MB-231 and MCF7 cells, but not in Jurkat cells. 31 
Independent studies have shown expression of KEAP1 in HeLa cells is much less than in 
MDA-MB-231 and MCF7 cells by Western Blot. 33 The low amounts of KEAP1 protein in 
the sample may account for this result. Future work to further investigate the targets of 
alkylation by MIND4-17 it would be beneficially to use cell lysates from a HD model cell 
line, as this will more closely mimic protein expression levels and reactivity characteristic 
of the disease. 
 
 
The following results and discussion pertains to the unnatural amino acid project. 
 
Functionally Replacing the TrpRS-tRNATrp pair of E. coli 
Focus was directed to the development of the tryptophanyl-tRNA synthetase 
(TrpRS-tRNATrp) pair for genetic code expansion of E. coli and eukaryotes (Figure 3-8). 
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For this strategy to be applicable for unnatural amino acid incorporation into eukaryotes, it 
was necessary to confirm successful incorporation and orthogonality of TAG-suppressing 
E. coli tRNATrp (tRNAEcTrpCUA) in eukaryotic cells. To evaluate incorporation, TAG-
suppressing E. coli tRNATrp (tRNAEcTrpCUA) and an enhanced green fluorescent protein 
(EGFP) reporter containing a stop codon at a permissive site (EGFP-39-TAG) was co-
expressing in HEK293T, with or without the EcTrpRS synthetase. EGFP expression was 
only observed with EcTrpRS present confirming TAG suppression efficiency and supports 
no cross-reactivity in eukaryotic cells (Figure 3-9). Focus was then directed towards the 
substitution and subsequent deletion of the TrpRS-tRNATrp pair.  
 
Figure 3-8. Strategy to create an aaRS-tRNA pair that can drive genetic code expansion in 
both eukaryotes and E. coli by liberating the endogenous E. coli TrpRS-tRNATrp. 
 
Figure 3-9. Fluorescence microscopy images of HEK293T cells co-expressing EGFP-39-
TAG reporter and tRNAEcTrpCUA with and without co-expression of the cognate EcTrpRS. 
Robust EGFP-39-TAG expression is observed only when EcTrpRS is co-expressed. This 
confirms no cross-reactivity of tRNAEcTrpCUA. 
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Previously, an S. cerevisiae-derived ScTrpRS-tRNAScTrp pair has been optimized 
in E. coli for highly efficient nonsense suppression. A plasmid containing ScTrpRS-
tRNAScTrpCCA was engineered and incorporated which then allow for deletion of trpS 
(encoding EcTrpRS) and trpT (encoding tRNATrpCAA), resulting in the ATMW1 strain. 
Growth rate studies of the ATMW1 strain compared to its progenitor EcNR1G strain 
showed no inhibition of growth, confirming efficient functional substitution by the 
engineered pair from S. cerevisiae (Figure 3-10). 
 
Figure 3-10. ATMW1 exhibits comparable growth rate to progenitor EcNR1G strain 
containing ScTrpRS-tRNAScTrp complementation plasmid. 
 
Reintroducing the EcTrpRS-tRNAEcTrp pair into ATMW1 
 Next, the potential to reintroduce the liberated EcTrpRS-tRNAEcTrp pair was tested. 
The tRNAEcTrp was supplied as a nonsense suppressor for TAG, however previous reports 
indicate TAG suppressor tRNAEcTrpCUA is mischarged by E. coli glutamyl-tRNA synthetase 
(EcGlnRS). 34,35Although tRNAEcTrp and tRNAEcGln have very little sequence homology, 
the observed mischarge is likely due to the overall structural similarity of the tRNA in 
addition to the similarity of the anticodons, CUA and CUG, for the TAG suppressor 
tRNAEcTrpCUA and tRNAEcGln respectively (Figure 3-11). Knowing the precedence of cross-
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reactivity, we sought to evaluate the impact on protein expression of a superfolder GFP 
(sfGFP) reporter in the ATMW1 strain (Figure 3-12). The high levels of sfGFP expression 
in the ATMW1 strain with tRNAEcTrpCUA indicate cross-talk. However, when the codon is 
switched to TGA (opal) from TAG (amber), and the anticodon of the tRNAEcTrp  is changed 
from CUA to UCA in the absence of EcTrpRS there is no expression of sfGFP, indicating 
a noncross-talk system.  
 
 
Figure 3-11. Overlay of tRNAEcTrp (blue, PDB: 4YCP) and tRNAEcGln (red, PDB: 1QTQ) 
show high structural similarity despite low sequence homology. 
 
 
Figure 3-12. Evaluating the nonsense-suppression efficiencies of tRNAEcTrpCUA and 
tRNAEcTrpUCA using sfGFP-151-TAG or sfGFP-151-TGA as reporters. 
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 To identify the synthetase mischarging the tRNAEcTrpCUA sfGFP-151-TAG was 
purified from ATMW1 tRNAEcTrpCUA expressed in the absence of EcTrpRS. The sfGFP-
151-TAG protein was purified by Ni-NTA affinity purification. The purified sfGFP-151-
TAG was analyzed by whole protein mass spectrometry and tryptic digestion mass 
spectrometry (LC-MS/MS). The mass wild-type sfGFP is 27617 Da, however the observed 
mass by whole protein mass spectrometry is 27562 Da (Figure 3-13). The observed mass 
indicates the misincorporation of a Q, E, or K residue into sfGFP at the nonsense codon 
(Table 3-3). Incorporation of W is not expected due to the absence of EcTrpRS. The 
expected mass of sfGFP-151-TAG with successful tryptophan incorporation is 27620 Da. 
The misincorporation of a natural amino acid can be traced to a mischarged tRNAEcTrpCUA 
by EcGlnRS, EcGluRs, or EcLysRS.  
 
 
 
Figure 3-13. Deconvoluted mass of purified whole sfGFP co-expressed in ATMW1 with 
tRNAEcTrpCUA in the absence of EcTrpRS. 
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Tryptic Peptide Calculated Mass  of sfGFP (Da) 
LEYNFNSHNVQITADK 27562 
LEYNFNSHNVEITADK 27563 
LEYNFNSHNVK 27562 
LEYNFNSHNVWITADK 27620 
 
Table 3-3. Table of tryptic peptides for natural amino acid residues potentially 
misincorporated into sfGFP-151-TAG and the corresponding calculated mass of sfGFP 
with the misincorporation. 
 
 The resolution of whole protein mass spectrometry presented an experimental 
challenge. Whole protein mass spectrometry was able to confirm full length sfGFP was 
being produced, but was not able to differentiate the exact natural amino acid being 
incorporated into the 151 site. This presents a significant challenge for further optimization 
of the system, since identification of the EcRS involved in the cross talk with tRNAEcTrpCUA 
is a critical player. To overcome this challenge, sfGFP-151-TAG expressed in the absence 
of EcTrpRS was analyzed by tryptic digestion tandem mass spectrometry (Figure 3-14).  
 
 
 
Figure 3-14. Workflow if tryptic digest tandem protein mass spectrometry analysis of 
sfGFP-151-TAG. 
 
Trypsin Digest LC-MS/MS
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EcGlnRS Mischarges tRNAEcTrpCUA 
 First we searched for the m/z values, within window of 5 ppm, for the predicted 
tryptic peptides (Figure 3-15A). Extraction of the calculated glutamine containing peptide 
m/z resulted in a peak characteristic of peptide elution in the chromatogram, though there 
is a small signal in the same region for the expected glutamate containing peptide. To 
confirm the signal is indeed the glutamine containing peptide, we extracted the average 
MS1 spectra for the time corresponding to the elution peak. Examination of the average 
MS1 isotopic envelope revealed the m/z of the [M+2]2+ peptide to be  946.9574 (Figure 3-
15B). This value corresponds to the calculated m/z for the [M+2]2+ of the glutamine 
containing peptide (Table 3-4). To further confirm the identity of the amino acid in position 
151 of sfGFP we analyzed the fragmentation spectra (MS2) of the 946.9574 ion (Figure 3-
16). The high accuracy of the orbitrap mass analyzer in conjunction with the data from the 
fragmentation spectra allowed us to identify the natural amino acid incorporated into the 
position corresponding to the nonsense TAG codon as glutamine.  
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Figure 3-15. (A) Extracted masses from LC-MS/MS chromatogram for the [M+2]2+ tryptic 
peptides for the three potentially incorporated natural amino acids in sfGFP-151-TAG. (B) 
Isotopic envelop of the extracted average MS1 of the peak indicates the m/z of the [M+2]2+ 
tryptic peptide is 946.9574 which corresponds to the calculated m/z of the tryptic peptide 
with glutamine incorporation (946.9605). 
 
Trypic Peptide [M] [M+1]+ [M+2]2+ [M+3]3+ 
LEYNFNSHNVQITADK 1891.9065 1892.9138 946.9605 631.6428 
LEYNFNSHNVEITADK 1892.8905 1893.8978 947.4526 631.9708 
LEYNFNSHNVK 1363.6521 1364.6594 682.8334 455.5580 
 
Table 3-4. Calculated m/z values for the tryptic peptides of the predicted natural amino 
acid incorporations. 
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Figure 3-16. Annotation of the MS2 fragmentation spectra of the 946.9574 ion indicates 
glutamine is incorporated as the 151st residue in sfGFP. 
 
Despite the homology between tRNAEcTrp and tRNAEcGln, EcGlnRS only 
recognizes tRNAEcGln due to the use of the U residing in the anticodon as a major identity 
element. 34,36To circumvent this issue the tRNAEcTrpCUA was changed to tRNAEcTrpUCA and 
tryptophan incorporation at TGA was observed (Figure 3-17). 
 
Figure 4-17. Deconvoluted mass of purified whole sfGFP-151-TGA co-expressed in 
ATMW1 with tRNAEcTrpUCA and EcTrpRS indicates incorporation of tryptophan into the 
opal suppression 151. 
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Conclusion 
 Here we report the tandem mass spectrometry data from two collaborations. In the 
first collaboration, we evaluated the promiscuity of a cysteine reactive small molecule 
using a global quantitative cysteine reactivity strategy. We found cysteine residues on four 
proteins, C726 of PLA2G4A, C1904 of PRKDC, C111 of PSMB5, and C66 of RPS5, to 
be sensitive to alkylation of MIND4-17. We did not identify KEAP1 as a target of MIND4-
17 in our dataset likely due to the low protein abundance of KEAP1 in HeLa cells. Future 
work using HD model cell lines would enhance the characterization of proteins susceptible 
to alkylation by MIND4-17. Furthermore, assessment of NRF2 signaling in KO studies of 
PLA2G4A, PRKDC, PSMB5, RPS5 will better characterize the role of these proteins and 
the effects of alkylation by MIND4-17 in the enhanced expression of antioxidant enzymes. 
 In the second collaboration, we take advantage of the high resolution of the orbitrap 
mass analyzer to accurately identify the sequence of a tryptic peptide from sfGFP. We 
found a glutamine residue was incorporated into the amber nonsense codon during the 
translation of sfGFP-151-TAG. This observation correlated with previous work that 
showed EcGlnRS will charge tRNAEcTrpCUA due to improper recognition of the anticodon. 
By identifying the mechanism of misincorporation, through peptide sequencing, we were 
able to make the necessary improvements to the experimental design to eliminate RS-tRNA 
cross-talk. This drawback was overcome by changing the nonsense codon from amber 
(TAG) to opal (TGA). Reporter protein sfGFP-151-TGA is only expressed when co-
expressed with the reintroduced EcTrpRS-tRNAEcTrpUCA pair. 
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Kanegan, M. J. Van, Kaltenbach, L. S., Crawford, L. A., Fuszard, M., Higgins, M., Miller, 
J. R. C. R., Farmer, R. E., Potluri, V., Samajdar, S., Meisel, L., Zhang, N., Snyder, A., 
Stein, R., Hersch, S. M., Ellerby, L. M., Weerapana, E., Schwarzschild, M. A., Steegborn, 
C., Leavitt, B. R., Degterev, A., Tabrizi, S. J., Lo, D. C., DiFiglia, M., Thompson, L. M., 
Dinkova-Kostova, A. T., Kazantsev, A. G. 2017. KEAP1-Modifying Small Molecule 
Reveals Muted NRF2 Signaling Responses in Neural Stem Cells from Huntington’s 
Disease Patients. Proc. Natl. Acad. Sci. U.S.A., 114, 23, E4676–E4685. 
 
Compound Source and Storage 
Compounds were procured from ChemBridge Corporation (purity quality control 
ensured by provided NMR spectroscopy data), dissolved in molecular-biology–grade 
DMSO to 10 mM stock concentrations, aliquoted, and stored at −80 °C. MIND4-17 was 
resynthesized (purity, >95%) and showed essentially identical potency of NRF2 activation 
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to MIND4-17 in multiple batches purchased from ChemBridge. DMF was purchased from 
Sigma and SFP from LKT Laboratories. 
 
NQO1 Bioassay 
Inducer potency was quantified by use of the NQO1 bioassay in Hepa1c1c7 cells 
as described. 30 In brief, cells grown in 96-well plates were exposed to serial dilutions of 
each compound for 48 hr, and the NQO1 enzyme activity was determined in cell lysates. 
Results are shown as average values of eight replicate wells. The SD in each case was less 
than 5% 
 
Compound Activity Test in the Rat Embryonic Striatal Cell Lines ST14A 
ST14A cells (a generous gift from E. Cattaneo, University of Milan, Milan) stably 
express either a mutant expanded repeat (128Q) or WT (26Q) 546-aa HTT fragment and 
were treated with compounds for 24 hr. Protein levels of NQO1, GCLM, and α-tubulin 
(loading control) were detected in ST14A by immunoblotting with NQO1 (Sigma; 
1:1,000), GCLM (Abcam; 1:800), and GAPDH (Millipore; 1:10,000) antibodies. 
 
Compound Activity Test in Mouse Embryonic Fibroblasts 
MEFs from WT, NRF2- knockout (NRF2-KO), or KEAP1-knockout (KEAP1-KO) 
mice (59) were cultured in plastic dishes (Invitrogen) coated for 30 min with 0.1% (wt/vol) 
gelatin. For experiments, cells (250,000 per well) were grown for 24 hr on six-well plates, 
and then treated with solvent control [0.1% DMSO (vol/vol)] or compounds for 24 h. For 
Western blot analysis, cells were lysed in radio-immunoprecipitation assay (RIPA) buffer 
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containing 1 protease inhibitor mixture tablet (Roche) per 10 mL of buffer. Proteins were 
resolved by SDS/ PAGE and immunoblotted with specific antibodies against NQO1 
(1:1,000) or NRF2 (1:1,000), both gifts from John D. Hayes (University of Dundee, 
Dundee, UK), and β-actin (Sigma; mouse monoclonal; 1:10,000).  
 
Nuclear-Cytoplasmic Extract Separation 
WT MEFs (500,000 per dish) were grown for 24 hr on 6-cm plates, and then treated 
with solvent control [0.1% DMSO (vol/vol)] or 0.5 µM MIND4-17. At the end of each 
treatment time, cells were washed twice in PBS and lysed in buffer A [10 mM KCl, 5 mM 
MgCl2, 50 mM Tris·HCl (pH 7.5), 0.5% Nonidet P-40, 1 mM DTT], containing 1 protease 
inhibitor and 1 phosphatase inhibitor tablets (Roche) per 10 mL of buffer. Lysates were 
subjected to centrifugation at 1,000 × g for 5 min at 4 °C, and supernatant (cytoplasmic 
fraction) was transferred to a fresh microfuge tube. The pellet (nuclear fraction) was 
washed three times in buffer A before being dissolved in buffer B [2% SDS, 150 mM NaCl, 
65 mM Tris·HCl (pH 8.0)] and sonicated for 30 s. Finally, the lysates were subjected to 
Western blot analysis with NRF2 antibody and with GAPDH (rabbit polyclonal; 1:5,000) 
and lamin A/C (rabbit polyclonal; 1:1,000; Gene Tex) to confirm fraction purity and equal 
protein loading. 
 
Proteomic Analysis by Quantitative MS of MIND4-17 
Preparation of MS samples for reactive cysteine profiling. HeLa soluble protein 
lysates (500 µL, 2 mg/mL) were aliquoted, and MIND4-17 (10 µM), or DMSO was added 
to the appropriate samples at the designated concentration. Two aliquots were made for 
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each inhibitor concentration or DMSO equaling four tubes for one final sample. The 
samples were incubated at room temperature (RT) for 1 hr. IA-alkyne (100 µM) was added 
to the samples and incubated at RT for 1 hr. Inhibitor-treated and DMSO samples were 
functionalized with Azo-H tag or Azo-L tag (100 µM, 50× stock in DMSO), respectively 
(68). All samples were then treated with TCEP (1 mM, 50× fresh stock in water), TBTA 
ligand (100 µM, 17× stock in DMSO:t-butanol = 1:4), and copper(II) sulfate (1 mM, 50× 
stock in water) followed by incubation at RT for 1 h. Samples were combined pairwise to 
combine inhibitor and DMSO-treated samples and centrifuged (6,500 × g, 4 min, 4 °C) to 
pellet the precipitated proteins. The pellets were resuspended in cold methanol by 
sonication, and the two samples were combined. Centrifugation was followed by a second 
methanol wash, after which the pellet was solubilized in Dulbecco’s PBS (DPBS) 
containing 1.2% SDS via sonication and heating (90 °C, 5 min). The sample resulting from 
inhibitor pretreatment, IA-alkyne incubation, and Azo-H or Azo-L labeling are as follows: 
Heavy (DMSO, 100 µM IA-Alkyne)/light (10 µM MIND4-17, 100 µM IA-Alkyne). 
The SDS-solubilized proteome samples were diluted by 5 mL of DPBS for a final 
SDS concentration of 0.2%. The solution was incubated with 100 µL of streptavidin-
agarose beads (Thermo Scientific; washed three times with DPBS to remove storage 
buffer) overnight at 4 °C. Samples were rotated at RT for 2 hr before washed by 5 mL of 
0.2% SDS/DPBS, 3 × 5 mL of DPBS, and 3 × 5 mL of water. The beads were pelleted by 
centrifugation (1,400 × g, 3 min) between washes.  
The washed beads were suspended in 500 µL of 6 M urea/ DPBS and 10 mM DTT 
(from 20× stock in water) and placed in a 65 °C heat block for 15 min. Iodoacetamide (20 
mM from 50× stock in water) was then added, and the samples were allowed to react at 37 
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°C for 30 min. Following reduction and alkylation, the beads were pelleted by 
centrifugation and resuspended in 200 µL of 2 M urea/DPBS, 1 mM CaCl2 (100× stock in 
water), and trypsin (2 µg). The digestion was allowed to proceed overnight at 37 °C. The 
beads were pelleted by centrifugation and washed with 3 × 500 µL of DPBS and 3 × 500 
µL of water. The azo-benzene cleavage was carried out by incubating the beads with 50 
µL of 25 mM sodium dithionite at RT for 1 hr. The cleavage process was then repeated 
twice with 75 µL of 25 and 50 mM sodium dithionite, and all of the supernatants were 
combined. The beads were then washed twice with 75 µL of water, and the wash was 
combined with the supernatant from the cleavage step to reach 350 µL final. Formic acid 
(17.5 µL) was added to the sample, which was stored at -20 °C until MS analysis.  
LC/LC-MS/MS analysis was performed on an LTQ-Orbitrap Discovery mass 
spectrometer (Thermo Fisher) coupled to an Agilent 1200 series HPLC. Peptide digests 
were pressure loaded onto a 250-µm fused silica desalting column packed with 4 cm of 
Aqua C18 reverse phase resin (Phenom- enex). The peptides were eluted onto a biphasic 
column [100-µm fused silica with a 5-µm tip, packed with 10-cm C 18 and 4-cm 
Partisphere strong cation exchange resin (SCX, Whatman)] us- ing a gradient 5–100% 
Buffer B in Buffer A (Buffer A: 95% water, 5% acetonitrile, 0.1% formic acid; Buffer B: 
20% water, 80% acetonitrile, 0.1% formic acid). The peptides were then eluted from the 
SCX onto the C18 resin and into the mass spectrometer using four salt steps previously 
described. The flow rate through the column was set to ∼0.25 µL/min, and the spray voltage 
was set to 2.75 kV. One full MS scan (FTMS) (400–1,800 Mr) was followed by eight data-
dependent scans (ITMS) of the nth most intense ions.  
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The tandem MS data were searched using the SEQUEST algorithm using a 
concatenated target/decoy variant of the human IPI databases. A static modification of 
+57.02146 on cysteine was specified to account for alkylation by iodoacetamide, and 
differential modifications of +462.2987 (IA-alkyne and cleaved Azo-H) and +456.2849 
(IA-alkyne and cleaved Azo-L) were specified on cysteine to account for probe 
modifications. SEQUEST output files were filtered using DTASelect. Quantification of 
heavy/light ratios (RH/L) was performed using the CIMAGE quantification package as 
previously described.  
Cysteine reactivity in proteomes pretreated with MIND4-17 (heavy-labeled) were 
compared with DMSO-treated samples (light-labeled). For every cysteine-containing 
peptide, a heavy/light ratio was calculated that reflects the extent of cysteine reactivity in 
the inhibitor-treated vs. DMSO samples. A ratio of 1 indicates that there was no change in 
cysteine reactivity, whereas ratio values >>1 show a loss in cysteine reactivity upon 
inhibitor treatment.  
 
The following experimental procedures are from Italia, J. S., Addy, P. S., Wrobel, C. J. J., 
Crawford, L. A., Lajoie, M. J., Zheng, Y., Chatterjee, A. 2017. An Orthogonalized Platform 
for Genetic Code Expansion in Both Bacteria and Eukaryotes. Nat. Chem. Biol. 13, 4, 446–
450. 
General Methods 
For cloning and plasmid propagation, the DH10b (Life Technologies) strain of E. 
coli was used. Polymerase chain reaction (PCR) was performed using the Phusion Hot Start 
II DNA Polymerase (Fisher Scientific) using the manufacturer’s protocol. For purification 
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of DNA (plasmid as well as PCR products, etc.) spin columns from Epoch Life Science 
were used. Restriction enzymes and T4 DNA ligase were obtained from New England 
BioLabs (NEB). DNA oligomers for PCR were purchased from Integrated DNA 
Technologies (IDT). Verification of cloned DNA by Sanger sequencing was performed by 
Eton Biosciences. Antibiotics, isopropyl β-D-1- thiogalactopyranoside (IPTG), and L-
arabinose were purchased from Sigma-Aldrich or Fisher Scientific. Components of media 
were obtained from Fisher Scientific. Bacteria were grown on LB or M63 agar plates and 
LB liquid medium with the following antibiotic concentrations unless otherwise 
mentioned: 95 µg/mL spectinomycin, 20 µg/mL chloramphenicol, and 100 µg/mL 
ampicillin, 30 µg/mL kanamycin, 15 µg/mL zeocin, 12 µg/mL tetracycline, 10 µg/mL 
gentamycin. 
 
Statistical Methods  
For all expression analyses (sfGFP in bacteria or EGFP in HEK293T cells), the 
mean of three independent experiments was reported, and error bars represent standard 
deviation. For the growth rate analysis, each data point represents the mean OD600 of three 
independent cultures of the same strain (error bars represent standard deviation). In our 
experience, a mean of three experiments provides adequate levels of accuracy for these 
experiments. 
 
 Strains, Cell Lines 
The EcNR1 strain was a gift from G.M. Church. The HEK293T cell line was 
obtained from ATCC, and propagated without further confirmation. Cell lines are regularly 
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monitored for Mycoplasma contamination. Even though HEK293T is listed under 
misidentified cell lines in the ICLAC database, we used it for our expression analyses as a 
representative mammalian cell line. Given the widespread use of this cell line as a model 
mammalian expression host, and since our conclusions do not rely on its specific identity 
(beyond a representative mammalian cell-line), we believe that the use of this strain is 
justified. 
 
Building ATMW1 
EcNR1 was transformed with pUltraG_ScW40CCA. To remove the E. coli 
tryptophanyl–tRNA synthetase (trpS) from this strain, the gene encoding zeocin resistance 
(ShBle) driven by the EM-7 promoter and the CYC1 transcription terminator was PCR 
amplified using primers TrpRS.Z.ab-F and TrpRS.Z.ab-R to generate the PCR product 
trpS::ZeoR. 50 ng of the trpS::ZeoR PCR cassette was transformed in the recombination 
following the aforementioned protocol, and the resulting strains were plated on LB–Agar 
plates supplemented with zeocin. The resulting colonies were screened via colony PCR 
using TrpRS150F + TrpRS150R, TrpRS150F + Zeo-iR, and TrpRS150F + TrpRS_sqiR, 
as well as sequencing these colony PCR products. This strain was named EZ4. 
To replace the E. coli tryptophanyl-tRNACCA (trpT), the trpT::GentR PCR cassette 
was amplified using trpTKO.Gent-F and trpTKO.Gent-R (965 bp). 50 ng of trpT::GentR 
PCR cassette was transformed into EZ4, induced as previously described. Resulting 
gentamycin-resistant colonies were screened for the desired recombination using colony 
PCR primers trpT GsqF and trpT GsqR, as well as sequencing of the PCR product. The 
resulting strain was named EZG4. 
 162 
2 µM 90 bp oligo, galK.90 del, was used to delete galK from the endogenous 
genomic location. Following transformation, cells were recovered for 6 hrs and washed 
twice with M9 minimal media at 5,000 × g for 5 min. 100 µl of a 104 dilution was plated 
on M63 minimal media supplemented with glycerol and 2-deoxygalactose to select for 
successful galK deletion. Colony PCR was used to verify the deletion of galK using 
galK_KO_verf-F/R. The resulting strain was named G4. 
galK.PCR cassette containing the endogenous promoter dlambda.GalK-F and 
dlambda.galK dterm-R (1,348 bp) was amplified and was used to remove the λ-RED genes 
from the 4 strain. Following transformation of 50 ng of this PCR product into strain 4, 
successful insertion of the galK.PCR cassette into the λ-RED site was selected by plating 
the cells on M63 plates containing galactose as the sole carbon source for 3 days. Surviving 
colonies were screened by colony PCR using dlambda.sqF with dlambda.sqR or 
dLambda.sqiR for the desired deletion. This final strain was named ATMW1 (EcNR1 
trpS::ZeoR trpT::GentR ΔgalK λ-RED::galK). 
 
Growth Comparison 
5 mL starter cultures of EcNR1G, EcNR1G + pUltraG_ScW40CCA, and ATMW1 
strains were grown for 16 hrs in LB with all strain-dependent antibiotics. For each strain, 
the starter culture was diluted to an initial OD600 of 0.01 in three identical cultures of 80 
mL LB with no antibiotics and allowed to grow in 250 mL sterile Erlenmeyer flasks at 30 
°C, with shaking (250 r.p.m.). Growth was monitored every 30 min by measuring OD600 
in a 10 mm cuvette. 
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Assessment of aaRS–tRNA Activity Using a Chloramphenicol Reporter 
Overnight cultures of ATMW1 harboring pRepAC-EcW-TAG or pRepJI-EcW- 
 TGA, with or without pBK–EcWRSwt, were diluted to an OD600 of 0.1, and 3 µL was spot 
plated on LB agar plates supplemented with kanamycin (+pBK plates), spectinomycin, 
tetracycline, and varying chloramphenicol concentrations. Growth was analyzed after 48 
hrs of incubation at 37 °C. 
 
Assessment of aaRS–tRNA Activity Using a sfGFP151 Reporter 
EcNR1 or ATMW1 harboring pEvolT5-EcW sfGFP151 (TAG or TGA) with or without 
pBK-EcWRSwt was grown overnight in LB. The starter cultures were diluted in LB 
supplemented with required antibiotics to 0.05 OD600. Cultures were grown at 30 °C or 37 
°C (30 °C when comparing to progenitor strain EcNR1) until 0.55 OD600, at which point 
the sfGFP expression was induced with a final concentration of 1 mM IPTG. Unnatural 
amino acids (UAA) were added during induction to a final concentration of 1 mM. Cultures 
were grown for an additional 17–20 hrs at 37 °C with shaking. To evaluate sfGFP 
expression, cells from 150 µL of the cultures were pelleted at 5,000 × g, resuspended in 
150 µL PBS, and transferred to a 96-well clearbottom assay plate. Fluorescence was 
measured by using a SpectraMAX M5 (Molecular Devices) (Ex. 488 nm; Em. 534 nm). 
Fluorescence for each sample was normalized using its OD600. 
 
Protein Purification 
The tRNAEcTrpUCA was expressed from the proK promoter. The sfGFP reporter 
gene (sfGFP-151-TGA or wild type sfGFP) was expressed from pET22b-T5lac plasmid 
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driven by the strong t5.lac promoter. Overnight expression cultures were centrifuged and 
resuspended in lysis buffer: B-PER Bacterial Protein Extraction Reagent (Thermo 
Scientific) + 1× Halt Protease Inhibitor Cocktail (Thermo Scientific) + 0.01% Pierce 
Universal Nuclease (Thermo Scientific). After 30 min incubation at room temperature, the 
lysate was clarified by centrifuging at 22,000 × g for 5 min. The C-terminally polyhistidine 
tagged soluble sfGFP in the supernatant was purified using a HisPur Ni-NTA resin 
(Thermo Scientific) following manufacturer’s protocol. Protein purity was confirmed by 
SDS–PAGE and purified protein molecular weight was confirmed by ESI–MS (Agilent 
Technologies, 1260 Inifinity ESI–TOF). 
 
Assessing Activity of tRNAEcTrpCUA and Synthetase Hits in HEK293T 
Dulbecco’s modified Eagle’s medium (high glucose DMEM) supplemented with 10% FBS 
(FBS) and penicillin–streptomycin (0.5×) was used to culture HEK293T cells. Cells were 
incubated in a humidified incubator at 37 °C in the presence of 5% CO2. HEK293T were 
seeded at a density of 600,000 cells per well for a 12-well plate 1 day before transfection 
and transfected at ~70% confluence. Polyethylenimine (PEI, Sigma) and DNA were mixed 
at a ratio of 4 µL PEI (1 mg/mL) to 1 µg DNA in DMEM. After 20 min incubation, 100 
µL of this mixture was used to transfect one single well in a 12-well plate. For these 
transfections, 500 ng of pAcBac EGFP39* U6-EcWtR TAG was transfected in the 
presence or absence of pAcBac-TrpRS (wt, h14, or h9) U6-EcWtR TAG. UAAs were 
added to the culture medium to a final concentration of 1 mM at the time of transfection. 
Fluorescence images were taken at 48 h post-transfection using a Zeiss Axio Observer 
fluorescence microscope. 
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To obtain EGFP39* expression data, cells were harvested, washed once with PBS 
buffer (5,000 × g), and lysed with CelLytic M lysis buffer (Sigma) supplemented with 1× 
Halt protease inhibitor and 0.01% Pierce universal nuclease. 50 µL lysis buffer was used 
for each well of a 12-well plate, and was allowed to incubate for 20 min. After incubation, 
the lysate was clarified by centrifuging at 22,000 × g for 5 min and was transferred to a 
clear bottom 96-well assay plate. Fluorescence was measured using a SpectraMAX M5 
(Molecular Devices) (Ex. 488 nm; Em. 534 nm). 
 
Tryptic Digestion and LC–MS/MS Analysis of Reporter Proteins 
12 µg purified reporter protein was treated with DMSO and precipitated with 5 µl 
100% solution of trichloracetic acid. Sample was frozen at -80 °C overnight. Thawed 
sample was centrifuged at 15,000 r.p.m. for 10 min at room temperature. Supernatant was 
removed and pellets were vortexed to resuspend in 500 µL cold acetone. Samples were 
then centrifuged at 5,000 r.p.m. for 10 min. Acetone was then removed and pellet was 
allowed to air dry. Pellet was resuspended in 30 µL 8 M urea in PBS followed by 70 µL 
100 mM ammonium bicarbonate, and then 1.5 µL 1 M DTT was added. Samples were 
incubated at 65 °C for 15 min. After incubation, 2.5 µL of 500 mM iodoacetamide in PBS 
was added and the sample was left at room temperature for 30 min. Following incubation, 
120 µL PBS was added to each sample and vortexed rapidly. 2 µg of trypsin was added to 
the samples followed by 2.5 µL 100 mM CaCl2. Samples were then agitated for 37 °C 
overnight. Trypsin was then quenched with 10 µL formic acid and pelleted at 15,000 r.p.m 
for 20 min. Supernatants were stored at -20 °C. Samples were subsequently analyzed by 
LC–MS/MS using a LTQ Orbitrap XL mass spectrometer (Thermo Fisher) coupled to an 
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EASY-nLC 1000 nanoLC (Thermo Fisher). 10 µL samples were loaded onto 100 µm fused 
silica column with a 5 µm tip packed with 10 cm of Aqua C18 reverse-phase resin 
(Phenomenex) using the EASY-nLC 1000 autosampler. The digests were eluted using a 
gradient 0–100% buffer B in buffer A (buffer A: 95% water, 5% acetonitrile, 0.1% formic 
acid; buffer B; 20% water, 80% acetonitrile, 0.1% formic acid). The flow rate through the 
column was set to 400 nL/min and the spray voltage was set to 3.5 kV. One full MS scan 
(FTMS) (400–1800 MW) was followed by seven data-dependent scans (ITMS) of the nth 
most intense ion from the imported mass list with dynamic exclusion. The tandem MS data 
were searched using the SEQUEST algorithm using a concatenated target/decoy variant of 
the human IPI databases with addition of sfGFP. A static modification of +57.02146 on  
 cysteine was specified to account for iodoacetamide alkylation. SEQUEST output files 
were filtered using DTASelect 2.0. 
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pent-4-yn-1-yl 4-methylbenzenesulfonate 
1H-NMR 
 
13C-NMR 
 
  
 174 
methyl pent-4-yn-1-yl-L-leucinate  
1H-NMR 
 
13C-NMR 
 
 175 
4,6-dichloro-N-(4-methoxybenzyl)-N-(pent-4-yn-1-yl)-1,3,5-triazin-2-amine (LAS1) 
1H-NMR 
 
13C-NMR 
 
  
 176 
4,6-dichloro-N-(4-fluorobenzyl)-N-(pent-4-yn-1-yl)-1,3,5-triazin-2-amine (LAS2) 
1H-NMR 
 
13C-NMR 
 
  
 177 
4,6-dichloro-N-(2,3-dihydro-1H-inden-1-yl)-N-(pent-4-yn-1-yl)-1,3,5-triazin-2-amine 
(LAS3) 
1H-NMR 
 
13C-NMR 
 
 178 
4,6-dichloro-N-(3-methoxybenzyl)-N-(pent-4-yn-1-yl)-1,3,5-triazin-2-amine (LAS4) 
1H-NMR 
 
13C-NMR 
 
  
 179 
4,6-dichloro-N-(naphthalen-2-ylmethyl)-N-(pent-4-yn-1-yl)-1,3,5-triazin-2-amine 
(LAS5) 
1H-NMR 
 
13C-NMR 
 
 180 
4,6-dichloro-N-(furan-2-ylmethyl)-N-(pent-4-yn-1-yl)-1,3,5-triazin-2-amine (LAS6) 
1H-NMR 
 
13C-NMR 
 
  
 181 
4,6-dichloro-N-octyl-N-(pent-4-yn-1-yl)-1,3,5-triazin-2-amine (LAS7) 
1H-NMR 
 
13C-NMR 
 
  
 182 
4,6-dichloro-N-cyclopropyl-N-(pent-4-yn-1-yl)-1,3,5-triazin-2-amine (LAS8) 
1H-NMR 
 
13C-NMR 
 
  
 183 
2-((4,6-dichloro-1,3,5-triazin-2-yl)(pent-4-yn-1-yl)amino)ethan-1-ol (LAS8) 
1H-NMR 
 
13C-NMR 
 
  
 184 
methyl 2-((4,6-dichloro-1,3,5-triazin-2-yl)(pent-4-yn-1-yl)amino)-3-(1H-indol-3-yl)-2-
methylpropanoate (LAS10) 
1H-NMR 
 
13C-NMR 
 
 185 
methyl N-(4,6-dichloro-1,3,5-triazin-2-yl)-N-(pent-4-yn-1-yl)-L-phenylalaninate 
(LAS11) 
1H-NMR 
 
13C-NMR 
 
 186 
methyl N-(4,6-dichloro-1,3,5-triazin-2-yl)-N-(pent-4-yn-1-yl)-D-phenylalaninate 
(LAS12) 
1H-NMR 
 
13C-NMR 
 
 187 
methyl N-(4,6-dichloro-1,3,5-triazin-2-yl)-N-(pent-4-yn-1-yl)-L-methioninate 
(LAS13) 
1H-NMR 
 
13C-NMR 
 
 188 
methyl N-(4,6-dichloro-1,3,5-triazin-2-yl)-N-(pent-4-yn-1-yl)-D-methioninate 
(LAS14) 
1H-NMR 
 
13C-NMR 
 
 189 
dimethyl N-(4,6-dichloro-1,3,5-triazin-2-yl)-N-(pent-4-yn-1-yl)-L-glutamate (LAS15) 
1H-NMR 
 
13C-NMR 
 
  
 190 
dimethyl N-(4,6-dichloro-1,3,5-triazin-2-yl)-N-(pent-4-yn-1-yl)-D-glutamate (LAS16) 
1H-NMR 
 
13C-NMR 
 
  
 191 
methyl N-(4,6-dichloro-1,3,5-triazin-2-yl)-N-(pent-4-yn-1-yl)-L-leucinate (LAS17) 
1H-NMR 
 
13C-NMR 
 
  
 192 
methyl N-(4,6-dichloro-1,3,5-triazin-2-yl)-N-(pent-4-yn-1-yl)-D-leucinate (LAS18) 
1H-NMR 
 
13C-NMR 
 
  
 193 
methyl N-(4,6-dichloro-1,3,5-triazin-2-yl)-N-(pent-4-yn-1-yl)-L-tyrosinate (LAS19) 
1H-NMR 
 
13C-NMR 
 
  
 194 
methyl N-(4,6-dichloro-1,3,5-triazin-2-yl)-N-(pent-4-yn-1-yl)-D-tyrosinate (LAS20) 
1H-NMR 
 
13C-NMR 
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Table 1A-1. Tryptic digests of HeLa lysates +/- LAS17. 
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P09211 GSTP1_HUMAN - GSTP1 Glutathione S-transferase P 23342 0 0 0 36 23 13 0.0 24.0 24.0 
P00558 PGK1_HUMAN - PGK1 Phosphoglycerate kinase 1 44615 3 0 0 3 8 31 1.0 14.0 14.0 
P07900 HS90A_HUMAN - HSP90AA1 Heat shock protein HSP 90-alpha 84660 0 0 0 5 0 31 0.0 12.0 12.0 
P02545 LMNA_HUMAN - LMNA Prelamin-A/C 74140 2 0 0 0 3 17 0.7 6.7 10.0 
P04406 G3P_HUMAN - GAPDH Glyceraldehyde-3-phosphate dehydrogenase 36053 2 0 0 2 0 16 0.7 6.0 9.0 
Q01813 K6PP_HUMAN - PFKP 6-phosphofructokinase type C 85596 2 0 0 7 5 6 0.7 6.0 9.0 
P13639 EF2_HUMAN - EEF2 Elongation factor 2 95338 0 0 2 6 0 11 0.7 5.7 8.5 
P26639 SYTC_HUMAN - TARS Threonine--tRNA ligase, cytoplasmic 83435 2 0 0 2 3 11 0.7 5.3 8.0 
Q05639 EF1A2_HUMAN - EEF1A2 Elongation factor 1-alpha 2 50470 0 0 4 4 0 26 1.3 10.0 7.5 
P62736 ACTA_HUMAN - ACTA2 Actin, aortic smooth muscle 42009 0 0 2 0 0 15 0.7 5.0 7.5 
P68133 ACTS_HUMAN - ACTA1 Actin, alpha skeletal muscle 42051 0 0 2 0 0 15 0.7 5.0 7.5 
P11021 GRP78_HUMAN - HSPA5 78 kDa glucose-regulated protein 72333 0 0 0 0 2 19 0.0 7.0 7.0 
P29401 TKT_HUMAN - TKT Transketolase 67878 7 0 3 15 8 46 3.3 23.0 6.9 
P08238 HS90B_HUMAN - HSP90AB1 Heat shock protein HSP 90-beta 83264 11 0 0 8 11 53 3.7 24.0 6.5 
P04075 ALDOA_HUMAN - ALDOA Fructose-bisphosphate aldolase A 39420 2 0 0 2 0 11 0.7 4.3 6.5 
P11142 HSP7C_HUMAN - HSPA8 Heat shock cognate 71 kDa protein 70898 0 0 2 5 0 8 0.7 4.3 6.5 
P62258 1433E_HUMAN - YWHAE 14-3-3 protein epsilon 29174 0 0 0 0 0 19 0.0 6.3 6.3 
P06744 G6PI_HUMAN - GPI Glucose-6-phosphate isomerase 63147 2 0 0 0 0 12 0.7 4.0 6.0 
P18669 PGAM1_HUMAN - PGAM1 Phosphoglycerate mutase 1 28804 0 0 0 0 0 18 0.0 6.0 6.0 
P14625 ENPL_HUMAN - HSP90B1 Endoplasmin 92469 2 0 0 0 0 11 0.7 3.7 5.5 
P68366 TBA4A_HUMAN - TUBA4A Tubulin alpha-4A chain 49924 8 0 5 4 13 48 4.3 21.7 5.0 
O43707 ACTN4_HUMAN - ACTN4 Alpha-actinin-4 104854 0 0 3 0 3 12 1.0 5.0 5.0 
P10809 CH60_HUMAN - HSPD1 60 kDa heat shock protein, mitochondrial 61055 0 0 0 4 0 11 0.0 5.0 5.0 
P12956 XRCC6_HUMAN - XRCC6 X-ray repair cross-complementing protein 6 69843 0 0 0 0 2 13 0.0 5.0 5.0 
P07195 LDHB_HUMAN - LDHB L-lactate dehydrogenase B chain 36639 0 0 0 6 3 5 0.0 4.7 4.7 
Q9Y490 TLN1_HUMAN - TLN1 Talin-1 269765 0 0 0 3 5 6 0.0 4.7 4.7 
Q16658 FSCN1_HUMAN - FSCN1 Fascin 54530 0 0 0 0 0 14 0.0 4.7 4.7 
Q15149 PLEC_HUMAN - PLEC Plectin 531796 2 0 0 2 0 7 0.7 3.0 4.5 
Q14697 GANAB_HUMAN - GANAB Neutral alpha-glucosidase AB 106874 3 0 0 2 0 11 1.0 4.3 4.3 
P55072 TERA_HUMAN - VCP Transitional endoplasmic reticulum ATPase 89322 0 0 0 0 0 13 0.0 4.3 4.3 
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P14618 KPYM_HUMAN - PKM Pyruvate kinase isozymes M1/M2 57937 7 5 5 7 5 55 5.7 22.3 3.9 
P68104 EF1A1_HUMAN - EEF1A1 Elongation factor 1-alpha 1 50141 12 0 4 4 0 57 5.3 20.3 3.8 
P07205 PGK2_HUMAN - PGK2 Phosphoglycerate kinase 2 44796 3 0 0 3 8 0 1.0 3.7 3.7 
P53396 ACLY_HUMAN - ACLY ATP-citrate synthase 120839 0 0 0 0 0 11 0.0 3.7 3.7 
P60174 TPIS_HUMAN - TPI1 Triosephosphate isomerase 30791 5 0 0 0 0 18 1.7 6.0 3.6 
P21333 FLNA_HUMAN - FLNA Filamin-A 280737 12 0 5 9 9 42 5.7 20.0 3.5 
P31948 STIP1_HUMAN - STIP1 Stress-induced-phosphoprotein 1 62639 0 0 2 0 0 7 0.7 2.3 3.5 
P07437 TBB5_HUMAN - TUBB Tubulin beta chain 49671 5 8 4 15 10 33 5.7 19.3 3.4 
P38646 GRP75_HUMAN - HSPA9 Stress-70 protein, mitochondrial 73681 0 0 0 0 2 8 0.0 3.3 3.3 
P68371 TBB4B_HUMAN - TUBB4B Tubulin beta-4B chain 49831 5 8 0 0 10 33 4.3 14.3 3.3 
P35579 MYH9_HUMAN - MYH9 Myosin-9 226530 5 0 4 5 3 21 3.0 9.7 3.2 
P06733 ENOA_HUMAN - ENO1 Alpha-enolase 47169 4 0 2 3 0 16 2.0 6.3 3.2 
P49327 FAS_HUMAN - FASN Fatty acid synthase 273424 3 0 2 0 2 13 1.7 5.0 3.0 
P40926 MDHM_HUMAN - MDH2 Malate dehydrogenase, mitochondrial 35503 0 0 0 0 0 9 0.0 3.0 3.0 
Q00610 CLH1_HUMAN - CLTC Clathrin heavy chain 1 191613 4 0 4 5 4 14 2.7 7.7 2.9 
Q14315 FLNC_HUMAN - FLNC Filamin-C 291020 3 0 2 7 3 4 1.7 4.7 2.8 
P31327 CPSM_HUMAN - CPS1 Carbamoyl-phosphate synthase 164939 0 0 3 3 0 5 1.0 2.7 2.7 
O75369 FLNB_HUMAN - FLNB Filamin-B 278162 0 0 0 3 0 5 0.0 2.7 2.7 
P60660 MYL6_HUMAN - MYL6 Myosin light polypeptide 6 16930 0 0 0 0 0 8 0.0 2.7 2.7 
P22314 UBA1_HUMAN - UBA1 Ubiquitin-like modifier-activating enzyme 1 117849 0 0 0 0 0 8 0.0 2.7 2.7 
P17812 PYRG1_HUMAN - CTPS1 CTP synthase 1 66690 0 0 0 0 0 8 0.0 2.7 2.7 
P60709 ACTB_HUMAN - ACTB Actin, cytoplasmic 1 41737 14 2 10 10 3 48 8.7 20.3 2.3 
P08107 HSP71_HUMAN - HSPA1B Heat shock 70 kDa protein 1A/1B 70052 0 0 0 3 0 4 0.0 2.3 2.3 
P07237 PDIA1_HUMAN - P4HB Protein disulfide-isomerase 57116 0 0 0 2 0 5 0.0 2.3 2.3 
P00338 LDHA_HUMAN - LDHA L-lactate dehydrogenase A chain 36689 0 0 0 0 0 7 0.0 2.3 2.3 
P25786 PSA1_HUMAN - PSMA1 Proteasome subunit alpha type-1 29556 0 0 0 0 0 7 0.0 2.3 2.3 
B4DEV8 B4DEV8_HUMAN - PSMA1 Proteasome subunit alpha type 18458 0 0 0 0 0 7 0.0 2.3 2.3 
Q04695 K1C17_HUMAN - KRT17 Keratin, type I cytoskeletal 17 48106 2 0 0 2 0 2 0.7 1.3 2.0 
P17987 TCPA_HUMAN - TCP1 T-complex protein 1 subunit alpha 60344 0 0 2 4 0 0 0.7 1.3 2.0 
P07477 TRY1_HUMAN - PRSS1 Trypsin-1 26558 0 0 0 2 4 0 0.0 2.0 2.0 
P07478 TRY2_HUMAN - PRSS2 Trypsin-2 26488 0 0 0 2 4 0 0.0 2.0 2.0 
P52209 6PGD_HUMAN - PGD 6-phosphogluconate dehydrogenase, decarboxylating 53140 0 0 0 0 2 4 0.0 2.0 2.0 
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P48643 TCPE_HUMAN - CCT5 T-complex protein 1 subunit epsilon 59671 0 0 0 0 2 4 0.0 2.0 2.0 
P09488 GSTM1_HUMAN - GSTM1 Glutathione S-transferase Mu 1 25712 0 0 0 0 6 0 0.0 2.0 2.0 
Q03013 GSTM4_HUMAN - GSTM4 Glutathione S-transferase Mu 4 25561 0 0 0 0 6 0 0.0 2.0 2.0 
P46439 GSTM5_HUMAN - GSTM5 Glutathione S-transferase Mu 5 25675 0 0 0 0 6 0 0.0 2.0 2.0 
P31040 DHSA_HUMAN - SDHA Succinate dehydrogenase 72692 0 0 0 0 2 4 0.0 2.0 2.0 
P31153 METK2_HUMAN - MAT2A S-adenosylmethionine synthase isoform type-2 43661 0 0 0 0 0 6 0.0 2.0 2.0 
Q562R1 ACTBL_HUMAN - ACTBL2 Beta-actin-like protein 2 42003 0 0 0 0 0 6 0.0 2.0 2.0 
P14324 FPPS_HUMAN - FDPS Farnesyl pyrophosphate synthase 48276 0 0 0 0 0 6 0.0 2.0 2.0 
O00231 
PSD11_HUMAN - PSMD11 26S 
proteasome non-ATPase regulatory subunit 
11 
47464 0 0 0 0 0 6 0.0 2.0 2.0 
Q92769 HDAC2_HUMAN - HDAC2 Histone deacetylase 2 55364 0 0 0 0 0 6 0.0 2.0 2.0 
Q13813 SPTN1_HUMAN - SPTAN1 Spectrin alpha chain, non-erythrocytic 1 284538 0 0 0 0 0 6 0.0 2.0 2.0 
P50454 SERPH_HUMAN - SERPINH1 Serpin H1 46441 0 0 0 0 0 6 0.0 2.0 2.0 
P28074 PSB5_HUMAN - PSMB5 Proteasome subunit beta type-5 28480 0 0 0 2 0 3 0.0 1.7 1.7 
P23528 COF1_HUMAN - CFL1 Cofilin-1 18502 0 0 0 0 2 3 0.0 1.7 1.7 
Q02790 FKBP4_HUMAN - FKBP4 Peptidyl-prolyl cis-trans isomerase FKBP4 51805 0 0 0 0 2 3 0.0 1.7 1.7 
O00763 ACACB_HUMAN - ACACB Acetyl-CoA carboxylase 2 276539 0 0 0 0 5 0 0.0 1.7 1.7 
P26447 S10A4_HUMAN - S100A4 Protein S100-A4 11728 0 0 0 0 0 5 0.0 1.7 1.7 
Q13162 PRDX4_HUMAN - PRDX4 Peroxiredoxin-4 30540 0 0 0 0 0 5 0.0 1.7 1.7 
P36873 
PP1G_HUMAN - PPP1CC 
Serine/threonine-protein phosphatase PP1-
gamma catalytic subunit 
36984 0 0 0 0 0 5 0.0 1.7 1.7 
P62136 
PP1A_HUMAN - PPP1CA 
Serine/threonine-protein phosphatase PP1-
alpha catalytic subunit 
37512 0 0 0 0 0 5 0.0 1.7 1.7 
P62140 
PP1B_HUMAN - PPP1CB 
Serine/threonine-protein phosphatase PP1-
beta catalytic subunit 
37187 0 0 0 0 0 5 0.0 1.7 1.7 
P08670 VIME_HUMAN - VIM Vimentin 53652 0 0 0 0 0 5 0.0 1.7 1.7 
P50395 GDIB_HUMAN - GDI2 Rab GDP dissociation inhibitor beta 50663 0 0 0 0 0 5 0.0 1.7 1.7 
Q9H4A4 AMPB_HUMAN - RNPEP Aminopeptidase B 72596 0 0 0 0 0 5 0.0 1.7 1.7 
P20618 PSB1_HUMAN - PSMB1 Proteasome subunit beta type-1 26489 0 0 0 0 0 5 0.0 1.7 1.7 
P13797 PLST_HUMAN - PLS3 Plastin-3 70811 0 0 0 0 0 5 0.0 1.7 1.7 
P0CG48 UBC_HUMAN - UBC Polyubiquitin-C 77039 0 0 0 0 0 5 0.0 1.7 1.7 
J3QRK5 J3QRK5_HUMAN - UBBP4 Protein UBBP4 25797 0 0 0 0 0 5 0.0 1.7 1.7 
P62987 RL40_HUMAN - UBA52 Ubiquitin-60S ribosomal protein L40 14728 0 0 0 0 0 5 0.0 1.7 1.7 
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P62979 RS27A_HUMAN - RPS27A Ubiquitin-40S ribosomal protein S27a 17965 0 0 0 0 0 5 0.0 1.7 1.7 
P07814 SYEP_HUMAN - EPRS Bifunctional glutamate/proline--tRNA ligase 170590 0 0 0 0 0 5 0.0 1.7 1.7 
O43143 
DHX15_HUMAN - DHX15 Putative pre-
mRNA-splicing factor ATP-dependent RNA 
helicase DHX15 
90933 0 0 0 0 0 5 0.0 1.7 1.7 
Q71U36 TBA1A_HUMAN - TUBA1A Tubulin alpha-1A chain 50136 8 0 5 4 14 0 4.3 6.0 1.4 
Q13748 TBA3C_HUMAN - TUBA3D Tubulin alpha-3C/D chain 49960 8 0 5 4 14 0 4.3 6.0 1.4 
P02649 APOE_HUMAN - APOE Apolipoprotein E 36154 9 0 2 7 6 2 3.7 5.0 1.4 
P49368 TCPG_HUMAN - CCT3 T-complex protein 1 subunit gamma 60534 0 0 0 4 0 0 0.0 1.3 1.3 
O75874 IDHC_HUMAN - IDH1 Isocitrate dehydrogenase 46659 0 0 0 0 2 2 0.0 1.3 1.3 
Q93008 
USP9X_HUMAN - USP9X Probable 
ubiquitin carboxyl-terminal hydrolase FAF-
X 
292278 0 0 0 0 2 2 0.0 1.3 1.3 
P60842 IF4A1_HUMAN - EIF4A1 Eukaryotic initiation factor 4A-I 46154 0 0 0 0 0 4 0.0 1.3 1.3 
P42330 AK1C3_HUMAN - AKR1C3 Aldo-keto reductase family 1 member C3 36853 0 0 0 0 0 4 0.0 1.3 1.3 
P61158 ARP3_HUMAN - ACTR3 Actin-related protein 3 47371 0 0 0 0 0 4 0.0 1.3 1.3 
P78417 GSTO1_HUMAN - GSTO1 Glutathione S-transferase omega-1 27566 0 0 0 0 0 4 0.0 1.3 1.3 
P43686 PRS6B_HUMAN - PSMC4 26S protease regulatory subunit 6B 47366 0 0 0 0 0 4 0.0 1.3 1.3 
P15559 NQO1_HUMAN - NQO1 NAD(P)H dehydrogenase 30868 0 0 0 0 0 4 0.0 1.3 1.3 
P54577 SYYC_HUMAN - YARS Tyrosine--tRNA ligase, cytoplasmic 59144 0 0 0 0 0 4 0.0 1.3 1.3 
P61160 ARP2_HUMAN - ACTR2 Actin-related protein 2 44761 0 0 0 0 0 4 0.0 1.3 1.3 
P35520 CBS_HUMAN - CBS Cystathionine beta-synthase 60587 0 0 0 0 0 4 0.0 1.3 1.3 
O75828 CBR3_HUMAN - CBR3 Carbonyl reductase 30850 0 0 0 0 0 4 0.0 1.3 1.3 
P16152 CBR1_HUMAN - CBR1 Carbonyl reductase 30375 0 0 0 0 0 4 0.0 1.3 1.3 
P12814 ACTN1_HUMAN - ACTN1 Alpha-actinin-1 103058 0 0 0 0 0 4 0.0 1.3 1.3 
Q99460 
PSMD1_HUMAN - PSMD1 26S 
proteasome non-ATPase regulatory subunit 
1 
105836 0 0 0 0 0 4 0.0 1.3 1.3 
P41250 SYG_HUMAN - GARS Glycine--tRNA ligase 83166 0 0 0 0 0 4 0.0 1.3 1.3 
Q99832 TCPH_HUMAN - CCT7 T-complex protein 1 subunit eta 59367 0 0 0 0 0 4 0.0 1.3 1.3 
B0V043 B0V043_HUMAN - VARS Valyl-tRNA synthetase 140466 0 0 0 0 0 4 0.0 1.3 1.3 
P62266 RS23_HUMAN - RPS23 40S ribosomal protein S23 15808 3 0 2 0 0 6 1.7 2.0 1.2 
P09429 HMGB1_HUMAN - HMGB1 High mobility group protein B1 24894 0 0 5 0 0 6 1.7 2.0 1.2 
P11498 PYC_HUMAN - PC Pyruvate carboxylase, mitochondrial 129634 40 34 45 52 43 37 
39.
7 44.0 1.1 
P04792 HSPB1_HUMAN - HSPB1 Heat shock protein beta-1 22783 2 0 0 0 0 2 0.7 0.7 1.0 
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O76009 KT33A_HUMAN - KRT33A Keratin, type I cuticular Ha3-I 45940 2 0 0 0 2 0 0.7 0.7 1.0 
P02533 K1C14_HUMAN - KRT14 Keratin, type I cytoskeletal 14 51561 2 0 0 2 0 0 0.7 0.7 1.0 
Q14566 MCM6_HUMAN - MCM6 DNA replication licensing factor MCM6 92889 0 0 2 0 0 2 0.7 0.7 1.0 
P17066 HSP76_HUMAN - HSPA6 Heat shock 70 kDa protein 6 71028 0 0 0 3 0 0 0.0 1.0 1.0 
O60361 NDK8_HUMAN - NME2P1 Putative nucleoside diphosphate kinase 15529 0 0 0 0 0 3 0.0 1.0 1.0 
P22392 NDKB_HUMAN - NME2 Nucleoside diphosphate kinase B 17298 0 0 0 0 0 3 0.0 1.0 1.0 
P36952 SPB5_HUMAN - SERPINB5 Serpin B5 42100 0 0 0 0 0 3 0.0 1.0 1.0 
P30101 PDIA3_HUMAN - PDIA3 Protein disulfide-isomerase A3 56782 0 0 0 0 0 3 0.0 1.0 1.0 
P23381 SYWC_HUMAN - WARS Tryptophan--tRNA ligase, cytoplasmic 53165 0 0 0 0 0 3 0.0 1.0 1.0 
Q01105 SET_HUMAN - SET Protein SET 33489 0 0 0 0 0 3 0.0 1.0 1.0 
Q15008 
PSMD6_HUMAN - PSMD6 26S 
proteasome non-ATPase regulatory subunit 
6 
45531 0 0 0 0 0 3 0.0 1.0 1.0 
Q96FW1 OTUB1_HUMAN - OTUB1 Ubiquitin thioesterase OTUB1 31284 0 0 0 0 0 3 0.0 1.0 1.0 
Q9H832 UBE2Z_HUMAN - UBE2Z Ubiquitin-conjugating enzyme E2 Z 38210 0 0 0 0 0 3 0.0 1.0 1.0 
P00390 GSHR_HUMAN - GSR Glutathione reductase, mitochondrial 56257 0 0 0 0 0 3 0.0 1.0 1.0 
Q13838 DX39B_HUMAN - DDX39B Spliceosome RNA helicase DDX39B 48991 0 0 0 0 0 3 0.0 1.0 1.0 
P50213 IDH3A_HUMAN - IDH3A Isocitrate dehydrogenase 39592 0 0 0 0 0 3 0.0 1.0 1.0 
P31943 HNRH1_HUMAN - HNRNPH1 Heterogeneous nuclear ribonucleoprotein H 49229 0 0 0 0 0 3 0.0 1.0 1.0 
P55795 
HNRH2_HUMAN - HNRNPH2 
Heterogeneous nuclear ribonucleoprotein 
H2 
49264 0 0 0 0 0 3 0.0 1.0 1.0 
P26641 EF1G_HUMAN - EEF1G Elongation factor 1-gamma 50119 0 0 0 0 0 3 0.0 1.0 1.0 
E7EMT2 E7EMT2_HUMAN - Uncharacterized protein 24182 0 0 0 0 0 3 0.0 1.0 1.0 
Q99798 ACON_HUMAN - ACO2 Aconitate hydratase, mitochondrial 85425 0 0 0 0 0 3 0.0 1.0 1.0 
P11766 ADHX_HUMAN - ADH5 Alcohol dehydrogenase class-3 39724 0 0 0 0 0 3 0.0 1.0 1.0 
Q9Y263 PLAP_HUMAN - PLAA Phospholipase A-2-activating protein 87157 0 0 0 0 0 3 0.0 1.0 1.0 
P06576 ATPB_HUMAN - ATP5B ATP synthase subunit beta, mitochondrial 56560 0 0 0 0 0 3 0.0 1.0 1.0 
P34932 HSP74_HUMAN - HSPA4 Heat shock 70 kDa protein 4 94331 0 0 0 0 0 3 0.0 1.0 1.0 
Q9NSE4 SYIM_HUMAN - IARS2 Isoleucine--tRNA ligase, mitochondrial 113791 0 0 0 0 0 3 0.0 1.0 1.0 
Q15029 U5S1_HUMAN - EFTUD2 116 kDa U5 small nuclear ribonucleoprotein component 109436 0 0 0 0 0 3 0.0 1.0 1.0 
Q12931 TRAP1_HUMAN - TRAP1 Heat shock protein 75 kDa, mitochondrial 80110 0 0 0 0 0 3 0.0 1.0 1.0 
Q14980 NUMA1_HUMAN - NUMA1 Nuclear mitotic apparatus protein 1 238257 0 0 0 0 0 3 0.0 1.0 1.0 
Q14974 IMB1_HUMAN - KPNB1 Importin subunit beta-1 97170 0 0 0 0 0 3 0.0 1.0 1.0 
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Q13085 ACACA_HUMAN - ACACA Acetyl-CoA carboxylase 1 265551 50 22 39 43 41 23 
37.
0 35.7 1.0 
P05165 PCCA_HUMAN - PCCA Propionyl-CoA carboxylase alpha chain, mitochondrial 80059 18 7 10 7 14 10 
11.
7 10.3 0.9 
P13645 K1C10_HUMAN - KRT10 Keratin, type I cytoskeletal 10 58827 8 0 15 13 6 0 7.7 6.3 0.8 
Q9BVA1 TBB2B_HUMAN - TUBB2B Tubulin beta-2B chain 49953 5 8 0 0 10 0 4.3 3.3 0.8 
Q96RQ3 
MCCA_HUMAN - MCCC1 
Methylcrotonoyl-CoA carboxylase subunit 
alpha, mitochondrial 
80473 15 0 6 4 4 8 7.0 5.3 0.8 
Q9UI26 IPO11_HUMAN - IPO11 Importin-11 112535 0 0 0 2 0 0 0.0 0.7 0.7 
P09622 DLDH_HUMAN - DLD Dihydrolipoyl dehydrogenase, mitochondrial 54177 0 0 0 2 0 0 0.0 0.7 0.7 
P35900 K1C20_HUMAN - KRT20 Keratin, type I cytoskeletal 20 48487 0 0 0 2 0 0 0.0 0.7 0.7 
P19012 K1C15_HUMAN - KRT15 Keratin, type I cytoskeletal 15 49212 0 0 0 2 0 0 0.0 0.7 0.7 
P13646 K1C13_HUMAN - KRT13 Keratin, type I cytoskeletal 13 49588 0 0 0 2 0 0 0.0 0.7 0.7 
P08779 K1C16_HUMAN - KRT16 Keratin, type I cytoskeletal 16 51268 0 0 0 2 0 0 0.0 0.7 0.7 
Q14525 KT33B_HUMAN - KRT33B Keratin, type I cuticular Ha3-II 46214 0 0 0 0 2 0 0.0 0.7 0.7 
Q8NBS9 TXND5_HUMAN - TXNDC5 Thioredoxin domain-containing protein 5 47629 0 0 0 0 2 0 0.0 0.7 0.7 
Q7Z794 K2C1B_HUMAN - KRT77 Keratin, type II cytoskeletal 1b 61901 0 0 0 0 2 0 0.0 0.7 0.7 
P31947 1433S_HUMAN - SFN 14-3-3 protein sigma 27774 0 0 0 0 0 2 0.0 0.7 0.7 
P33316 
DUT_HUMAN - DUT Deoxyuridine 5'-
triphosphate nucleotidohydrolase, 
mitochondrial 
26563 0 0 0 0 0 2 0.0 0.7 0.7 
P52907 CAZA1_HUMAN - CAPZA1 F-actin-capping protein subunit alpha-1 32923 0 0 0 0 0 2 0.0 0.7 0.7 
P21266 GSTM3_HUMAN - GSTM3 Glutathione S-transferase Mu 3 26560 0 0 0 0 0 2 0.0 0.7 0.7 
P09651 
ROA1_HUMAN - HNRNPA1 
Heterogeneous nuclear ribonucleoprotein 
A1 
38747 0 0 0 0 0 2 0.0 0.7 0.7 
P07355 ANXA2_HUMAN - ANXA2 Annexin A2 38604 0 0 0 0 0 2 0.0 0.7 0.7 
P04818 TYSY_HUMAN - TYMS Thymidylate synthase 35716 0 0 0 0 0 2 0.0 0.7 0.7 
P55209 NP1L1_HUMAN - NAP1L1 Nucleosome assembly protein 1-like 1 45374 0 0 0 0 0 2 0.0 0.7 0.7 
P38919 IF4A3_HUMAN - EIF4A3 Eukaryotic initiation factor 4A-III 46871 0 0 0 0 0 2 0.0 0.7 0.7 
O43175 SERA_HUMAN - PHGDH D-3-phosphoglycerate dehydrogenase 56651 0 0 0 0 0 2 0.0 0.7 0.7 
O00148 DX39A_HUMAN - DDX39A ATP-dependent RNA helicase DDX39A 49130 0 0 0 0 0 2 0.0 0.7 0.7 
P52597 HNRPF_HUMAN - HNRNPF Heterogeneous nuclear ribonucleoprotein F 45672 0 0 0 0 0 2 0.0 0.7 0.7 
P62333 PRS10_HUMAN - PSMC6 26S protease regulatory subunit 10B 44173 0 0 0 0 0 2 0.0 0.7 0.7 
P07954 FUMH_HUMAN - FH Fumarate hydratase, mitochondrial 54637 0 0 0 0 0 2 0.0 0.7 0.7 
Q13263 TIF1B_HUMAN - TRIM28 Transcription intermediary factor 1-beta 88550 0 0 0 0 0 2 0.0 0.7 0.7 
P78371 TCPB_HUMAN - CCT2 T-complex protein 1 subunit beta 57488 0 0 0 0 0 2 0.0 0.7 0.7 
 202 
IPI Protein 
M
ol W
eight 
(D
a) 
D
M
SO
_1 
D
M
SO
_2 
D
M
SO
_3 
LA
S17_1 
LA
S17_2 
LA
S17_3 
D
M
SO
 
A
verage 
LA
S17 
A
verage 
Fold C
hange 
P23526 SAHH_HUMAN - AHCY Adenosylhomocysteinase 47716 0 0 0 0 0 2 0.0 0.7 0.7 
P08195 4F2_HUMAN - SLC3A2 4F2 cell-surface antigen heavy chain 67994 0 0 0 0 0 2 0.0 0.7 0.7 
P35237 SPB6_HUMAN - SERPINB6 Serpin B6 42622 0 0 0 0 0 2 0.0 0.7 0.7 
Q15084 PDIA6_HUMAN - PDIA6 Protein disulfide-isomerase A6 48121 0 0 0 0 0 2 0.0 0.7 0.7 
Q9UBB4 ATX10_HUMAN - ATXN10 Ataxin-10 53489 0 0 0 0 0 2 0.0 0.7 0.7 
Q15067 ACOX1_HUMAN - ACOX1 Peroxisomal acyl-coenzyme A oxidase 1 74424 0 0 0 0 0 2 0.0 0.7 0.7 
P15170 
ERF3A_HUMAN - GSPT1 Eukaryotic 
peptide chain release factor GTP-binding 
subunit ERF3A 
55756 0 0 0 0 0 2 0.0 0.7 0.7 
P13861 
KAP2_HUMAN - PRKAR2A cAMP-
dependent protein kinase type II-alpha 
regulatory subunit 
45518 0 0 0 0 0 2 0.0 0.7 0.7 
Q00839 HNRPU_HUMAN - HNRNPU Heterogeneous nuclear ribonucleoprotein U 90585 0 0 0 0 0 2 0.0 0.7 0.7 
Q08J23 NSUN2_HUMAN - NSUN2 tRNA (cytosine(34)-C(5))-methyltransferase 86471 0 0 0 0 0 2 0.0 0.7 0.7 
P13010 XRCC5_HUMAN - XRCC5 X-ray repair cross-complementing protein 5 82705 0 0 0 0 0 2 0.0 0.7 0.7 
O00154 BACH_HUMAN - ACOT7 Cytosolic acyl coenzyme A thioester hydrolase 41796 0 0 0 0 0 2 0.0 0.7 0.7 
Q96QK1 VPS35_HUMAN - VPS35 Vacuolar protein sorting-associated protein 35 91707 0 0 0 0 0 2 0.0 0.7 0.7 
P00491 PNPH_HUMAN - PNP Purine nucleoside phosphorylase 32118 0 0 0 0 0 2 0.0 0.7 0.7 
P33991 MCM4_HUMAN - MCM4 DNA replication licensing factor MCM4 96558 0 0 0 0 0 2 0.0 0.7 0.7 
P49588 SYAC_HUMAN - AARS Alanine--tRNA ligase, cytoplasmic 106810 0 0 0 0 0 2 0.0 0.7 0.7 
P18206 VINC_HUMAN - VCL Vinculin 123799 0 0 0 0 0 2 0.0 0.7 0.7 
P78347 GTF2I_HUMAN - GTF2I General transcription factor II-I 112416 0 0 0 0 0 2 0.0 0.7 0.7 
Q15021 CND1_HUMAN - NCAPD2 Condensin complex subunit 1 157182 0 0 0 0 0 2 0.0 0.7 0.7 
Q86VP6 CAND1_HUMAN - CAND1 Cullin-associated NEDD8-dissociated protein 1 136375 0 0 0 0 0 2 0.0 0.7 0.7 
Q04637 IF4G1_HUMAN - EIF4G1 Eukaryotic translation initiation factor 4 gamma 1 175490 0 0 0 0 0 2 0.0 0.7 0.7 
P30876 RPB2_HUMAN - POLR2B DNA-directed RNA polymerase II subunit RPB2 133896 0 0 0 0 0 2 0.0 0.7 0.7 
Q92973 TNPO1_HUMAN - TNPO1 Transportin-1 102355 0 0 0 0 0 2 0.0 0.7 0.7 
P46940 IQGA1_HUMAN - IQGAP1 Ras GTPase-activating-like protein IQGAP1 189251 0 0 0 0 0 2 0.0 0.7 0.7 
O75116 ROCK2_HUMAN - ROCK2 Rho-associated protein kinase 2 160899 0 0 0 0 0 2 0.0 0.7 0.7 
O75643 U520_HUMAN - SNRNP200 U5 small nuclear ribonucleoprotein 200 kDa helicase 244505 0 0 0 0 0 2 0.0 0.7 0.7 
Q92616 GCN1L_HUMAN - GCN1L1 Translational activator GCN1 292756 0 0 0 0 0 2 0.0 0.7 0.7 
Q9Y4I1 MYO5A_HUMAN - MYO5A Unconventional myosin-Va 215403 0 0 0 0 0 2 0.0 0.7 0.7 
O00507 
USP9Y_HUMAN - USP9Y Probable 
ubiquitin carboxyl-terminal hydrolase FAF-
Y 
291075 0 0 0 0 0 2 0.0 0.7 0.7 
P12270 TPR_HUMAN - TPR Nucleoprotein TPR 267290 0 0 0 0 0 2 0.0 0.7 0.7 
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Q14204 DYHC1_HUMAN - DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 532412 0 0 0 0 0 2 0.0 0.7 0.7 
P04264 K2C1_HUMAN - KRT1 Keratin, type II cytoskeletal 1 66039 17 5 28 14 9 5 
16.
7 9.3 0.6 
P06748 NPM_HUMAN - NPM1 Nucleophosmin 32575 8 0 3 0 0 6 3.7 2.0 0.5 
P13647 K2C5_HUMAN - KRT5 Keratin, type II cytoskeletal 5 62378 11 2 4 9 0 0 5.7 3.0 0.5 
Q9P258 RCC2_HUMAN - RCC2 Protein RCC2 56085 4 0 2 0 0 3 2.0 1.0 0.5 
Q15323 K1H1_HUMAN - KRT31 Keratin, type I cuticular Ha1 47237 4 0 0 0 2 0 1.3 0.7 0.5 
P35908 K22E_HUMAN - KRT2 Keratin, type II cytoskeletal 2 epidermal 65433 15 2 11 10 2 0 9.3 4.0 0.4 
Q5T749 KPRP_HUMAN - KPRP Keratinocyte proline-rich protein 64136 2 0 3 2 0 0 1.7 0.7 0.4 
P35527 K1C9_HUMAN - KRT9 Keratin, type I cytoskeletal 9 62064 4 2 7 3 0 0 4.3 1.0 0.2 
Q86YZ3 HORN_HUMAN - HRNR Hornerin 282389 2 0 7 0 2 0 3.0 0.7 0.2 
P02538 K2C6A_HUMAN - KRT6A Keratin, type II cytoskeletal 6A 60045 10 2 0 0 0 0 4.0 0.0 0.0 
Q14978 NOLC1_HUMAN - NOLC1 Nucleolar and coiled-body phosphoprotein 1 73603 7 0 2 0 0 0 3.0 0.0 0.0 
P19338 NUCL_HUMAN - NCL Nucleolin 76615 5 0 3 0 0 0 2.7 0.0 0.0 
I3L2F9 I3L2F9_HUMAN - Uncharacterized protein 45399 0 8 0 0 0 0 2.7 0.0 0.0 
Q3ZCM7 TBB8_HUMAN - TUBB8 Tubulin beta-8 chain 49776 0 8 0 0 0 0 2.7 0.0 0.0 
O43790 KRT86_HUMAN - KRT86 Keratin, type II cuticular Hb6 53501 6 0 0 0 0 0 2.0 0.0 0.0 
Q14533 KRT81_HUMAN - KRT81 Keratin, type II cuticular Hb1 54928 6 0 0 0 0 0 2.0 0.0 0.0 
P78385 KRT83_HUMAN - KRT83 Keratin, type II cuticular Hb3 54195 6 0 0 0 0 0 2.0 0.0 0.0 
P78386 KRT85_HUMAN - KRT85 Keratin, type II cuticular Hb5 55802 6 0 0 0 0 0 2.0 0.0 0.0 
Q13428 TCOF_HUMAN - TCOF1 Treacle protein 152105 6 0 0 0 0 0 2.0 0.0 0.0 
Q9BYQ8 KRA49_HUMAN - KRTAP4-9 Keratin-associated protein 4-9 22405 5 0 0 0 0 0 1.7 0.0 0.0 
Q15185 TEBP_HUMAN - PTGES3 Prostaglandin E synthase 3 18697 4 0 0 0 0 0 1.3 0.0 0.0 
Q14247 SRC8_HUMAN - CTTN Src substrate cortactin 61586 2 0 2 0 0 0 1.3 0.0 0.0 
P25205 MCM3_HUMAN - MCM3 DNA replication licensing factor MCM3 90981 3 0 0 0 0 0 1.0 0.0 0.0 
Q9C0C9 UBE2O_HUMAN - UBE2O Ubiquitin-conjugating enzyme E2 O 141293 3 0 0 0 0 0 1.0 0.0 0.0 
Q9P2J5 SYLC_HUMAN - LARS Leucine--tRNA ligase, cytoplasmic 134466 3 0 0 0 0 0 1.0 0.0 0.0 
Q9UQ35 SRRM2_HUMAN - SRRM2 Serine/arginine repetitive matrix protein 2 299616 3 0 0 0 0 0 1.0 0.0 0.0 
Q09666 AHNK_HUMAN - AHNAK Neuroblast differentiation-associated protein AHNAK 629114 3 0 0 0 0 0 1.0 0.0 0.0 
P15311 EZRI_HUMAN - EZR Ezrin 69413 0 0 3 0 0 0 1.0 0.0 0.0 
Q92764 KRT35_HUMAN - KRT35 Keratin, type I cuticular Ha5 50361 2 0 0 0 0 0 0.7 0.0 0.0 
P62269 RS18_HUMAN - RPS18 40S ribosomal protein S18 17719 2 0 0 0 0 0 0.7 0.0 0.0 
Q9UNF1 MAGD2_HUMAN - MAGED2 Melanoma-associated antigen D2 64954 2 0 0 0 0 0 0.7 0.0 0.0 
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O14980 XPO1_HUMAN - XPO1 Exportin-1 123386 2 0 0 0 0 0 0.7 0.0 0.0 
I3L1M0 I3L1M0_HUMAN - Uncharacterized protein 49431 2 0 0 0 0 0 0.7 0.0 0.0 
Q13620 CUL4B_HUMAN - CUL4B Cullin-4B 103982 2 0 0 0 0 0 0.7 0.0 0.0 
P0CG38 POTEI_HUMAN - POTEI POTE ankyrin domain family member I 121282 0 2 0 0 0 0 0.7 0.0 0.0 
Q6S8J3 POTEE_HUMAN - POTEE POTE ankyrin domain family member E 121363 0 2 0 0 0 0 0.7 0.0 0.0 
P0CG39 POTEJ_HUMAN - POTEJ POTE ankyrin domain family member J 117390 0 2 0 0 0 0 0.7 0.0 0.0 
P0C0S8 H2A1_HUMAN - HIST1H2AM Histone H2A type 1 14091 0 0 2 0 0 0 0.7 0.0 0.0 
Q9BTM1 H2AJ_HUMAN - H2AFJ Histone H2A.J 14019 0 0 2 0 0 0 0.7 0.0 0.0 
Q96QV6 H2A1A_HUMAN - HIST1H2AA Histone H2A type 1-A 14233 0 0 2 0 0 0 0.7 0.0 0.0 
Q8IUE6 H2A2B_HUMAN - HIST2H2AB Histone H2A type 2-B 13995 0 0 2 0 0 0 0.7 0.0 0.0 
Q16777 H2A2C_HUMAN - HIST2H2AC Histone H2A type 2-C 13988 0 0 2 0 0 0 0.7 0.0 0.0 
P22626 
ROA2_HUMAN - HNRNPA2B1 
Heterogeneous nuclear ribonucleoproteins 
A2/B1 
37430 0 0 2 0 0 0 0.7 0.0 0.0 
P54652 HSP72_HUMAN - HSPA2 Heat shock-related 70 kDa protein 2 70021 0 0 2 0 0 0 0.7 0.0 0.0 
Q12873 CHD3_HUMAN - CHD3 Chromodomain-helicase-DNA-binding protein 3 226590 0 0 2 0 0 0 0.7 0.0 0.0 
Q8TDI0 CHD5_HUMAN - CHD5 Chromodomain-helicase-DNA-binding protein 5 223047 0 0 2 0 0 0 0.7 0.0 0.0 
Q14839 CHD4_HUMAN - CHD4 Chromodomain-helicase-DNA-binding protein 4 218003 0 0 2 0 0 0 0.7 0.0 0.0 
 
Table 3A-1. Tryptic digests of HeLa lysates +/- LAS1, LAS6, LAS12. 
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P08238 HS90B_HUMAN - HSP90AB1 Heat shock protein HSP 90-beta 23342 0 26 27.5 21 
P10809 CH60_HUMAN - HSPD1 60 kDa heat shock protein, mitochondrial 61055 0 11 22 29 
P07900 HS90A_HUMAN - HSP90AA1 Heat shock protein HSP 90-alpha 22110 0 20 19.5 17.5 
P09211 GSTP1_HUMAN - GSTP1 Glutathione S-transferase P 28804 0 4 24 27.5 
P53396 ACLY_HUMAN - ACLY ATP-citrate synthase 35077 0 11 14.5 21 
P00558 PGK1_HUMAN - PGK1 Phosphoglycerate kinase 1 95338 0 21 11.5 8 
P13639 EF2_HUMAN - EEF2 Elongation factor 2 44615 0 6 8 24.5 
P18669 PGAM1_HUMAN - PGAM1 Phosphoglycerate mutase 1 39420 0 9 9 13.5 
P04075 ALDOA_HUMAN - ALDOA Fructose-bisphosphate aldolase A 70052 0 13 4.5 6.5 
Q14697 GANAB_HUMAN - GANAB Neutral alpha-glucosidase AB 83435 0 7 7 8 
O75369 FLNB_HUMAN - FLNB Filamin-B 30791 0 4 7 8 
P22102 PUR2_HUMAN - GART Trifunctional purine biosynthetic protein adenosine-3 120839 0 5 5 6 
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P04406 G3P_HUMAN - GAPDH Glyceraldehyde-3-phosphate dehydrogenase 56651 345 
14
4 
647.
5 
167.
5 
P11498 PYC_HUMAN - PC Pyruvate carboxylase, mitochondrial 83264 131 54 
238.
5 95 
P60709 ACTB_HUMAN - ACTB Actin, cytoplasmic 1 63147 41 88 91.5 64.5 
P29401 TKT_HUMAN - TKT Transketolase 50119 8 56 70.5 101 
Q13085 ACACA_HUMAN - ACACA Acetyl-CoA carboxylase 1 84660 56 17 138 40.5 
P07437 TBB5_HUMAN - TUBB Tubulin beta chain 48121 35 40 57.5 52.5 
P21333 FLNA_HUMAN - FLNA Filamin-A 69843 10 33 46.5 47.5 
P68133 ACTS_HUMAN - ACTA1 Actin, alpha skeletal muscle 67820 36 43 51 26.5 
P68104 EF1A1_HUMAN - EEF1A1 Elongation factor 1-alpha 1 97170 5 39 37.5 40.5 
P07237 PDIA1_HUMAN - P4HB Protein disulfide-isomerase 67994 62 18 63 20.5 
P14618 KPYM_HUMAN - PKM Pyruvate kinase isozymes M1/M2 56560 7 33 28.5 38 
P06733 ENOA_HUMAN - ENO1 Alpha-enolase 269765 4 38 24.5 37 
P04264 K2C1_HUMAN - KRT1 Keratin, type II cytoskeletal 1 106874 17 16 67 11 
P49327 FAS_HUMAN - FASN Fatty acid synthase 191613 2 14 21 36.5 
P30101 PDIA3_HUMAN - PDIA3 Protein disulfide-isomerase A3 47518 26 7 42.5 19.5 
P11021 GRP78_HUMAN - HSPA5 78 kDa glucose-regulated protein 107767 9 6 43.5 14.5 
P31327 CPSM_HUMAN - CPS1 Carbamoyl-phosphate synthase 24423 5 10 16.5 37.5 
P35579 MYH9_HUMAN - MYH9 Myosin-9 104854 6 14 21.5 24 
P13645 K1C10_HUMAN - KRT10 Keratin, type I cytoskeletal 10 60344 3 17 14.5 8.5 
P35908 K22E_HUMAN - KRT2 Keratin, type II cytoskeletal 2 epidermal 101559 8 16 11 6.5 
P30041 PRDX6_HUMAN - PRDX6 Peroxiredoxin-6 469093 4 6 20 5.5 
P09429 HMGB1_HUMAN - HMGB1 High mobility group protein B1 59144 3 5 14 12.5 
P62937 PPIA_HUMAN - PPIA Peptidyl-prolyl cis-trans isomerase A 532412 12 6 7 5.5 
Q01813 K6PP_HUMAN - PFKP 6-phosphofructokinase type C 278162 0 14 5 58.5 
Q15084 PDIA6_HUMAN - PDIA6 Protein disulfide-isomerase A6 36053 0 2 23 9 
Q00610 CLH1_HUMAN - CLTC Clathrin heavy chain 1 129634 0 2 10 15 
Q06830 PRDX1_HUMAN - PRDX1 Peroxiredoxin-1 56782 0 3 7 15 
P26038 MOES_HUMAN - MSN Moesin 18012 0 3 11.5 9.5 
P60174 TPIS_HUMAN - TPI1 Triosephosphate isomerase 25035 0 10 5 4.5 
O43707 ACTN4_HUMAN - ACTN4 Alpha-actinin-4 41737 0 7 7 5.5 
P63244 GBLP_HUMAN - GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 57937 0 2 8 9 
Q9Y490 TLN1_HUMAN - TLN1 Talin-1 57116 0 4 7 8 
P17174 AATC_HUMAN - GOT1 Aspartate aminotransferase, cytoplasmic 67878 0 4 11.5 3.5 
Q14974 IMB1_HUMAN - KPNB1 Importin subunit beta-1 24894 0 5 6 7 
Q99832 TCPH_HUMAN - CCT7 T-complex protein 1 subunit eta 49671 0 0 5 12.5 
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P12956 XRCC6_HUMAN - XRCC6 X-ray repair cross-complementing protein 6 47169 0 5 4 6.5 
Q92616 GCN1L_HUMAN - GCN1L1 Translational activator GCN1 26210 0 0 4 10.5 
O43175 SERA_HUMAN - PHGDH D-3-phosphoglycerate dehydrogenase 65433 0 2 5.5 6.5 
P23528 COF1_HUMAN - CFL1 Cofilin-1 265551 0 0 8.5 5.5 
Q71U36 TBA1A_HUMAN - TUBA1A Tubulin alpha-1A chain 58827 28 48 16.5 83 
P68366 TBA4A_HUMAN - TUBA4A Tubulin alpha-4A chain 72333 28 0 50 74.5 
P68371 TBB4B_HUMAN - TUBB4B Tubulin beta-4B chain 50141 35 0 56 47.5 
Q9BUF5 TBB6_HUMAN - TUBB6 Tubulin beta-6 chain 42051 12 10 22 5 
Q9HB71 CYBP_HUMAN - CACYBP Calcyclin-binding protein 72692 6 6 18.5 4 
Q96RQ3 MCCA_HUMAN - MCCC1 Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial 66039 5 4 18 3 
P12277 KCRB_HUMAN - CKB Creatine kinase B-type 164939 3 0 14 7 
P31040 DHSA_HUMAN - SDHA Succinate dehydrogenase 273424 2 2 6.5 9.5 
P78527 PRKDC_HUMAN - PRKDC DNA-dependent protein kinase catalytic subunit 226530 0 2 4.5 18.5 
P38117 ETFB_HUMAN - ETFB Electron transfer flavoprotein subunit beta 280737 0 9 14.5 1.5 
P08107 HSP71_HUMAN - HSPA1B Heat shock 70 kDa protein 1A/1B 18502 0 7 2.5 11.5 
P62826 RAN_HUMAN - RAN GTP-binding nuclear protein Ran 85596 0 2 13.5 5.5 
O76003 GLRX3_HUMAN - GLRX3 Glutaredoxin-3 46248 0 5 15.5 0 
P06576 ATPB_HUMAN - ATP5B ATP synthase subunit beta, mitochondrial 53140 0 2 14 4 
Q562R1 ACTBL_HUMAN - ACTBL2 Beta-actin-like protein 2 36639 0 10 9 0 
P11586 C1TC_HUMAN - MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic 59367 0 10 2 6 
P26639 SYTC_HUMAN - TARS Threonine--tRNA ligase, cytoplasmic 22391 0 2 3.5 12 
P07195 LDHB_HUMAN - LDHB L-lactate dehydrogenase B chain 26560 0 6 1.5 8 
P08195 4F2_HUMAN - SLC3A2 4F2 cell-surface antigen heavy chain 41351 0 3 4.5 7.5 
P00505 AATM_HUMAN - GOT2 Aspartate aminotransferase, mitochondrial 41924 0 5 3.5 6 
Q16881 TRXR1_HUMAN - TXNRD1 Thioredoxin reductase 1, cytoplasmic 54530 0 0 8 5.5 
P62258 1433E_HUMAN - YWHAE 14-3-3 protein epsilon 70756 0 4 0 9 
Q9P2J5 SYLC_HUMAN - LARS Leucine--tRNA ligase, cytoplasmic 49542 0 0 2.5 8.5 
P11142 HSP7C_HUMAN - HSPA8 Heat shock cognate 71 kDa protein 21892 0 0 5 5.5 
P55060 XPO2_HUMAN - CSE1L Exportin-2 22783 0 0 2 8.5 
P37802 TAGL2_HUMAN - TAGLN2 Transgelin-2 60534 0 3 5 2 
P42765 THIM_HUMAN - ACAA2 3-ketoacyl-CoA thiolase, mitochondrial 59671 0 2 2 6 
P17812 PYRG1_HUMAN - CTPS1 CTP synthase 1 117849 0 0 5 5 
P00338 LDHA_HUMAN - LDHA L-lactate dehydrogenase A chain 35937 0 0 2.5 6.5 
P42704 LPPRC_HUMAN - LRPPRC Leucine-rich PPR motif-containing protein, mitochondrial 70898 0 0 4.5 4 
P13797 PLST_HUMAN - PLS3 Plastin-3 85182 0 0 5.5 2.5 
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P27708 PYR1_HUMAN - CAD CAD protein 46441 0 0 3 4 
P07814 SYEP_HUMAN - EPRS Bifunctional glutamate/proline--tRNA ligase 66690 0 0 2 5 
Q15149 PLEC_HUMAN - PLEC Plectin 81308 0 0 2 4 
Q14315 FLNC_HUMAN - FLNC Filamin-C 57488 0 0 2 4 
P62736 ACTA_HUMAN - ACTA2 Actin, aortic smooth muscle 157904 36 0 9 26.5 
P05165 PCCA_HUMAN - PCCA Propionyl-CoA carboxylase alpha chain, mitochondrial 140958 14 0 18 9 
P35241 RADI_HUMAN - RDX Radixin 292756 5 3 11.5 5.5 
Q13509 TBB3_HUMAN - TUBB3 Tubulin beta-3 chain 144734 0 0 0 35.5 
Q05639 EF1A2_HUMAN - EEF1A2 Elongation factor 1-alpha 2 90585 0 0 12 16.5 
P13667 PDIA4_HUMAN - PDIA4 Protein disulfide-isomerase A4 54235 0 0 16.5 0 
P06744 G6PI_HUMAN - GPI Glucose-6-phosphate isomerase 115935 0 8 3 4 
P52895 AK1C2_HUMAN - AKR1C2 Aldo-keto reductase family 1 member C2 242981 0 9 1.5 3 
P26641 EF1G_HUMAN - EEF1G Elongation factor 1-gamma 629114 0 7 2 4 
Q14204 DYHC1_HUMAN - DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 27844 0 2 2.5 7.5 
P52209 6PGD_HUMAN - PGD 6-phosphogluconate dehydrogenase, decarboxylating 49924 0 4 1 7 
P08237 K6PF_HUMAN - PFKM 6-phosphofructokinase, muscle type 50136 0 2 1.5 8.5 
P04792 HSPB1_HUMAN - HSPB1 Heat shock protein beta-1 49831 0 4 5 2 
P22314 UBA1_HUMAN - UBA1 Ubiquitin-like modifier-activating enzyme 1 42644 0 0 3 7.5 
P17858 K6PL_HUMAN - PFKL 6-phosphofructokinase, liver type 68564 0 0 1.5 9 
P17987 TCPA_HUMAN - TCP1 T-complex protein 1 subunit alpha 49857 0 2 3 4.5 
P49411 EFTU_HUMAN - TUFM Elongation factor Tu, mitochondrial 80473 0 0 2.5 7 
Q08211 DHX9_HUMAN - DHX9 ATP-dependent RNA helicase A 80059 0 2 1 6.5 
Q99714 HCD2_HUMAN - HSD17B10 3-hydroxyacyl-CoA dehydrogenase type-2 29174 0 4 1.5 4 
P19338 NUCL_HUMAN - NCL Nucleolin 46154 0 0 8 1.5 
P46782 RS5_HUMAN - RPS5 40S ribosomal protein S5 13944 0 0 0 9.5 
P40227 TCPZ_HUMAN - CCT6A T-complex protein 1 subunit zeta 13952 0 2 0 7 
P48643 TCPE_HUMAN - CCT5 T-complex protein 1 subunit epsilon 13989 0 0 4 4.5 
P61978 HNRPK_HUMAN - HNRNPK Heterogeneous nuclear ribonucleoprotein K 13920 0 0 1 7.5 
P33992 MCM5_HUMAN - MCM5 DNA replication licensing factor MCM5 13920 0 5 0 3.5 
Q9BWD1 THIC_HUMAN - ACAT2 Acetyl-CoA acetyltransferase, cytosolic 58024 0 2 2.5 3.5 
P49368 TCPG_HUMAN - CCT3 T-complex protein 1 subunit gamma 15529 0 2 1.5 4.5 
P78371 TCPB_HUMAN - CCT2 T-complex protein 1 subunit beta 17298 0 4 1 3 
P80723 BASP1_HUMAN - BASP1 Brain acid soluble protein 1 50976 0 3 5 0 
P62805 H4_HUMAN - HIST4H4 Histone H4 38604 0 6 0 2 
P14625 ENPL_HUMAN - HSP90B1 Endoplasmin 64616 0 6 0 2 
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P04179 SODM_HUMAN - SOD2 Superoxide dismutase 39724 0 0 7.5 0 
P21266 GSTM3_HUMAN - GSTM3 Glutathione S-transferase Mu 3 36689 0 0 3.5 3.5 
P53597 SUCA_HUMAN - SUCLG1 Succinyl-CoA ligase 55805 0 0 3.5 3.5 
Q9BR76 COR1B_HUMAN - CORO1B Coronin-1B 56158 0 0 4 2.5 
P60842 IF4A1_HUMAN - EIF4A1 Eukaryotic initiation factor 4A-I 29226 0 2 2 2.5 
P04040 CATA_HUMAN - CAT Catalase 47716 0 0 5.5 1 
P34932 HSP74_HUMAN - HSPA4 Heat shock 70 kDa protein 4 32575 0 0 0 6.5 
P57053 H2BFS_HUMAN - H2BFS Histone H2B type F-S 31284 0 0 1.5 4.5 
Q99880 H2B1L_HUMAN - HIST1H2BL Histone H2B type 1-L 25712 0 0 1.5 4.5 
Q99879 H2B1M_HUMAN - HIST1H2BM Histone H2B type 1-M 110417 0 0 1.5 4.5 
Q5QNW6 H2B2F_HUMAN - HIST2H2BF Histone H2B type 2-F 70811 0 0 1.5 4.5 
Q16778 H2B2E_HUMAN - HIST2H2BE Histone H2B type 2-E 134466 0 0 1.5 4.5 
P20810 ICAL_HUMAN - CAST Calpastatin 89322 0 0 5 1 
Q86VP6 CAND1_HUMAN - CAND1 Cullin-associated NEDD8-dissociated protein 1 82705 0 0 2.5 3.5 
P46940 IQGA1_HUMAN - IQGAP1 Ras GTPase-activating-like protein IQGAP1 69413 0 0 0 6 
P30876 RPB2_HUMAN - POLR2B DNA-directed RNA polymerase II subunit RPB2 36250 0 0 2 3 
P50395 GDIB_HUMAN - GDI2 Rab GDP dissociation inhibitor beta 123386 0 0 2 3 
P35580 MYH10_HUMAN - MYH10 Myosin-10 170590 0 0 2 3 
P07737 PROF1_HUMAN - PFN1 Profilin-1 76573 0 0 0 4.5 
O00429 DNM1L_HUMAN - DNM1L Dynamin-1-like protein 87302 0 0 0 4.5 
P25705 ATPA_HUMAN - ATP5A1 ATP synthase subunit alpha, mitochondrial 85018 0 0 0 4 
P23284 PPIB_HUMAN - PPIB Peptidyl-prolyl cis-trans isomerase B 90070 0 0 4 0 
P35527 K1C9_HUMAN - KRT9 Keratin, type I cytoskeletal 9 53652 3 0 31.5 0 
P12821 ACE_HUMAN - ACE Angiotensin-converting enzyme 24604 0 0 102.5 0 
Q6S8J3 POTEE_HUMAN - POTEE POTE ankyrin domain family member E 59257 0 48 0 0 
Q09666 AHNK_HUMAN - AHNAK Neuroblast differentiation-associated protein AHNAK 102355 0 0 14.5 2 
Q00839 HNRPU_HUMAN - HNRNPU Heterogeneous nuclear ribonucleoprotein U 59756 0 3 1.5 5.5 
P42330 AK1C3_HUMAN - AKR1C3 Aldo-keto reductase family 1 member C3 136375 0 9 0 1 
P13929 ENOB_HUMAN - ENO3 Beta-enolase 78806 0 0 0 10 
P0C0S8 H2A1_HUMAN - HIST1H2AM Histone H2A type 1 103058 0 9 0 0 
Q9BTM1 H2AJ_HUMAN - H2AFJ Histone H2A.J 132600 0 9 0 0 
Q16777 H2A2C_HUMAN - HIST2H2AC Histone H2A type 2-C 98064 0 9 0 0 
Q04828 AK1C1_HUMAN - AKR1C1 Aldo-keto reductase family 1 member C1 133896 0 9 0 0 
P32119 PRDX2_HUMAN - PRDX2 Peroxiredoxin-2 531796 0 3 4 1.5 
P15311 EZRI_HUMAN - EZR Ezrin 291020 0 3 0 5.5 
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P54577 SYYC_HUMAN - YARS Tyrosine--tRNA ligase, cytoplasmic 36735 0 3 3 2 
O15067 PUR4_HUMAN - PFAS Phosphoribosylformylglycinamidine synthase 26923 0 3 3 2 
P13010 XRCC5_HUMAN - XRCC5 X-ray repair cross-complementing protein 5 26478 0 0 1 7 
Q16658 FSCN1_HUMAN - FSCN1 Fascin 76615 0 2 1 4 
P31939 PUR9_HUMAN - ATIC Bifunctional purine biosynthesis protein PURH 88550 0 3 1 3 
P07355 ANXA2_HUMAN - ANXA2 Annexin A2 22693 0 3 1 2.5 
P08758 ANXA5_HUMAN - ANXA5 Annexin A5 42003 0 2 2 2 
P33993 MCM7_HUMAN - MCM7 DNA replication licensing factor MCM7 37432 0 0 2.5 3.5 
P23526 SAHH_HUMAN - AHCY Adenosylhomocysteinase 42009 0 2 0 4 
P54819 KAD2_HUMAN - AK2 Adenylate kinase 2, mitochondrial 15054 0 0 5 1 
P54652 HSP72_HUMAN - HSPA2 Heat shock-related 70 kDa protein 2 14121 0 5 0 1 
P50454 SERPH_HUMAN - SERPINH1 Serpin H1 22876 0 0 3 2.5 
Q96FW1 OTUB1_HUMAN - OTUB1 Ubiquitin thioesterase OTUB1 50433 0 2 1.5 2 
O14980 XPO1_HUMAN - XPO1 Exportin-1 11367 0 0 2.5 3 
Q06210 GFPT1_HUMAN - GFPT1 Glucosamine--fructose-6-phosphate aminotransferase 20778 0 0 1.5 4 
P54886 P5CS_HUMAN - ALDH18A1 Delta-1-pyrroline-5-carboxylate synthase 24205 0 0 3 2 
P63104 1433Z_HUMAN - YWHAZ 14-3-3 protein zeta/delta 50663 0 3 0 2 
P31153 METK2_HUMAN - MAT2A S-adenosylmethionine synthase isoform type-2 27764 0 3 0 2 
P12268 IMDH2_HUMAN - IMPDH2 Inosine-5'-monophosphate dehydrogenase 2 50470 0 0 1 3.5 
P09488 GSTM1_HUMAN - GSTM1 Glutathione S-transferase Mu 1 41943 0 0 2.5 2 
P23921 RIR1_HUMAN - RRM1 Ribonucleoside-diphosphate reductase large subunit 47079 0 0 2 2.5 
P27635 RL10_HUMAN - RPL10 60S ribosomal protein L10 26688 0 0 3.5 1 
Q9BTW9 TBCD_HUMAN - TBCD Tubulin-specific chaperone D 27745 0 0 1.5 3 
P22234 PUR6_HUMAN - PAICS Multifunctional protein ADE2 81877 0 2 0 2.5 
P08559 ODPA_HUMAN - PDHA1 Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial 59751 0 0 0 4.5 
Q9Y678 COPG1_HUMAN - COPG1 Coatomer subunit gamma-1 94331 0 0 0 4.5 
P33316 DUT_HUMAN - DUT Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial 47656 0 2 2.5 0 
P39023 RL3_HUMAN - RPL3 60S ribosomal protein L3 48043 0 0 4.5 0 
Q8WUM4 PDC6I_HUMAN - PDCD6IP Programmed cell death 6-interacting protein 44761 0 0 0 4.5 
P24752 THIL_HUMAN - ACAT1 Acetyl-CoA acetyltransferase, mitochondrial 92469 0 0 0 4.5 
O00763 ACACB_HUMAN - ACACB Acetyl-CoA carboxylase 2 68304 0 0 4.5 0 
Q9Y281 COF2_HUMAN - CFL2 Cofilin-2 43296 0 0 4.5 0 
Q92820 GGH_HUMAN - GGH Gamma-glutamyl hydrolase 36853 0 0 4.5 0 
P55072 TERA_HUMAN - VCP Transitional endoplasmic reticulum ATPase 51805 0 0 2 2 
P08670 VIME_HUMAN - VIM Vimentin 189251 0 0 3 1 
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P11413 G6PD_HUMAN - G6PD Glucose-6-phosphate 1-dehydrogenase 38747 0 0 1 3 
P62241 RS8_HUMAN - RPS8 40S ribosomal protein S8 34225 0 0 0 4 
P27348 1433T_HUMAN - YWHAQ 14-3-3 protein theta 90981 0 0 1 3 
Q9H7Z7 PGES2_HUMAN - PTGES2 Prostaglandin E synthase 2 59621 0 0 0 4 
P38606 VATA_HUMAN - ATP6V1A V-type proton ATPase catalytic subunit A 50680 0 0 0 4 
Q8N257 H2B3B_HUMAN - HIST3H2BB Histone H2B type 3-B 49130 0 0 1.5 2.5 
Q16576 RBBP7_HUMAN - RBBP7 Histone-binding protein RBBP7 48991 0 0 1.5 2.5 
Q7L7L0 H2A3_HUMAN - HIST3H2A Histone H2A type 3 140466 0 0 0 3.5 
Q09028 RBBP4_HUMAN - RBBP4 Histone-binding protein RBBP4 56085 0 0 0 3.5 
P53618 COPB_HUMAN - COPB1 Coatomer subunit beta 96865 0 0 0 3.5 
O00410 IPO5_HUMAN - IPO5 Importin-5 97718 0 0 0 3.5 
P14868 SYDC_HUMAN - DARS Aspartate--tRNA ligase, cytoplasmic 100200 0 0 1 2.5 
P47897 SYQ_HUMAN - QARS Glutamine--tRNA ligase 228997 0 0 2.5 1 
P62277 RS13_HUMAN - RPS13 40S ribosomal protein S13 91707 0 0 3.5 0 
P14174 MIF_HUMAN - MIF Macrophage migration inhibitory factor 107142 0 0 3.5 0 
P53999 TCP4_HUMAN - SUB1 Activated RNA polymerase II transcriptional coactivator p15 123630 0 0 3.5 0 
P50990 TCPQ_HUMAN - CCT8 T-complex protein 1 subunit theta 121682 0 0 0 3 
Q9P258 RCC2_HUMAN - RCC2 Protein RCC2 13908 0 0 2 1 
P13647 K2C5_HUMAN - KRT5 Keratin, type II cytoskeletal 5 43661 0 0 3 0 
P30153 2AAA_HUMAN - PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform 82286 0 0 0 3 
P53634 CATC_HUMAN - CTSC Dipeptidyl peptidase 1 47820 0 0 3 0 
P31946 1433B_HUMAN - YWHAB 14-3-3 protein beta/alpha 57136 0 0 0 2.5 
P31947 1433S_HUMAN - SFN 14-3-3 protein sigma 33361 0 0 0 2.5 
P21980 TGM2_HUMAN - TGM2 Protein-glutamine gamma-glutamyltransferase 2 69285 0 0 0 2.5 
Q03013 GSTM4_HUMAN - GSTM4 Glutathione S-transferase Mu 4 74140 0 0 2.5 0 
P41250 SYG_HUMAN - GARS Glycine--tRNA ligase 24182 0 0 0 2 
P36776 LONM_HUMAN - LONP1 Lon protease homolog, mitochondrial 55756 0 0 0 2 
Q12931 TRAP1_HUMAN - TRAP1 Heat shock protein 75 kDa, mitochondrial 63945 0 0 0 2 
P13804 ETFA_HUMAN - ETFA Electron transfer flavoprotein subunit alpha, mitochondrial 73461 0 0 0 2 
P05091 ALDH2_HUMAN - ALDH2 Aldehyde dehydrogenase, mitochondrial 73603 0 0 0 2 
Q99497 PARK7_HUMAN - PARK7 Protein DJ-1 87799 0 0 2 0 
O75083 WDR1_HUMAN - WDR1 WD repeat-containing protein 1 92889 0 0 2 0 
P54727 RD23B_HUMAN - RAD23B UV excision repair protein RAD23 homolog B 119516 0 0 2 0 
P11940 PABP1_HUMAN - PABPC1 Polyadenylate-binding protein 1 70021 0 0 2 0 
P12270 TPR_HUMAN - TPR Nucleoprotein TPR 26563 0 0 2 0 
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P42166 LAP2A_HUMAN - TMPO Lamina-associated polypeptide 2, isoform alpha 35503 0 0 2 0 
P42167 LAP2B_HUMAN - TMPO Lamina-associated polypeptide 2, isoforms beta/gamma 58487 0 0 2 0 
P30837 AL1B1_HUMAN - ALDH1B1 Aldehyde dehydrogenase X, mitochondrial 24722 0 0 2 0 
P00390 GSHR_HUMAN - GSR Glutathione reductase, mitochondrial 27402 0 0 2 0 
Q9BVA1 TBB2B_HUMAN - TUBB2B Tubulin beta-2B chain 23743 35 0 0 22 
P02538 K2C6A_HUMAN - KRT6A Keratin, type II cytoskeletal 6A 32193 2 0 3 0 
P51858 HDGF_HUMAN - HDGF Hepatoma-derived growth factor 31362 10 0 3 0 
Q04837 SSBP_HUMAN - SSBP1 Single-stranded DNA-binding protein, mitochondrial 28993 3 0 2 0 
O60361 NDK8_HUMAN - NME2P1 Putative nucleoside diphosphate kinase 72933 0 3 1.5 1.5 
P22392 NDKB_HUMAN - NME2 Nucleoside diphosphate kinase B 22591 0 3 1.5 1.5 
Q02218 ODO1_HUMAN - OGDH 2-oxoglutarate dehydrogenase, mitochondrial 17222 0 0 2 3 
Q92973 TNPO1_HUMAN - TNPO1 Transportin-1 30868 0 0 1.5 3 
P12814 ACTN1_HUMAN - ACTN1 Alpha-actinin-1 62378 0 2 1 1.5 
P61160 ARP2_HUMAN - ACTR2 Actin-related protein 2 46109 0 3 0 1.5 
P55809 SCOT1_HUMAN - OXCT1 Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial 191480 0 0 1.5 2.5 
Q13263 TIF1B_HUMAN - TRIM28 Transcription intermediary factor 1-beta 62064 0 0 3 1 
P18124 RL7_HUMAN - RPL7 60S ribosomal protein L7 60045 0 0 2.5 1 
P06748 NPM_HUMAN - NPM1 Nucleophosmin 34294 0 0 1 2.5 
Q92598 HS105_HUMAN - HSPH1 Heat shock protein 105 kDa 65309 0 2 0 1.5 
P09960 LKHA4_HUMAN - LTA4H Leukotriene A-4 hydrolase 46932 0 2 0 1.5 
P11766 ADHX_HUMAN - ADH5 Alcohol dehydrogenase class-3 28082 0 0 2 1 
P50570 DYN2_HUMAN - DNM2 Dynamin-2 17040 0 0 1 2 
P23396 RS3_HUMAN - RPS3 40S ribosomal protein S3 27774 0 0 0 3 
P25205 MCM3_HUMAN - MCM3 DNA replication licensing factor MCM3 47371 0 0 0 3 
B0V043 B0V043_HUMAN - VARS Valyl-tRNA synthetase 31350 0 0 1.5 1.5 
P32322 P5CR1_HUMAN - PYCR1 Pyrroline-5-carboxylate reductase 1, mitochondrial 47366 0 2 0 1 
Q96HC4 PDLI5_HUMAN - PDLIM5 PDZ and LIM domain protein 5 38714 0 0 1.5 1.5 
Q14978 NOLC1_HUMAN - NOLC1 Nucleolar and coiled-body phosphoprotein 1 37187 0 0 1.5 1.5 
Q14566 MCM6_HUMAN - MCM6 DNA replication licensing factor MCM6 33637 0 2 0 1 
P40926 MDHM_HUMAN - MDH2 Malate dehydrogenase, mitochondrial 16930 0 2 1 0 
P49419 AL7A1_HUMAN - ALDH7A1 Alpha-aminoadipic semialdehyde dehydrogenase 52352 0 2 1 0 
Q9UL46 PSME2_HUMAN - PSME2 Proteasome activator complex subunit 2 31387 0 0 3 0 
P84085 ARF5_HUMAN - ARF5 ADP-ribosylation factor 5 27566 0 3 0 0 
P15531 NDKA_HUMAN - NME1 Nucleoside diphosphate kinase A 83166 0 3 0 0 
P16152 CBR1_HUMAN - CBR1 Carbonyl reductase 46659 0 3 0 0 
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Q06323 PSME1_HUMAN - PSME1 Proteasome activator complex subunit 1 53165 0 3 0 0 
Q04760 LGUL_HUMAN - GLO1 Lactoylglutathione lyase 106489 0 0 1.5 1 
Q7L1Q6 BZW1_HUMAN - BZW1 Basic leucine zipper and W2 domain-containing protein 1 38497 0 0 1 1.5 
Q02790 FKBP4_HUMAN - FKBP4 Peptidyl-prolyl cis-trans isomerase FKBP4 43482 0 0 1.5 1 
Q16181 SEPT7_HUMAN - SEPT7 Septin-7 38580 0 0 0 2.5 
Q96QK1 VPS35_HUMAN - VPS35 Vacuolar protein sorting-associated protein 35 40746 0 0 0 2.5 
P02545 LMNA_HUMAN - LMNA Prelamin-A/C 57924 0 0 1 1.5 
O94925 GLSK_HUMAN - GLS Glutaminase kidney isoform, mitochondrial 63111 0 0 1.5 1 
O95373 IPO7_HUMAN - IPO7 Importin-7 77329 0 0 1.5 1 
Q07021 C1QBP_HUMAN - C1QBP Complement component 1 Q subcomponent-binding protein, mitochondrial 50909 0 0 2.5 0 
P09651 ROA1_HUMAN - HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 101997 0 0 1 1 
Q32P51 RA1L2_HUMAN - HNRNPA1L2 Heterogeneous nuclear ribonucleoprotein A1-like 2 42742 0 0 1 1 
O00148 DX39A_HUMAN - DDX39A ATP-dependent RNA helicase DDX39A 31122 0 0 1 1 
Q13838 DX39B_HUMAN - DDX39B Spliceosome RNA helicase DDX39B 106810 0 0 1 1 
Q13200 PSMD2_HUMAN - PSMD2 26S proteasome non-ATPase regulatory subunit 2 48551 0 0 1 1 
O00159 MYO1C_HUMAN - MYO1C Unconventional myosin-Ic 30540 0 0 1 1 
E7EMT2 E7EMT2_HUMAN - Uncharacterized protein 100071 0 0 1 1 
P15170 ERF3A_HUMAN - GSPT1 Eukaryotic peptide chain release factor GTP-binding subunit ERF3A 55103 0 0 1 1 
Q14192 FHL2_HUMAN - FHL2 Four and a half LIM domains protein 2 55364 0 0 2 0 
P30040 ERP29_HUMAN - ERP29 Endoplasmic reticulum resident protein 29 80110 0 0 2 0 
P46781 RS9_HUMAN - RPS9 40S ribosomal protein S9 53489 0 0 2 0 
P15559 NQO1_HUMAN - NQO1 NAD(P)H dehydrogenase 40283 0 0 2 0 
Q02952 AKA12_HUMAN - AKAP12 A-kinase anchor protein 12 82432 0 0 2 0 
Q9BUL8 PDC10_HUMAN - PDCD10 Programmed cell death protein 10 57221 0 2 0 0 
P36952 SPB5_HUMAN - SERPINB5 Serpin B5 67568 0 2 0 0 
Q14240 IF4A2_HUMAN - EIF4A2 Eukaryotic initiation factor 4A-II 69603 0 2 0 0 
P61764 STXB1_HUMAN - STXBP1 Syntaxin-binding protein 1 24519 0 2 0 0 
P08133 ANXA6_HUMAN - ANXA6 Annexin A6 54232 0 2 0 0 
P55884 EIF3B_HUMAN - EIF3B Eukaryotic translation initiation factor 3 subunit B 61398 0 2 0 0 
Q99733 NP1L4_HUMAN - NAP1L4 Nucleosome assembly protein 1-like 4 60587 0 2 0 0 
P17066 HSP76_HUMAN - HSPA6 Heat shock 70 kDa protein 6 112535 0 2 0 0 
P48741 HSP77_HUMAN - HSPA7 Putative heat shock 70 kDa protein 7 94512 0 2 0 0 
Q16836 HCDH_HUMAN - HADH Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial 113289 0 0 0 1.5 
P61158 ARP3_HUMAN - ACTR3 Actin-related protein 3 96023 0 0 0 1.5 
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P62140 PP1B_HUMAN - PPP1CB Serine/threonine-protein phosphatase PP1-beta catalytic subunit 96558 0 0 0 1.5 
Q16719 KYNU_HUMAN - KYNU Kynureninase 83550 0 0 0 1.5 
O75874 IDHC_HUMAN - IDH1 Isocitrate dehydrogenase 49229 0 0 0 1.5 
P07686 HEXB_HUMAN - HEXB Beta-hexosaminidase subunit beta 45672 0 0 0 1.5 
P48735 IDHP_HUMAN - IDH2 Isocitrate dehydrogenase 69367 0 0 0 1.5 
Q7KZF4 SND1_HUMAN - SND1 Staphylococcal nuclease domain-containing protein 1 62943 0 0 0 1.5 
P29692 EF1D_HUMAN - EEF1D Elongation factor 1-delta 76931 0 0 0 1.5 
P49588 SYAC_HUMAN - AARS Alanine--tRNA ligase, cytoplasmic 90933 0 0 0 1.5 
P26599 PTBP1_HUMAN - PTBP1 Polypyrimidine tract-binding protein 1 103276 0 0 0 1.5 
O60506 HNRPQ_HUMAN - SYNCRIP Heterogeneous nuclear ribonucleoprotein Q 115963 0 0 0 1.5 
O95757 HS74L_HUMAN - HSPA4L Heat shock 70 kDa protein 4L 103505 0 0 0 1.5 
Q96T76 MMS19_HUMAN - MMS19 MMS19 nucleotide excision repair protein homolog 51712 0 0 0 1.5 
P31943 HNRH1_HUMAN - HNRNPH1 Heterogeneous nuclear ribonucleoprotein H 88068 0 0 0 1.5 
P52597 HNRPF_HUMAN - HNRNPF Heterogeneous nuclear ribonucleoprotein F 97746 0 0 0 1.5 
O94808 GFPT2_HUMAN - GFPT2 Glucosamine--fructose-6-phosphate aminotransferase 109685 0 0 0 1.5 
Q9H8V3 ECT2_HUMAN - ECT2 Protein ECT2 144498 0 0 0 1.5 
Q15365 PCBP1_HUMAN - PCBP1 Poly(rC)-binding protein 1 193539 0 0 0 1.5 
P26583 HMGB2_HUMAN - HMGB2 High mobility group protein B2 205556 0 0 0 1.5 
P22695 QCR2_HUMAN - UQCRC2 Cytochrome b-c1 complex subunit 2, mitochondrial 171491 0 0 0 1.5 
P40429 RL13A_HUMAN - RPL13A 60S ribosomal protein L13a 780624 0 0 0 1.5 
O43252 PAPS1_HUMAN - PAPSS1 Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1 14865 0 0 0 1.5 
P10155 RO60_HUMAN - TROVE2 60 kDa SS-A/Ro ribonucleoprotein 45200 0 0 0 1.5 
Q92599 SEPT8_HUMAN - SEPT8 Septin-8 35080 0 0 0 1.5 
Q96AY3 FKB10_HUMAN - FKBP10 Peptidyl-prolyl cis-trans isomerase FKBP10 37498 0 0 0 1.5 
P05161 ISG15_HUMAN - ISG15 Ubiquitin-like protein ISG15 24034 0 0 1.5 0 
P02533 K1C14_HUMAN - KRT14 Keratin, type I cytoskeletal 14 38325 0 0 1.5 0 
P54725 RD23A_HUMAN - RAD23A UV excision repair protein RAD23 homolog A 48443 0 0 1.5 0 
Q93052 LPP_HUMAN - LPP Lipoma-preferred partner 23577 0 0 1.5 0 
Q9NTJ3 SMC4_HUMAN - SMC4 Structural maintenance of chromosomes protein 4 70833 0 0 1.5 0 
Q9UQ35 SRRM2_HUMAN - SRRM2 Serine/arginine repetitive matrix protein 2 25734 0 0 1.5 0 
Q9H773 DCTP1_HUMAN - DCTPP1 dCTP pyrophosphatase 1 60671 0 0 1.5 0 
O00299 CLIC1_HUMAN - CLIC1 Chloride intracellular channel protein 1 56381 0 0 1.5 0 
Q15942 ZYX_HUMAN - ZYX Zyxin 55756 0 0 1.5 0 
Q9NVI1 FANCI_HUMAN - FANCI Fanconi anemia group I protein 64245 0 0 1.5 0 
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P62841 RS15_HUMAN - RPS15 40S ribosomal protein S15 75379 0 0 0 1 
P47756 CAPZB_HUMAN - CAPZB F-actin-capping protein subunit beta 53249 0 0 0 1 
P43686 PRS6B_HUMAN - PSMC4 26S protease regulatory subunit 6B 79275 0 0 0 1 
P04083 ANXA1_HUMAN - ANXA1 Annexin A1 87680 0 0 0 1 
Q96C36 P5CR2_HUMAN - PYCR2 Pyrroline-5-carboxylate reductase 2 101272 0 0 0 1 
P60660 MYL6_HUMAN - MYL6 Myosin light polypeptide 6 107546 0 0 0 1 
P30084 ECHM_HUMAN - ECHS1 Enoyl-CoA hydratase, mitochondrial 244505 0 0 0 1 
P78417 GSTO1_HUMAN - GSTO1 Glutathione S-transferase omega-1 152785 0 0 0 1 
P23381 SYWC_HUMAN - WARS Tryptophan--tRNA ligase, cytoplasmic 14091 0 0 0 1 
P40937 RFC5_HUMAN - RFC5 Replication factor C subunit 5 14019 0 0 0 1 
Q6NVY1 HIBCH_HUMAN - HIBCH 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial 13988 0 0 0 1 
Q15366 PCBP2_HUMAN - PCBP2 Poly(rC)-binding protein 2 20530 0 0 0 1 
P55039 DRG2_HUMAN - DRG2 Developmentally-regulated GTP-binding protein 2 17149 0 0 0 1 
P50991 TCPD_HUMAN - CCT4 T-complex protein 1 subunit delta 30375 0 0 0 1 
P30740 ILEU_HUMAN - SERPINB1 Leukocyte elastase inhibitor 24702 0 0 0 1 
Q15645 PCH2_HUMAN - TRIP13 Pachytene checkpoint protein 2 homolog 121363 0 0 0 1 
Q13162 PRDX4_HUMAN - PRDX4 Peroxiredoxin-4 28723 0 0 0 1 
P35221 CTNA1_HUMAN - CTNNA1 Catenin alpha-1 42100 0 0 0 1 
Q13547 HDAC1_HUMAN - HDAC1 Histone deacetylase 1 46402 0 0 0 1 
Q92769 HDAC2_HUMAN - HDAC2 Histone deacetylase 2 67569 0 0 0 1 
Q9UBB4 ATX10_HUMAN - ATXN10 Ataxin-10 36788 0 0 0 1 
Q12792 TWF1_HUMAN - TWF1 Twinfilin-1 75873 0 0 0 1 
Q92499 DDX1_HUMAN - DDX1 ATP-dependent RNA helicase DDX1 92482 0 0 0 1 
P27824 CALX_HUMAN - CANX Calnexin 42823 0 0 0 1 
Q96L21 RL10L_HUMAN - RPL10L 60S ribosomal protein L10-like 71028 0 0 0 1 
Q15233 NONO_HUMAN - NONO Non-POU domain-containing octamer-binding protein 40244 0 0 0 1 
P00367 DHE3_HUMAN - GLUD1 Glutamate dehydrogenase 1, mitochondrial 276539 0 0 0 1 
P35520 CBS_HUMAN - CBS Cystathionine beta-synthase 19891 0 0 0 1 
Q9UI26 IPO11_HUMAN - IPO11 Importin-11 11250 0 0 0 1 
P33991 MCM4_HUMAN - MCM4 DNA replication licensing factor MCM4 14195 0 0 0 1 
Q02809 PLOD1_HUMAN - PLOD1 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 12712 0 0 0 1 
P02768 ALBU_HUMAN - ALB Serum albumin 12476 0 0 0 1 
O43776 SYNC_HUMAN - NARS Asparagine--tRNA ligase, cytoplasmic 13833 0 0 0 1 
O43143 DHX15_HUMAN - DHX15 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 33310 0 0 0 1 
P55786 PSA_HUMAN - NPEPPS Puromycin-sensitive aminopeptidase 22238 0 0 0 1 
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Q96P70 IPO9_HUMAN - IPO9 Importin-9 25561 0 0 0 1 
O75390 CISY_HUMAN - CS Citrate synthase, mitochondrial 16273 0 0 0 1 
P40763 STAT3_HUMAN - STAT3 Signal transducer and activator of transcription 3 20652 0 0 0 1 
Q9UQ16 DYN3_HUMAN - DNM3 Dynamin-3 16773 0 0 0 1 
P33176 KINH_HUMAN - KIF5B Kinesin-1 heavy chain 16793 0 0 0 1 
P41252 SYIC_HUMAN - IARS Isoleucine--tRNA ligase, cytoplasmic 24328 0 0 0 1 
A4D0S4 LAMB4_HUMAN - LAMB4 Laminin subunit beta-4 46588 0 0 0 1 
Q4ZHG4 FNDC1_HUMAN - FNDC1 Fibronectin type III domain-containing protein 1 17887 0 0 0 1 
Q9P265 DIP2B_HUMAN - DIP2B Disco-interacting protein 2 homolog B 57285 0 0 0 1 
Q5CZC0 FSIP2_HUMAN - FSIP2 Fibrous sheath-interacting protein 2 66194 0 0 0 1 
P62829 RL23_HUMAN - RPL23 60S ribosomal protein L23 51561 0 0 0 1 
Q00796 DHSO_HUMAN - SORD Sorbitol dehydrogenase 39609 0 0 0 1 
Q15102 PA1B3_HUMAN - PAFAH1B3 Platelet-activating factor acetylhydrolase IB subunit gamma 48634 0 0 0 1 
P54136 SYRC_HUMAN - RARS Arginine--tRNA ligase, cytoplasmic 26558 0 0 0 1 
Q9ULV4 COR1C_HUMAN - CORO1C Coronin-1C 26488 0 0 0 1 
Q9Y223 GLCNE_HUMAN - GNE Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase 38210 0 0 0 1 
Q13619 CUL4A_HUMAN - CUL4A Cullin-4A 44552 0 0 0 1 
Q9BXJ9 NAA15_HUMAN - NAA15 N-alpha-acetyltransferase 15, NatA auxiliary subunit 40447 0 0 0 1 
O95782 AP2A1_HUMAN - AP2A1 AP-2 complex subunit alpha-1 65746 0 0 0 1 
O75643 U520_HUMAN - SNRNP200 U5 small nuclear ribonucleoprotein 200 kDa helicase 43171 0 0 0 1 
P52701 MSH6_HUMAN - MSH6 DNA mismatch repair protein Msh6 18506 0 0 0 1 
Q9C005 DPY30_HUMAN - DPY30 Protein dpy-30 homolog 44744 0 0 1 0 
A6NHG4 DDTL_HUMAN - DDTL D-dopachrome decarboxylase-like protein 74404 0 0 1 0 
P30046 DOPD_HUMAN - DDT D-dopachrome decarboxylase 95786 0 0 1 0 
Q9NRX4 PHP14_HUMAN - PHPT1 14 kDa phosphohistidine phosphatase 70671 0 0 1 0 
Q9BPW8 NIPS1_HUMAN - NIPSNAP1 Protein NipSnap homolog 1 46871 0 0 1 0 
O43399 TPD54_HUMAN - TPD52L2 Tumor protein D54 56196 0 0 1 0 
P62263 RS14_HUMAN - RPS14 40S ribosomal protein S14 68330 0 0 1 0 
Q9Y2B0 CNPY2_HUMAN - CNPY2 Protein canopy homolog 2 51902 0 0 1 0 
Q6IS14 IF5AL_HUMAN - EIF5AL1 Eukaryotic translation initiation factor 5A-1-like 128979 0 0 1 0 
Q9GZV4 IF5A2_HUMAN - EIF5A2 Eukaryotic translation initiation factor 5A-2 68935 0 0 1 0 
Q9UKK9 NUDT5_HUMAN - NUDT5 ADP-sugar pyrophosphatase 103187 0 0 1 0 
P11310 ACADM_HUMAN - ACADM Medium-chain specific acyl-CoA dehydrogenase, mitochondrial 128302 0 0 1 0 
P19013 K2C4_HUMAN - KRT4 Keratin, type II cytoskeletal 4 55993 0 0 1 0 
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P35998 PRS7_HUMAN - PSMC2 26S protease regulatory subunit 7 147182 0 0 1 0 
P07477 TRY1_HUMAN - PRSS1 Trypsin-1 73115 0 0 1 0 
P07478 TRY2_HUMAN - PRSS2 Trypsin-2 113744 0 0 1 0 
Q9H832 UBE2Z_HUMAN - UBE2Z Ubiquitin-conjugating enzyme E2 Z 94623 0 0 1 0 
P07339 CATD_HUMAN - CTSD Cathepsin D 267290 0 0 1 0 
H7C469 H7C469_HUMAN - Uncharacterized protein 284538 0 0 1 0 
P60981 DEST_HUMAN - DSTN Destrin 299615 0 0 1 0 
Q9NTK5 OLA1_HUMAN - OLA1 Obg-like ATPase 1 526612 0 0 1 0 
Q14166 TTL12_HUMAN - TTLL12 Tubulin--tyrosine ligase-like protein 12 358201 0 0 1 0 
P45974 UBP5_HUMAN - USP5 Ubiquitin carboxyl-terminal hydrolase 5 475986 0 0 1 0 
P38919 IF4A3_HUMAN - EIF4A3 Eukaryotic initiation factor 4A-III 14395 0 0 1 0 
Q16401 PSMD5_HUMAN - PSMD5 26S proteasome non-ATPase regulatory subunit 5 17862 0 0 1 0 
Q15637 SF01_HUMAN - SF1 Splicing factor 1 18681 0 0 1 0 
Q01518 CAP1_HUMAN - CAP1 Adenylyl cyclase-associated protein 1 18737 0 0 1 0 
Q8WUM0 NU133_HUMAN - NUP133 Nuclear pore complex protein Nup133 75492 0 0 1 0 
Q9H0B6 KLC2_HUMAN - KLC2 Kinesin light chain 2 50670 0 0 1 0 
O75185 AT2C2_HUMAN - ATP2C2 Calcium-transporting ATPase type 2C member 2 35964 0 0 1 0 
Q93009 UBP7_HUMAN - USP7 Ubiquitin carboxyl-terminal hydrolase 7 26923 0 0 1 0 
P34897 GLYM_HUMAN - SHMT2 Serine hydroxymethyltransferase, mitochondrial 47629 0 0 1 0 
Q92945 FUBP2_HUMAN - KHSRP Far upstream element-binding protein 2 57206 0 0 1 0 
O00754 MA2B1_HUMAN - MAN2B1 Lysosomal alpha-mannosidase 94270 0 0 1 0 
P43243 MATR3_HUMAN - MATR3 Matrin-3 56257 0 0 1 0 
Q13813 SPTN1_HUMAN - SPTAN1 Spectrin alpha chain, non-erythrocytic 1 46638 0 0 1 0 
P98088 MUC5A_HUMAN - MUC5AC Mucin-5AC 61277 0 0 1 0 
P49792 RBP2_HUMAN - RANBP2 E3 SUMO-protein ligase RanBP2 51854 0 0 1 0 
Q9C0G6 DYH6_HUMAN - DNAH6 Dynein heavy chain 6, axonemal 89988 0 0 1 0 
P68036 UB2L3_HUMAN - UBE2L3 Ubiquitin-conjugating enzyme E2 L3 149323 0 0 1 0 
Q8NBS9 TXND5_HUMAN - TXNDC5 Thioredoxin domain-containing protein 5 149714 0 0 1 0 
Q13099 IFT88_HUMAN - IFT88 Intraflagellar transport protein 88 homolog 137499 0 0 1 0 
P43034 LIS1_HUMAN - PAFAH1B1 Platelet-activating factor acetylhydrolase IB subunit alpha 
381596
5 0 0 1 0 
Q2QGD7 ZXDC_HUMAN - ZXDC Zinc finger protein ZXDC 17260 0 0 1 0 
P55201 BRPF1_HUMAN - BRPF1 Peregrin 26788 0 0 1 0 
Q8WZ42 TITIN_HUMAN - TTN Titin 49953 0 0 1 0 
Q8NHL6 LIRB1_HUMAN - LILRB1 Leukocyte immunoglobulin-like receptor subfamily B member 1 70819 0 0 0 0 
Q13748 TBA3C_HUMAN - TUBA3D Tubulin alpha-3C/D chain 49960 28 0 0 0 
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888 P47712 PLA2G4A Cytosolic phospholipase A2 CSVSLSNVEAR 3.37 
514 P78527 PRKDC DNA-dependent protein kinase catalytic subunit INQVFHGSCITEGNELTK 2.4 
201 P28074 PSMB5 Proteasome subunit beta type-5 VIEINPYLLGTMAGGAADCSFWER 2.29 
118 P46782 RPS5 40S ribosomal protein S5 AQCPIVER 2.09 
252 Q96CD2 PPCDC Phosphopantothenoylcysteine decarboxylase ASCPAAAPLMER 1.62 
839 Q9P258 RCC2 Protein RCC2 AVQDLCGWR 1.56 
497 P12955 PEPD Xaa-Pro dipeptidase YCTDTGVLFR 1.52 
800 O14744 PRMT5 Protein arginine N-methyltransferase 5 DLNCVPEIADTLGAVAK 1.44 
598 P32320 CDA Cytidine deaminase GCNIENACYPLGICAER 1.41 
440 Q9Y3F4 STRAP Serine-threonine kinase receptor-associated protein CVLPEEDSGELAK 1.39 
239 Q7RTV0 PHF5A PHD finger-like domain-containing protein 5A PCTLVR 1.38 
537 P36578 RPL4 60S ribosomal protein L4 SGQGAFGNMCR 1.33 
748 Q9NUP9 LIN7C Protein lin-7 homolog C VLQSEFCNAVR 1.33 
654 P29034 S100A2 Protein S100-A2 YSCQEGDK 1.3 
225 Q9UNH7 SNX6 Sorting nexin-6 IGSSLYALGTQDSTDICK 1.3 
549 Q9H4A6 GOLPH3 Golgi phosphoprotein 3 LQLEACGMR 1.28 
887 O00469 PLOD2 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 LDPDMALCR 1.25 
268 O14980 XPO1 Exportin-1 LDINLLDNVVNCLYHGEGAQQR 1.22 
709 O43707 ACTN4 Alpha-actinin-4 EGLLLWCQR 1.21 
166 Q9Y277 VDAC3 Voltage-dependent anion-selective channel protein VCNYGLTFTQK 1.19 
397 O60361 NME2P1 Putative nucleoside diphosphate kinase GDFCIQVGR 1.18 
778 Q9Y570 PPME1 Protein phosphatase methylesterase 1 GLSNLFLSCPIPK 1.18 
742 P49327 FASN Fatty acid synthase LGMLSPEGTCK 1.17 
295 Q9UPQ0 LIMCH1 LIM and calponin homology domains-containing prote AANSCTSYSGTTLNLK 1.16 
619 P23921 RRM1 Ribonucleoside-diphosphate reductase large subunit IIDINYYPVPEACLSNK 1.16 
17 P45880 VDAC2 Voltage-dependent anion-selective channel protein SCSGVEFSTSGSSNTDTGK 1.16 
117 P38606 ATP6V1A V-type proton ATPase catalytic subunit A VLDALFPCVQGGTTAIPGAFGCGK 1.16 
788 P32322 PYCR1 Pyrroline-5-carboxylate reductase 1, mitochondrial CMTNTPVVVR 1.15 
104 P23396 RPS3 40S ribosomal protein S3 GLCAIAQAESLR 1.14 
352 P55060 CSE1L Exportin-2 ICAVGITK 1.14 
207 Q14192 FHL2 Four and a half LIM domains protein 2 DDFAYCLNCFCDLYAK 1.12 
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380 P00505 GOT2 Aspartate aminotransferase, mitochondrial TCGFDFTGAVEDISK 1.12 
747 P30084 ECHS1 Enoyl-CoA hydratase, mitochondrial EMQNLSFQDCYSSK 1.12 
158 P34932 HSPA4 Heat shock 70 kDa protein 4 LMSANASDLPLSIECFMNDVDVSGTMNR 1.12 
328 P30084 ECHS1 Enoyl-CoA hydratase, mitochondrial ALNALCDGLIDELNQALK 1.11 
373 P36507 MAP2K2 Dual specificity mitogen-activated protein kinase LCDFGVSGQLIDSMANSFVGTR 1.11 
68 P28062 PSMB8 Proteasome subunit beta type-8 LLSNMMCQYR 1.11 
705 Q16658 FSCN1 Fascin LSCFAQTVSPAEK 1.1 
61 P05388 RPLP0 60S acidic ribosomal protein P0 CFIVGADNVGSK 1.1 
507 P36873 PPP1CC Serine/threonine-protein phosphatase PP1-gamma cat GNHECASINR 1.09 
342 J3KR12 Uncharacterized protein SLLINAVEASCIR 1.09 
671 P46782 RPS5 40S ribosomal protein S5 VNQAIWLLCTGAR 1.09 
395 Q96QK1 VPS35 Vacuolar protein sorting-associated protein 35 TQCALAASK 1.09 
249 P28838 LAP3 Cytosol aminopeptidase SAGACTAAAFLK 1.08 
70 P60174 TPI1 Triosephosphate isomerase VPADTEVVCAPPTAYIDFAR 1.08 
653 Q96FW1 OTUB1 Ubiquitin thioesterase OTUB1 QEPLGSDSEGVNCLAYDEAIMAQQDR 1.08 
363 P68366 TUBA4A Tubulin alpha-4A chain YMACCLLYR 1.08 
339 Q9UL46 PSME2 Proteasome activator complex subunit 2 CGFLPGNEK 1.08 
284 P15880 RPS2 40S ribosomal protein S2 GCTATLGNFAK 1.07 
240 Q9BUF5 TUBB6 Tubulin beta-6 chain EIVHIQAGQCGNQIGTK 1.06 
898 O15020 SPTBN2 Spectrin beta chain, non-erythrocytic 2 IHCLENVDK 1.06 
548 P31153 MAT2A S-adenosylmethionine synthase isoform type-2 TCNVLVALEQQSPDIAQGVHLDR 1.05 
140 P08238 HSP90AB1 Heat shock protein HSP 90-beta VFIMDSCDELIPEYLNFIR 1.05 
95 Q14432 PDE3A cGMP-inhibited 3,5-cyclic phosphodiesterase A ISPLSSPCSSPLQGTPASSLVSK 1.05 
303 P49327 FASN Fatty acid synthase AFDTAGNGYCR 1.04 
206 P13797 PLS3 Plastin-3 VDLNSNGFICDYELHELFK 1.03 
366 P68366 TUBA4A Tubulin alpha-4A chain AVCMLSNTTAIAEAWAR 1.03 
846 O75521 ECI2 Enoyl-CoA delta isomerase 2, mitochondrial WLSDECTNAVVNFLSR 1.03 
116 O95372 LYPLA2 Acyl-protein thioesterase 2 TYPGVMHSSCPQEMAAVK 1.03 
536 Q86W42 THOC6 THO complex subunit 6 homolog AQVPGSSPGLLSLSLNQQPAAPECK 1.02 
341 P57721 PCBP3 Poly(rC)-binding protein 3 INISEGNCPER 1.02 
48 P36952 SERPINB5 Serpin B5 ACLENLGLK 1.02 
149 A6NDG6 PGP Phosphoglycolate phosphatase FIAGTGCLVR 1.02 
244 O43583 DENR Density-regulated protein VLYCGVCSLPTEYCEYMPDVAK 1.02 
765 O95456 PSMG1 Proteasome assembly chaperone 1 VFGSCPR 1.02 
78 P57721 PCBP3 Poly(rC)-binding protein 3 LVVPASQCGSLIGK 1.02 
343 P18085 ARF4 ADP-ribosylation factor 4 NICFTVWDVGGQDR 1.01 
75 P53396 ACLY ATP-citrate synthase FICTTSAIQNR 1.01 
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39 P60174 TPI1 Triosephosphate isomerase IAVAAQNCYK 1.01 
801 P35579 MYH9 Myosin-9 VEDMAELTCLNEASVLHNLK 1.01 
155 P18669 PGAM1 Phosphoglycerate mutase 1 YADLTEDQLPSCESLK 1.01 
837 P10768 ESD S-formylglutathione hydrolase CPALYWLSGLTCTEQNFISK 1.01 
113 P60709 ACTB Actin, cytoplasmic 1 LCYVALDFEQEMATAASSSSLEK 1 
32 Q15365 PCBP1 Poly(rC)-binding protein 1 LVVPATQCGSLIGK 1 
37 P00505 GOT2 Aspartate aminotransferase, mitochondrial VGAFTMVCK 1 
547 P07737 PFN1 Profilin-1 CYEMASHLR 1 
574 P60174 TPI1 Triosephosphate isomerase IIYGGSVTGATCK 1 
340 P07900 HSP90AA1 Heat shock protein HSP 90-alpha VFIMDNCEELIPEYLNFIR 1 
312 P62753 RPS6 40S ribosomal protein S6 LNISFPATGCQK 1 
614 P40227 CCT6A T-complex protein 1 subunit zeta NAIDDGCVVPGAGAVEVAMAEALIK 1 
144 Q9BWD1 ACAT2 Acetyl-CoA acetyltransferase, cytosolic ATVAPEDVSEVIFGHVLAAGCGQNPVR 1 
645 Q52LJ0 FAM98B Protein FAM98B SLCNLEESITSAGR 1 
251 Q9NVG8 TBC1D13 TBC1 domain family member 13 LLQDYPITDVCQILQK 1 
647 Q9NQ88 TIGAR Fructose-2,6-bisphosphatase TIGAR EQFSQGSPSNCLETSLAEIFPLGK 1 
107 Q9BWD1 ACAT2 Acetyl-CoA acetyltransferase, cytosolic QASVGAGIPYSVPAWSCQMICGSGLK 1 
300 P53384 NUBP1 Cytosolic Fe-S cluster assembly factor NUBP1 GASCQGCPNQR 1 
325 P61158 ACTR3 Actin-related protein 3 YSYVCPDLVK 1 
19 P12532 CKMT1B Creatine kinase U-type, mitochondrial LGYILTCPSNLGTGLR 1 
368 Q7L1Q6 BZW1 Basic leucine zipper and W2 domain-containing prot FDPTQFQDCIIQGLTETGTDLEAVAK 1 
45 P16455 MGMT Methylated-DNA--protein-cysteine methyltransferase VVCSSGAVGNYSGGLAVK 1 
355 Q99832 CCT7 T-complex protein 1 subunit eta EGTDSSQGIPQLVSNISACQVIAEAVR 1 
394 P49721 PSMB2 Proteasome subunit beta type-2 NLADCLR 0.99 
47 P26641 EEF1G Elongation factor 1-gamma FPEELTQTFMSCNLITGMFQR 0.99 
399 P78347 GTF2I General transcription factor II-I SILSPGGSCGPIK 0.99 
126 Q08J23 NSUN2 tRNA (cytosine(34)-C(5))-methyltransferase MVYSTCSLNPIEDEAVIASLLEK 0.99 
526 Q9UGI8 TES Testin LPCEMDAQGPK 0.99 
256 P50914 RPL14 60S ribosomal protein L14 ALVDGPCTQVR 0.99 
316 P33240 CSTF2 Cleavage stimulation factor subunit 2 LCVQNSPQEAR 0.99 
296 P10809 HSPD1 60 kDa heat shock protein, mitochondrial AAVEEGIVLGGGCALLR 0.99 
675 P68366 TUBA4A Tubulin alpha-4A chain TIGGGDDSFTTFFCETGAGK 0.99 
288 P29401 TKT Transketolase MAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFR 0.99 
354 P62829 RPL23 60S ribosomal protein L23 ISLGLPVGAVINCADNTGAK 0.99 
44 P31327 CPS1 Carbamoyl-phosphate synthase TSACFEPSLDYMVTK 0.98 
601 P07954 FH Fumarate hydratase, mitochondrial FEALAAHDALVELSGAMNTTACSLMK 0.98 
138 Q14181 POLA2 DNA polymerase alpha subunit B VLGCPEALTGSYK 0.98 
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375 P62306 SNRPF Small nuclear ribonucleoprotein F CNNVLYIR 0.98 
38 P00338 LDHA L-lactate dehydrogenase A chain VIGSGCNLDSAR 0.98 
101 Q01813 PFKP 6-phosphofructokinase type C NESCSENYTTDFIYQLYSEEGK 0.98 
51 P68366 TUBA4A Tubulin alpha-4A chain AYHEQLSVAEITNACFEPANQMVK 0.98 
386 P07437 TUBB Tubulin beta chain LTTPTYGDLNHLVSATMSGVTTCLR 0.98 
40 P12004 PCNA Proliferating cell nuclear antigen CAGNEDIITLR 0.97 
102 F5H284 PPIAL4D Peptidyl-prolyl cis-trans isomerase IIPGFMCQGGDFTR 0.97 
587 P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- AEPPQCTSLAWSADGQTLFAGYTDNLVR 0.97 
630 Q9HB90 RRAGC Ras-related GTP-binding protein C SCGHQTSASSLK 0.97 
58 P07814 EPRS Bifunctional glutamate/proline--tRNA ligase LGVENCYFPMFVSQSALEK 0.97 
98 P29401 TKT Transketolase QAFTDVATGSLGQGLGAACGMAYTGK 0.97 
804 Q96I99 SUCLG2 Succinyl-CoA ligase IDATQVEVNPFGETPEGQVVCFDAK 0.97 
886 P13639 EEF2 Elongation factor 2 TFCQLILDPIFK 0.97 
444 Q96HC4 PDLIM5 PDZ and LIM domain protein 5 GALYCELCYEK 0.96 
262 A6NDG6 PGP Phosphoglycolate phosphatase NNQESDCVSK 0.96 
525 P30041 PRDX6 Peroxiredoxin-6 DFTPVCTTELGR 0.96 
267 O75822 EIF3J Eukaryotic translation initiation factor 3 subunit ITNSLTVLCSEK 0.96 
314 P07203 GPX1 Glutathione peroxidase 1 FQTIDIEPDIEALLSQGPSCA 0.96 
385 P21291 CSRP1 Cysteine and glycine-rich protein 1 SCFLCMVCK 0.96 
629 Q14847 LASP1 LIM and SH3 domain protein 1 ACFHCETCK 0.96 
310 Q99832 CCT7 T-complex protein 1 subunit eta QLCDNAGFDATNILNK 0.96 
362 P50990 CCT8 T-complex protein 1 subunit theta IAVYSCPFDGMITETK 0.96 
361 P68366 TUBA4A Tubulin alpha-4A chain SIQFVDWCPTGFK 0.96 
734 P37235 HPCAL1 Hippocalcin-like protein 1 LLQCDPSSASQF 0.96 
36 I3L2F9 Uncharacterized protein TAVCDIPPR 0.96 
218 P42677 RPS27 40S ribosomal protein S27 LTEGCSFR 0.96 
369 P13639 EEF2 Elongation factor 2 STLTDSLVCK 0.96 
46 P53597 SUCLG1 Succinyl-CoA ligase LIGPNCPGVINPGECK 0.96 
65 O75874 IDH1 Isocitrate dehydrogenase SEGGFIWACK 0.95 
590 Q9UHD8 SEPT9 Septin-9 LTVIDTPGFGDHINNENCWQPIMK 0.95 
304 P31327 CPS1 Carbamoyl-phosphate synthase VVAVDCGIK 0.95 
27 O95336 PGLS 6-phosphogluconolactonase AACCLAGAR 0.95 
246 Q13418 ILK Integrin-linked protein kinase FSFQCPGR 0.95 
76 P62280 RPS11 40S ribosomal protein S11 DVQIGDIVTVGECR 0.95 
90 Q15365 PCBP1 Poly(rC)-binding protein 1 VMTIPYQPMPASSPVICAGGQDR 0.95 
818 Q14192 FHL2 Four and a half LIM domains protein 2 DNQNFCVPCYEK 0.95 
24 P46782 RPS5 40S ribosomal protein S5 TIAECLADELINAAK 0.95 
25 Q07020 RPL18 60S ribosomal protein L18 GCGTVLLSGPR 0.94 
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346 P08670 VIM Vimentin QVQSLTCEVDALK 0.94 
131 Q09666 AHNAK Neuroblast differentiation-associated protein AHNA GPFVEAEVPDVDLECPDAK 0.94 
370 O43684 BUB3 Mitotic checkpoint protein BUB3 TPCNAGTFSQPEK 0.94 
234 Q9NP73 ALG13 UDP-N-acetylglucosamine transferase subunit ALG13 ADLVISHAGAGSCLETLEK 0.94 
605 P21333 FLNA Filamin-A LQVEPAVDTSGVQCYGPGIEGQGVFR 0.94 
277 P67936 TPM4 Tropomyosin alpha-4 chain EENVGLHQTLDQTLNELNCI 0.94 
628 Q15370 TCEB2 Transcription elongation factor B polypeptide 2 ADDTFEALCIEPFSSPPELPDVMK 0.94 
1 Q9Y696 CLIC4 Chloride intracellular channel protein 4 AGSDGESIGNCPFSQR 0.94 
220 P08238 HSP90AB1 Heat shock protein HSP 90-beta LVSSPCCIVTSTYGWTANMER 0.94 
390 Q9Y3F4 STRAP Serine-threonine kinase receptor-associated protei IGFPETTEEELEEIASENSDCIFPSAPDVK 0.94 
389 I3L2F9 Uncharacterized protein NMMAACDPR 0.94 
735 Q15181 PPA1 Inorganic pyrophosphatase GISCMNTTLSESPFK 0.94 
290 Q9UFW8 CGGBP1 CGG triplet repeat-binding protein 1 PLTASLQCNSTAQTEK 0.94 
393 Q01813 PFKP 6-phosphofructokinase type C LPLMECVQMTQDVQK 0.94 
327 P09211 GSTP1 Glutathione S-transferase P ASCLYGQLPK 0.94 
376 P48735 IDH2 Isocitrate dehydrogenase SSGGFVWACK 0.94 
323 Q13501 SQSTM1 Sequestosome-1 FSFCCSPEPEAEAEAAAGPGPCER 0.94 
106 O00244 ATOX1 Copper transport protein ATOX1 HEFSVDMTCGGCAEAVSR 0.93 
274 P31947 SFN 14-3-3 protein sigma GEELSCEER 0.93 
97 P38606 ATP6V1A V-type proton ATPase catalytic subunit A YSNSDVIIYVGCGER 0.93 
572 P63208 SKP1 S-phase kinase-associated protein 1 ENQWCEEK 0.93 
217 Q9NZL4 HSPBP1 Hsp70-binding protein 1 DACDTVR 0.93 
721 Q9NQ88 TIGAR Fructose-2,6-bisphosphatase TIGAR EECPVFTPPGGETLDQVK 0.93 
378 H7C455 Uncharacterized protein DCK 0.93 
213 P61978 HNRNPK Heterogeneous nuclear ribonucleoprotein K 
IIPTLEEGLQLPSPTATSQLPLESDAVECLNYQH
YK 0.93 
297 P23528 CFL1 Cofilin-1 HELQANCYEEVK 0.92 
279 Q96EY8 MMAB Cob(I)yrinic acid a,c-diamide adenosyltransferase, IQCTLQDVGSALATPCSSAR 0.92 
309 P62826 RAN GTP-binding nuclear protein Ran VCENIPIVLCGNK 0.92 
356 P26641 EEF1G Elongation factor 1-gamma AAAPAPEEEMDECEQALAAEPK 0.92 
228 P55769 NHP2L1 NHP2-like protein 1 LLDLVQQSCNYK 0.92 
652 P21266 GSTM3 Glutathione S-transferase Mu 3 IAAYLQSDQFCK 0.92 
93 O00299 CLIC1 Chloride intracellular channel protein 1 IGNCPFSQR 0.92 
706 P30084 ECHS1 Enoyl-CoA hydratase, mitochondrial ICPVETLVEEAIQCAEK 0.92 
22 P78417 GSTO1 Glutathione S-transferase omega-1 FCPFAER 0.92 
329 Q15019 SEPT2 Septin-2 LTVVDTPGYGDAINCR 0.92 
398 Q99714 HSD17B10 3-hydroxyacyl-CoA dehydrogenase type-2 LGNNCVFAPADVTSEK 0.92 
895 Q9Y5Y2 NUBP2 Cytosolic Fe-S cluster assembly factor NUBP2 AVHQCDR 0.92 
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559 Q16555 DPYSL2 Dihydropyrimidinase-related protein 2 FQLTDCQIYEVLSVIR 0.91 
83 P14866 HNRNPL Heterogeneous nuclear ribonucleoprotein L LCFSTAQHAS 0.91 
53 O15067 PFAS Phosphoribosylformylglycinamidine synthase FCDNSSAIQGK 0.91 
626 Q13748 TUBA3D Tubulin alpha-3C/D chain TIQFVDWCPTGFK 0.91 
253 Q13526 PIN1 Peptidyl-prolyl cis-trans isomerase NIMA-interacti SGEEDFESLASQFSDCSSAK 0.91 
41 O95861 BPNT1 3(2),5-bisphosphate nucleotidase 1 TCATDLQTK 0.91 
56 P49327 FASN Fatty acid synthase DPETLVGYSMVGCQR 0.91 
306 P22695 UQCRC2 Cytochrome b-c1 complex subunit 2, mitochondrial NALANPLYCPDYR 0.91 
120 Q6XQN6 NAPRT1 Nicotinate phosphoribosyltransferase LQALVNSLCAGQSP 0.9 
326 P11802 CDK4 Cyclin-dependent kinase 4 LMDVCATSR 0.9 
280 P49327 FASN Fatty acid synthase AINCATSGVVGLVNCLR 0.9 
618 P60981 DSTN Destrin CSTPEEIK 0.9 
28 P08237 PFKM 6-phosphofructokinase, muscle type LPLMECVQVTK 0.9 
211 P61289 PSME3 Proteasome activator complex subunit 3 LDECEEAFQGTK 0.9 
359 P37802 TAGLN2 Transgelin-2 NMACVQR 0.9 
291 P23396 RPS3 40S ribosomal protein S3 GCEVVVSGK 0.9 
344 P21291 CSRP1 Cysteine and glycine-rich protein 1 DGEIYCK 0.9 
54 Q14258 TRIM25 E3 ubiquitin/ISG15 ligase TRIM25 NTVLCNVVEQFLQADLAR 0.9 
165 Q04695 KRT17 Keratin, type I cytoskeletal 17 LSGGLGAGSCR 0.9 
293 P02795 MT2A Metallothionein-2 SCCSCCPVGCAK 0.89 
94 P60981 DSTN Destrin LGGSLIVAFEGCPV 0.89 
132 P62937 PPIA Peptidyl-prolyl cis-trans isomerase A ITIADCGQLE 0.89 
388 P42330 AKR1C3 Aldo-keto reductase family 1 member C3 WVDPNSPVLLEDPVLCALAK 0.89 
392 P27348 YWHAQ 14-3-3 protein theta YLAEVACGDDR 0.89 
651 P08238 HSP90AB1 Heat shock protein HSP 90-beta GFEVVYMTEPIDEYCVQQLK 0.89 
745 P23528 CFL1 Cofilin-1 DCR 0.89 
787 Q9NUU7 DDX19A ATP-dependent RNA helicase DDX19A VLVTTNVCAR 0.89 
803 Q9Y3D2 MSRB2 Methionine-R-sulfoxide reductase B2, mitochondrial GQAGGGGPGTGPGLGEAGSLATCELPLAK 0.89 
324 P09110 ACAA1 3-ketoacyl-CoA thiolase, peroxisomal DCLIPMGITSENVAER 0.88 
99 O43865 AHCYL1 Putative adenosylhomocysteinase 2 LCVPAMNVNDSVTK 0.88 
286 Q9NVG8 TBC1D13 TBC1 domain family member 13 SLDDSQCGITYK 0.88 
381 Q7L2H7 EIF3M Eukaryotic translation initiation factor 3 subunit VAASCGAIQYIPTELDQVR 0.88 
92 P37802 TAGLN2 Transgelin-2 DGTVLCELINALYPEGQAPVK 0.88 
91 P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase VPTANVSVVDLTCR 0.88 
315 P14618 PKM Pyruvate kinase isozymes M1/M2 CCSGAIIVLTK 0.88 
114 Q9NQR4 NIT2 Omega-amidase NIT2 VGLGICYDMR 0.88 
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311 P21291 CSRP1 Cysteine and glycine-rich protein 1 TVYFAEEVQCEGNSFHK 0.88 
347 Q15417 CNN3 Calponin-3 CASQAGMTAYGTR 0.88 
391 P27635 RPL10 60S ribosomal protein L10 MLSCAGADR 0.88 
334 P05388 RPLP0 60S acidic ribosomal protein P0 AGAIAPCEVTVPAQNTGLGPEK 0.88 
125 P04732 MT1E Metallothionein-1E CAQGCVCK 0.87 
577 P00558 PGK1 Phosphoglycerate kinase 1 GCITIIGGGDTATC*C*AK 0.87 
222 Q2TAA2 IAH1 Isoamyl acetate-hydrolyzing esterase 1 homolog VILITPTPLCETAWEEQCIIQGCK 0.87 
865 P51610 HCFC1 Host cell factor 1 ACAAGTPAVIR 0.87 
74 P24752 ACAT1 Acetyl-CoA acetyltransferase, mitochondrial QAVLGAGLPISTPCTTINK 0.87 
69 P12277 CKB Creatine kinase B-type FCTGLTQIETLFK 0.86 
513 Q9Y508 RNF114 RING finger protein 114 DCGGAAQLAGPAAEADPLGR 0.86 
317 P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase IISNASCTTNCLAPLAK 0.86 
209 P60709 ACTB Actin, cytoplasmic 1 CPEALFQPSFLGMESCGIHETTFNSIMK 0.86 
576 P07195 LDHB L-lactate dehydrogenase B chain GMYGIENEVFLSLPCILNAR 0.86 
575 P00338 LDHA L-lactate dehydrogenase A chain DDVFLSVPCILGQNGISDLVK 0.86 
358 Q13185 CBX3 Chromobox protein homolog 3 LTWHSCPEDEAQ 0.86 
604 P62879 GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) TFVSGACDASIK 0.86 
650 Q9NRP4 ACN9 Protein ACN9 homolog, mitochondrial ACFGTFLPEEK 0.86 
258 P49411 TUFM Elongation factor Tu, mitochondrial GEETPVIVGSALCALEGR 0.86 
115 O75663 TIPRL TIP41-like protein VACAEEWQESR 0.86 
322 P62249 RPS16 40S ribosomal protein S16 TATAVAHCK 0.86 
281 Q86SX6 GLRX5 Glutaredoxin-related protein 5, mitochondrial GTPEQPQCGFSNAVVQILR 0.86 
561 Q9Y5Y2 NUBP2 Cytosolic Fe-S cluster assembly factor NUBP2 VGILDVDLCGPSIPR 0.85 
351 P62888 RPL30 60S ribosomal protein L30 VCTLAIIDPGDSDIIR 0.85 
43 Q9BRA2 TXNDC17 Thioredoxin domain-containing protein 17 SWCPDCVQAEPVVR 0.85 
744 P04183 TK1 Thymidine kinase, cytosolic LFAPQQILQCSPAN 0.85 
305 P25398 RPS12 40S ribosomal protein S12 LGEWVGLCK 0.85 
270 O14950 MYL12B Myosin regulatory light chain 12B NAFACFDEEATGTIQEDYLR 0.85 
162 Q14790 CASP8 Caspase-8 VFFIQACQGDNYQK 0.85 
534 Q7L8W6 ATPBD4 ATP-binding domain-containing protein 4 CEGDEVEDLYELLK 0.84 
233 P30044 PRDX5 Peroxiredoxin-5, mitochondrial ALNVEPDGTGLTCSLAPNIISQL 0.84 
603 Q9BY32 ITPA Inosine triphosphate pyrophosphatase GCQDFGWDPCFQPDGYEQTYAEMPK 0.84 
720 Q09666 AHNAK Neuroblast differentiation-associated protein AHNA LEGDLTGPSVGVEVPDVELECPDAK 0.84 
283 P10809 HSPD1 60 kDa heat shock protein, mitochondrial CEFQDAYVLLSEK 0.84 
840 P82932 MRPS6 28S ribosomal protein S6, mitochondrial ECEGIVPVPLAEK 0.84 
419 P62701 RPS4X 40S ribosomal protein S4, X isoform ECLPLIIFLR 0.83 
128 P00505 GOT2 Aspartate aminotransferase, mitochondrial EYLPIGGLAEFCK 0.83 
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111 Q01518 CAP1 Adenylyl cyclase-associated protein 1 ALLVTASQCQQPAENK 0.83 
332 P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- FSPNSSNPIIVSCGWDK 0.83 
10 P21291 CSRP1 Cysteine and glycine-rich protein 1 NLDSTTVAVHGEEIYCK 0.83 
364 Q99439 CNN2 Calponin-2 AGQCVIGLQMGTNK 0.83 
408 P30153 PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa reg LNIISNLDCVNEVIGIR 0.82 
88 P33316 DUT Deoxyuridine 5-triphosphate nucleotidohydrolase, IAQLICER 0.82 
34 Q96I99 SUCLG2 Succinyl-CoA ligase SCNGPVLVGSPQGGVDIEEVAASNPELIFK 0.82 
50 P04075 ALDOA Fructose-bisphosphate aldolase A ALANSLACQGK 0.82 
82 P10809 HSPD1 60 kDa heat shock protein, mitochondrial CIPALDSLTPANEDQK 0.82 
333 Q9Y5P6 GMPPB Mannose-1-phosphate guanyltransferase beta LCSGPGIVGNVLVDPSAR 0.82 
57 P40926 MDH2 Malate dehydrogenase, mitochondrial TIIPLISQCTPK 0.82 
330 P62316 SNRPD2 Small nuclear ribonucleoprotein Sm D2 NNTQVLINCR 0.81 
743 P50238 CRIP1 Cysteine-rich protein 1 CNK 0.81 
134 P14174 MIF Macrophage migration inhibitory factor LLCGLLAER 0.8 
157 P48047 ATP5O ATP synthase subunit O, mitochondrial GEVPCTVTSASPLEEATLSELK 0.8 
299 P30626 SRI Sorcin DTAQQGVVNFPYDDFIQCVMSV 0.78 
224 Q99873 PRMT1 Protein arginine N-methyltransferase 1 VIGIECSSISDYAVK 0.78 
62 Q9UI30 TRMT112 tRNA methyltransferase 112 homolog ICPVEFNPNFVAR 0.78 
152 P24752 ACAT1 Acetyl-CoA acetyltransferase, mitochondrial QGEYGLASICNGGGGASAMLIQK 0.78 
817 P60866 RPS20 40S ribosomal protein S20 TPCGEGSK 0.78 
387 P62333 PSMC6 26S protease regulatory subunit 10B AVASQLDCNFLK 0.77 
336 Q99439 CNN2 Calponin-2 CASQSGMTAYGTR 0.77 
77 Q7RTV0 PHF5A PHD finger-like domain-containing protein 5A ICDECNYGSYQGR 0.76 
377 P42166 TMPO Lamina-associated polypeptide 2, isoform alpha SGIQPLCPER 0.76 
372 P63220 RPS21 40S ribosomal protein S21 TYAICGAIR 0.75 
867 P35998 PSMC2 26S protease regulatory subunit 7 LCPNSTGAEIR 0.75 
203 Q9H479 FN3K Fructosamine-3-kinase AFGGPGAGCISEGR 0.75 
294 Q12849 GRSF1 G-rich sequence factor 1 YIELFLNSCPK 0.74 
762 O00233 PSMD9 26S proteasome non-ATPase regulatory subunit 9 GIGMNEPLVDCEGYPR 0.74 
163 P24752 ACAT1 Acetyl-CoA acetyltransferase, mitochondrial IHMGSCAENTAK 0.74 
307 P49458 SRP9 Signal recognition particle 9 kDa protein VTDDLVCLVYK 0.73 
589 P38117 ETFB Electron transfer flavoprotein subunit beta EVIAVSCGPAQCQETIR 0.72 
379 P21980 TGM2 Protein-glutamine gamma-glutamyltransferase 2 VVSGMVNCNDDQGVLLGR 0.7 
648 Q13200 PSMD2 26S proteasome non-ATPase regulatory subunit 2 GTLTLCPYHSDR 0.69 
200 Q9BW61 DDA1 DET1- and DDB1-associated protein 1 FHADSVCK 0.66 
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164 Q93052 LPP Lipoma-preferred partner TYITDPVSAPCAPPLQPK 0.66 
917 P31943 HNRNPH1 Heterogeneous nuclear ribonucleoprotein H DLNYCFSGMSDHR 0.66 
212 P34896 SHMT1 Serine hydroxymethyltransferase, cytosolic AVLEALGSCLNNK 0.64 
89 P68104 EEF1A1 Elongation factor 1-alpha 1 PMCVESFSDYPPLGR 0.63 
704 P23528 CFL1 Cofilin-1 AVLFCLSEDK 0.59 
18 P14649 MYL6B Myosin light chain 6B ILYSQCGDVMR 0.59 
913 Q14247 CTTN Src substrate cortactin HCSQVDSVR 0.59 
60 P49189 ALDH9A1 4-trimethylaminobutyraldehyde dehydrogenase GALMANFLTQGQVCCNGTR 0.57 
319 O14929 HAT1 Histone acetyltransferase type B catalytic subunit LCQDLPCFSR 0.56 
241 Q14919 DRAP1 Dr1-associated corepressor ACQVTQSR 0.5 
761 Q9H0L4 CSTF2T Cleavage stimulation factor subunit 2 tau variant LCVQNSHQEAR 0.35 
261 P83731 RPL24 60S ribosomal protein L24 VELCSFSGYK 0.3 
828 P62280 RPS11 40S ribosomal protein S11 CPFTGNVSIR 0.17 
 
